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A critical challenge in modern chemical biology is the site-specific modification of 
proteins. This is due to the large number of reactive functional groups typically present in 
the cellular environment. An area of intense research is in developing methods for the 
site-specific modification of proteins, because it has a wide range of utility in fields such 
as chemistry, biology and medicine. Site-specific protein modification experiments have 
been useful for oriented protein immobilization, for studies of naturally-occurring post-
translational modifications, for creating antibody-drug conjugates, for the introduction of 
fluorophores and other small molecules on to proteins, for examining protein structure, 
folding, dynamics and protein-protein interactions and for the preparation of protein-
polymer conjugates. One the most important approaches toward protein labeling is to 
incorporate bioorthogonal functionalities into proteins at specific sites via enzymatic 
reactions. The incorporated tags would enable reactions that are chemoselective, whose 
functional groups are both inert in biological media, and which do not natively occur in 
proteins or other macromolecules. This review article summarizes the enzymatic 
strategies, which enables site-specifically functionalizing proteins with a variety of 
different functional groups. The enzymes covered in this review include formylglycine 
generating enzyme, sialyl transferase, phosphopantetheinyl transferase, O-GlcNAc post-
translational modification, sortagging, transglutaminase, farnesyl transferase, biotin 
ligase, lipoic acid ligase and N-myristoyl transferase.  
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Introduction 
Site-specific modification of proteins is a challenging problem in modern chemical 
biology.
1–4
  With applications in fields including biology, chemistry, and medicine,
5
 
developing methods to site-specifically modify proteins is of great importance. Site-
specific protein modifications have been used to create antibody-drug conjugates,
6
 to 
study natural post-translational modifications, to introduce fluorophores and other small 
molecules for biophysical studies, oriented protein immobilization,
7
 to prepare protein-
polymer conjugates,
8
 and to examine the properties of proteins such as folding, dynamics 
and protein-protein interaction.
9
 Protein immobilization is an important first step for 
many biotechnology applications including the construction of protein microarrays and 
biosensors, immunoassays and protein conjugates used for medical therapies.
10,11
 One of 
the main advantages of site-specific protein modification is that it can be used to create 
structurally defined covalent linkages between proteins and surfaces, materials or 
biomolecules.
12
 This ensures homogeneous coverage and accessibility to the active site of 
the protein. These are important factors in studying protein expression and localization, to 
improve bioavailability and pharmacokinetics of protein-based drugs, in structure-
function studies, and in the development of biosensors.
13
  
Early methods of protein functionalization exploited the reactivity of either cysteine or 
lysine residues by reacting the protein with an excess of thiol- or amine-reactive reagents 
such as maleimides or N-hydroxysuccinimidyl esters. In addition to lysine and cysteine 
modifications, methods have also been developed to chemically modify tyrosine, the N- 
or C-terminus, and aspartiate or glutamate residues.
14
  Transimination
15–17
 and periodate 
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oxidation
4,18
 are also among common chemical methods for protein modifications which 
introduce an aldehyde or a ketone moiety at the N-terminus. Although all of these 
methods are currently in use and have widespread utility, a variety of alternative 
approaches have been developed to achieve greater reaction yield, higher selectivity and 
site-specificity, compatibility with complex biological systems, and improved reaction 
rates.
12
   
One approach to protein labeling is to use reactions that are chemoselective whose 
functional groups are both inert in biological media and which do not natively occur in 
proteins or other biological macromolecules. In many cases, a combined strategy of the 
described modification methods are used, such as taking advantage of the selectivity of 
the reactive functional groups on proteins (e.g. lysine of the C-terminus) which is used to 
introduce a new reactive group that then provides superior reaction kinetics for a second, 
more complex conjugation reaction. Using this strategy, a large excess of the initial 
reagent can be used to introduce a reactive handle into a protein, followed by a second 
reaction using stoichiometric quantities of the biomolecule or probe of interest, which can 
be more costly to obtain.  
The discovery and application of green fluorescent protein (GFP) and its derivatives into 
chemical biology has had a great impact on exploring protein behavior in living cells and 
has dramatically increased our knowledge of biological processes.
19–21
 However, the use 
of GFP to tag proteins comes with disadvantages; many proteins do not tolerate the 
fusion with GFP without compromising function or intracellular distribution. An 
alternative to using GFP is to chemically tag proteins with a fluorescent or affinity label 
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because this has the advantage of being relatively simple to perform and usually only 
uses a small molecule when compared to the protein. One of the major disadvantages is 
that if done non-site specifically, it lacks the precision of a genetically encoded tag. 
Another alternative to create site-specific protein conjugates is the incorporation of non-
natural amino acids in proteins. The incorporation of non-proteogenic residues allows 
functionality typically not found in proteins to be introduced and exploited. Several 
systems for expressing proteins with non-natural residues have been described and 
recently reviewed.
22
 Auxotrophic bacterial hosts are commonly used to incorporate a 
non-natural analog of an amino acid, and suppressor tRNA methods have been developed 
which can enable the incorporation of a variety of reactive amino acid analogs such as p-
azidophenylalanine, p-ethynylphenylalanine or p-acetylphenylalanine.
23–26
 
The development of new methods for site-specific modification of proteins that function 
under mild conditions is an area of intense research.
1,3,4,12
 Due to the structural sensitivity 
of proteins and complex cellular environment in which proteins inhabit, the chemical 
transformations of proteins need to proceed under mild conditions that are compatible 
with all functional groups present in the cell, which includes such diverse molecules as 
proteins, nucleic acids, carbohydrates, and various metabolites. The reaction should occur 
in water or aqueous solutions at or near physiological pH, have rapid kinetics even with 
low (sub-millimolar) concentrations of reactants, and occur at ambient temperatures. The 
search for chemical reactions that satisfy these requirements has revealed the utility of a 
number of key chemical reactions including the Huisgen [3 + 2] cycloaddition 
(commonly referred to as the “click” reaction),27–29 the Staudinger ligation,30 a 
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photoinducible reaction of an alkene with tetrazole,
31,32
 the Diels-Alder reaction,
33–35
 an 
inverse-electron-demand Diels Alder reaction,
36,37
 and oxime or hydrazone ligations.
38–40
 
To overcome many of the aforementioned challenges, chemoenzymatic methods that 
allow site-specific incorporation of labels into proteins have been developed and are an 
increasingly intense area of research.
2,41,42
 Such methods capitalize on the exquisite 
selectivity of enzymes to accomplish highly selective reactions. Here we review the most 
recent enzymatic methods for site-specific protein modification including formylglycine 
generating enzyme, sialylation, phosphopantetheinyl transferase, O-GlcNAc post-
translational modification, sortagging, transglutaminase, farnesyl transferase, biotin 
ligase, lipoic acid ligase and N-myristoyl transferase 
Enzymes used for protein modification 
Formylglycine generating enzyme (FGE). Formylglycine generating enzyme 
(FGE) performs a critical posttranslational modification of type I sulfatases by converting 
a cysteine within the motif CxPxR to the aldehyde-bearing residue formylglycine 
(FGly).
43–46
 By introducing this motif into proteins and subsequently reacting it with 
FGE, an aldehyde group can be site-specifically added to the protein, which can then be 
used for covalent modification using complimentary aminooxy- or hydrazide-
functionalized reagents (Figure 1.1). Bertozzi and coworkers have refined this strategy by 
screening FGE’s from Mycobacterium tuberculosis and Streptomyces coelicolor against 
synthetic peptide substrate libraries and identified new peptide sequences that diverge 
from the canonical FGE-recognized motif.
44
  Based on their study, Escherichia coli’s 
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FGE activity was found to be similarly promiscuous, which enables the use of novel 
aldehyde tag sequences for ex vivo modification of recombinant proteins. 
In another study, they introduced the peptide sequence recognized by the endoplasmic 
reticulum (ER)-resident FGE, into heterologous proteins expressed in mammalian cells. 
Applying the FGE technique, they were able to site-specifically modify monoclonal 
antibodies as well as membrane-associated and cytosolic proteins expressed in 
mammalian systems.
45
 
 
Figure 1.1 Site-specific modification of proteins containing a genetically encoded 
aldehyde tag incorporated using formylglycine generating enzyme (FGE). (A) FGE 
oxidizes a specific cysteine to formylglycine within a 5 residue consensus sequence. (B) 
Site-specific modification of a protein bearing the genetically encoded aldehyde tag 
followed by chemoselective bioorthogonal oxime ligation reaction to label the protein of 
interest. 
  
 8 
 
Plasma membrane-associated proteins, similar to secreted proteins, traffic through the 
secretory pathway and thus can potentially be substrates for the ER-resident FGE. They 
explored this idea by introducing a 13 residue aldehyde tagging sequence onto the N-
terminus of the platelet-derived growth factor receptor (PDGFR) transmembrane (TM) 
domain. This protein, along with human FGE, were expressed for 48 h in CHO cells. 
Next, the cells were reacted with biotin-hydrazide followed by Alexafluor488-
streptavidin and were analyzed by flow cytometry. Their results showed that CHO cells 
expressing aldehyde tagged PDGFR-TM had a clear increase in fluorescence compared 
with cells expressing the unmodified PDGFR-TM protein.
45
 
In additional work, a bacterial FGE homolog derived from Streptomyces coelicolor was 
introduced into a mammalian expression vector. A GFP was genetically encoded with a 
13 residue aldehyde tag at its N-terminus denoted as Ald13-GFP. Both proteins were 
expressed in HEK293T cells. After cell lysis and purification, the fusion protein was 
reacted with biotin-hydrazide and analyzed by non-reducing PAGE and Western blotting. 
Their results showed that the Ald13-GFP was efficiently labeled with biotin-hydrazide.
45
 
Overall, the aldehyde tag offers a versatile method for site-specific modification of 
membrane associated and cytosolic proteins in mammalian cells. It only requires a 
peptide sequence 6-13 residues in length that can be varied for the protein modification 
application. The 6 residue tag is smaller but the 13 residue tag provides higher levels of 
conversion of Cys to FGly presumably due the greater accessibility to the enzyme active 
site provided by the longer flanking sequences. Because of its site-selective nature, the 
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aldehyde tag is promising for the development of new protein-conjugates for research and 
therapeutic purposes. 
Sialylation. The surfaces of many cells, including both prokaryotes and 
eukaryotes, are decorated with glycan chains. These glycans play important roles in a 
wide range of biological processes such as cell–cell interaction, protein recognition and 
small molecule–cell recognition. One important type of glycan modification is the 
addition of sialic acid to proteins (Figure 1.2). Sialic acid is a monosaccharide with a 
nine-carbon backbone and is a generic term for the O- or N-substituted derivatives of 
neuraminic acid. Sialic acid refers to a wide family of related sugar acids that occur 
prominently at the terminal position of many eukaryotic surface-exposed 
glycoconjugates, where they confer important properties upon the resulting cell surface. 
One of the most abundant and best-studied sialic acid members is N-acetylneuraminic 
acid (Neu5Ac). Besides Neu5Ac, there are numerous naturally occurring variations of 
sialic acid including substitutions at the C-5 position, or modifications of different 
hydroxyl groups. Sialic acids are found widely distributed in animal tissues and to a 
lesser extent in other species, ranging from plants and fungi to yeasts and bacteria, 
predominantly in glycoproteins and gangliosides. 
Sialic acid-containing structures play important roles in cellular recognition and 
communication. Accordingly, many pathogenic bacteria have evolved the molecular 
machinery to decorate their cell surfaces with sialic acid to mimic that of their host. This 
results in the ability to resist the host’s innate immune response and also allows them to 
interact specifically with different host-cell surfaces. Therefore understanding sialylation 
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will enable a better understanding of how certain pathogens function and could be used to 
create more effective drugs. 
Unfortunately, the study of sialylation is difficult due to the complex structure of sialic 
acid which presents numerous synthetic challenges. This complexity is due to the 
hindered tertiary anomeric center and the lack of a neighboring participating group in 
sialic acids. Using enzymatic methods to create and conjugate sialic acid derivatives is a 
much more promising method to study sialylation. Thus, a highly active sialyltransferase 
with broad substrate functionality would be particularly useful in this field. 
 
 
Figure 1.2. (A) Synthesis of sialosides containing sialic acid modifications via a 
chemoenzymatic approach. (B) Application of sialyltransferase for cell surface labeling 
using sialic acid derivatives. Rx (X=5-9) represent groups that can contain an azide, an 
alkyne or other bioorthogonal functional groups. 
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Chen and coworkers reported the discovery of a water soluble and highly active 
multifunctional sialyltrasferase from Pasteurella multocida.
47
 They used a one-pot, three 
enzyme system for efficient synthesis of a diverse set of sialoside libraries (Figure 1.2).
48
  
In this system using a recombinant Escherichia coli K12 sialic acid aldolase and a 
recombinant Neisseria meningitidis CMP-Sia-synthetase, CMP-Sia derivatives were 
generated in situ from sialic acid precursors. They were able to perform these reactions 
under mild conditions at 37 
o
C, pH of 8.5, over the course of only a few hours; 
additionally they did not observe significant sialidase or α-2,6-SiaT activity. Overall, the 
newly discovered SiaT has broad substrate specificity, substantial expression levels, high 
solubility and is multifunctional. Thus, it should be a powerful tool for synthesizing 
structurally diverse sialosides to understand their important biological functions. 
Phosphopantetheinyl transferase (PPTase). Walsh and coworkers developed a 
strategy for the site-specific modification of proteins with small molecules using 
phosphopantetheinyl transferase, Sfp, a posttranslational modification enzyme. Recently, 
a number of groups have exploited the utility of Sfp to transfer a wide range of 
molecules, conjugated to the thiol moiety of Coenzyme A (CoA), onto different carrier 
proteins (Figure 1.3). Sfp and related PPTases have also been used to label proteins, 
containing the PPTase recognition sequence (peptide carrier protein, PCP, or acyl carrier 
protein ACP), with biotin
49
 or fluorophores, the former of which has been used to 
noncovalently immobilize arrays of protein onto avidin-coated slides.  
In the early work reported by Walsh and coworkers, the target proteins were expressed as 
fusions to PCP (75-80 amino acids), which were excised from nonribosomal peptide 
 12 
 
synthetase.
49
 Next Sfp was used to catalyze the covalent attachment of the small molecule 
phosphopantetheine to a specific serine residue within the PCP. The labeling reaction 
proceeds with high specificity and efficiency, targeting the PCP-fusion proteins in the 
cell lysate. The PCP tag was shown to be compatible with various proteins because its 
fusion onto proteins did not compromise the functional properties of the parent protein. 
Additionally, Sfp was shown to be promiscuous with respect to the small-molecule 
probes linked to CoA. This work highlighted the potential of the PCP tag for site-specific 
protein labeling with small molecules. Moreover, they employed a PCP tag for biotin 
labeling of proteins and then demonstrated that the resulting biotinylated proteins could 
be used to create a protein microarray for enzymatic screening. Overall, the relatively 
small size of the PCP domain (75-80 amino acids), the portability of PCP to various 
target proteins, the high efficiency of Sfp-catalyzed PCP posttranslational modification 
and the promiscuity of Sfp with various small-molecule probes makes this approach an 
attractive alternative for protein labeling. 
Having access to promiscuous metabolic pathways can provide an interesting alternative 
to chemical entry into small molecule engineering ex vivo. Burkat and coworkers used the 
PPTase strategy for protein labeling by harnessing an intrinsic bacterial metabolic 
pathway.
50,51
 They treated Escherichia coli cells with a cell-permeable, nonhydrolyzable, 
fluorescent pantetheine analogue (coumarin-derivative), which can be used by the CoA 
biosynthetic pathway to synthesize CoA-analogues ex vivo. Presumably, Escherichia coli 
internalizes the pantetheine analogue via a sodium-dependent symporter where it 
undergoes phosphorylation by CoAA. Further processing by CoAD and CoAE results in 
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stepwise adenylation and further phosphorylation yields the final CoA analogue. This 
compound is then retained within the cell and is available for downstream transfer into a 
carrier protein domain. This work showed how cell-penetratable analogues of metabolic 
precursors could be used ex vivo to site-specifically label proteins. The key feature of this 
approach is the availability of a viable uptake mechanism. Using this strategy, CoA-
bound reporter molecules were successfully generated for post-translational protein 
modification ex vivo. This method may be applicable to natural product pathway 
manipulation as well as applications in conventional molecular and cellular biology. The 
significant tolerance to structural modification manifested by the enzymes in this 
pathway should allow delivery of a wide variety of chemical moieties to ex vivo 
processes. 
 
Figure 1.3. (A) Sfp-catalyzed modification of PCP, ACP or ybbR tag at a specific Ser 
residue by CoA-SR conjugates. (B) Using Sfp or related PPTases for direct site-specific 
protein immobilization via surface immobilized CoA as a substrate and a protein of 
interest containing a genetically encoded carrier protein or a ybbR tag. (C) Labeling cell 
 14 
 
surface proteins naturally or recombinantly containing ACP, PCP or a ybbR tag using 
PPTase. 
In related work, Johnsson and coworkers used the PPTase strategy to site-specifically 
label cell surface proteins in eukaryotes and prokaryotes with a fluorescent probe.
52
 They 
expressed a-agglutinin receptor Aga2p as a C-terminal fusion with ACP (Aga2p-ACP) in 
Saccharomyces cerevisiae. Aga2p is known to interact with Aga1p through two disulfide 
bonds which causes its localization to the cell surface.
53
  Incubation of yeast cells that 
coexpressed Aga1p and Aga2p-ACP with CoA-Cy3 (a fluorescent analog of the natural 
substrate) and PPTase led to a clear fluorescent signal at the cell membrane. Aga2p-ACP 
was also modified with a biotinylated CoA analogue, and subsequently incubated with 
commercially available CdSe quantum dots conjugated to streptavidin. The resulting 
bright fluorescence of yeast displaying Aga2p-ACP was highly specific. The same results 
were observed when the experiments were performed on HEK293 cells. In that case, the 
ACP tag was appended to the N-terminus of a recombinant human G protein-coupled 
receptor neurokinin-1, one of the most important classes of therapeutic targets. 
The size of the PCP or ACP is relatively large (75-80 amino acids), thus Walsh and 
coworkers tried to identify smaller peptide substrates for Sfp catalyzed reactions. By 
studying a genomic library of Bacillus subtilis by phage display, they identified a series 
of peptides, the smallest being an 11-residue peptide with the sequence DSLEFIASKLA, 
as efficient substrates for Sfp phosphopantetheinyl transferase protein labeling by small 
molecule–CoA conjugates.54 The peptides were named “ybbR tags” because part of their 
sequence is derived from the ybbR ORF in the Bacillus subtilis genome. Importantly, 
they also demonstrated that the ybbR tag can be fused to the N- or C-termini of target 
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proteins or inserted in a flexible loop in the middle of a target protein for site-specific 
protein labeling by Sfp, highlighting the versatility of this approach. 
Overall, enzymatic labeling via Sfp by various small-molecule probes is highly specific 
and efficient. Sfp has broad substrate specificities regarding the small molecule probes 
conjugated to CoA, including fluorescent probes such as Alexafluor dyes and fluorescein, 
affinity probes such as glutathione and biotin, redox probes such as porphyrin and also 
sugar derivatives of CoA. The PPTase strategy can also be used for direct site-selective 
covalent protein immobilization on solid supports derivatized with CoA.
55
 
O-GlcNAc post-translational modification. The glycosylation of nuclear and 
cytoplasmic proteins at serine and threonine residues by the addition of a single GlcNAc 
residue (O-GlcNAc) is a widespread posttranslational modification (Figure 1.4). This 
modification has been found on numerous proteins such as nuclear pore proteins, 
enzymes and transcription factors. The enzyme catalyzing the O-GlcNAc modification of 
cellular proteins, UDP-Glc-NAc: polypeptidyltransferase (OGTase), is essential for cell 
viability in mammals and is conserved in a range of organisms from Arabidopsis thaliana 
to humans. Glycosylation levels are typically monitored by immunoblotting with a 
general O-GlcNAc antibody, which detects only a limited number of O-GlcNAc-
modified proteins and makes it difficult to identify proteins undergoing changes in 
glycosylation. Bertozzi and coworkers described a chemical strategy directed toward 
identifying O-GlcNAc-modified proteins from living cells or proteins modified in vitro.
56
 
They demonstrated, in vitro, that each enzyme in the hexosamine salvage pathway, and 
the enzymes that affect this dynamic modification (UDP-Glc-NAc: 
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polypeptidtyltransferase and O-GlcNAcase), tolerate structural modifications in which 
the N-acyl side chain of the natural substrate has been functionalized with a bio-
orthogonal azide moiety. Cells treated with N-azidoacetylglucosamine resulted in the 
metabolic incorporation of the azidosugar into nuclear and cytoplasmic proteins. These 
O-azidoacetylglucosamine-modified proteins could then be covalently derivatized with 
various biochemical probes at the site of protein glycosylation using the Staudinger 
ligation.  
The incorporation of GlcNAz onto proteins within cultured human cells was also 
investigated. Jurkat cells were cultured in the presence of a derivative of GlcNAz for 3 
days. Nuclear protein extracts were prepared and reacted with a FLAG-phosphine-based  
 
Figure 1.4. Chemoenzymatic labeling of O-GlcNAc-containg proteins using a T289L 
mutant -galactosyl transferase and UDP-galactose analog. The functionalized protein can 
then be used for chemoselective reactions, such as oxime or hydrazone ligations or azide-
alkyne [3+2] cycloaddition. 
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reagent. Subsequently, FLAG-modified glycoproteins were identified by western blot 
using a mouse anti-FLAG-mAb conjugated to HRP. As a control, cells that were not 
treated with the azide modified sugar were analyzed and no signal was detected for this 
sample. To further validate this approach, they selected a specific protein, the nuclear 
pore protein p62, which is known to be post-translationally modified with O-GlcNAc, 
and analyzed it from the GlcNAz-treated cells. Using this strategy, protein p62 was 
successfully labeled with the GlcNAz. 
Overall, the exciting result of this approach was that, they could analyze the O-GlcNAc-
modified proteins in the proteome. This strategy will prove useful for both the 
identification of O-GlcNAc-modified proteins and the elucidation of the specific residues 
that bear this saccharide. Additionally, this approach could also be used to derivatize O-
GlcNAc-modified proteins with a variety of other molecules.  
Direct enzymatic methods have also been used to detect O-GlcNAc posttranslational 
modifications. Hsieh-Wilson and coworkers reported an enzymatic strategy for a rapid 
and sensitive detection of O-GlcNAc posttranslational modifications.
57–60
 Their approach 
exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively 
transfer a ketone or azide onto O-GlcNAc glycosylated proteins (Figure 1.4) using a 
suitably functionalized carbohydrate precursor. Next, using a hyrdrazone or oxime 
ligation or an alkyne-azide cycloaddition reaction employing the transferred ketone or 
azide, they could site-specifically attach a biotin or a fluorophore to the proteins.  
In other work, using this same approach, Hsieh-Wilson and coworkers were able to 
rapidly visualize proteins that were present at the limits of detection of traditional 
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methods.
58
 As an advantage, this method bypasses the need for radioactive precursors and 
captures the glycosylated species without perturbing signaling pathways. They examined 
whether O-GlcNAc-modified proteins could be chemoenzymatically tagged and then 
imaged in cells. They fixed HeLa cells and cultured cortical neurons, permeabilized 
them, and then labeled them with GlcNAc-azide using the Y289L GalT-engineered 
enzyme. Next, they reacted the cells with biotin-alkyne or TAMRA-alkyne creating a 
covalent bond via azide-alkyne cycloaddition. The biotin-treated cells were further 
incubated with a streptavidin-Alexafluor488 conjugate. Results showed that O-GlcNAc-
glycosylated proteins were found in both the nucleus and cytoplasm in both type of cells. 
Moreover, they observed robust staining of proteins along neuronal processes. They 
labeled nuclear and cytosolic protein fractions from rat forebrain with azide-
functionalized O-GlcNAc and subsequently modified the material with a TAMRA-alkyne 
derivative. After enrichment of O-GlcNAc proteins by immunoprecipitation using an 
anti-TAMRA antibody, the precipitates were resolved by 1D or 2D gel electrophoresis, 
visualized by in-gel fluorescence imaging and then proteolytically digested, and 
subjected to nano-LC-MS/MS analysis. Those experiments showed minimal nonspecific 
labeling with the TAMRA-alkyne dye and also resulted in the identification of 213 
proteins, among which 67 were previously known and 146 were novel, putative O-
GlcNAc-modified proteins. Most of the proteins identified participate in neuronal 
signaling and synaptic function, which suggests important functional roles for O-GlcNAc 
in neuronal communication. Overall, this exciting method enables the direct fluorescence 
detection of O-GlcNAc proteins in gels which in turn facilitates proteomic studies and 
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extend the reach of existing technologies. This new tool for imaging O-GlcNAc-
glycosylated proteins also enables the monitoring of expression and dynamics of the 
modification in cells or tissues.  
Sortagging. Recently, the use of the enzyme sortase for labeling proteins has 
become an area of great interest. Sortase catalyzes a transpeptidase reaction between a 
specific internal sequence of a protein and an amine group present on the N-terminus of 
glycine. This method of labeling proteins has been denoted as “Sortagging”. One of the 
most common sortases is Sortase A (SrtA) derived from Staphylococcus aureus
61
 which 
recognizes the pentapeptide sequence LPXTG and cleaves the bond between the 
threonine and glycine, creating a thioester bond between a SrtA-derived cysteine residue 
and the substrate. This covalent intermediate then undergoes a subsequent aminolysis 
reaction with the N-terminus of an oligoglycine, thus creating a new covalent bond 
between the two substrates (Figure 1.5).
62
 Additional work has shown that sortagging can 
be carried out ex vivo and cell surface proteins expressing the LPXTG motif can be 
fluorescently labeled using a small fluorophore. Popp et al. showed that they could take 
HEK 293T cells expressing CD40L fused with GFP and an LPETG tag, and incubate 
them with sortase and a TAMRA labeled oligoglycine. They found that such proteins 
could be labeled ex vivo.
63
 This type of ex vivo labeling can be performed using a wide 
variety of cell types as well. 
Tanaka et al. added a sortase recognition tag, LPETGG to osteoclast differentiation factor 
(ODF), which is expressed as a cell membrane protein and transfected it into HEK 293T 
cells. They showed that upon incubating the cells with sortase and biotin connected to a 
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three-glycine oligomer, they were able to biotinylate on the surface of the cell. They 
expanded on this initial observation by demonstratng that this approach can work in 
multiple cell types, including CHO and HeLa cells, and that large molecules, such as 
eGFP containing a five glycine N-terminus, can be conjugated to the protein on the cells 
surface.
64
 Strijbis et al. showed that labeling can be done in both Saccharomyces 
cerievsie and in the lumen of the ER or cytosol of the HEK293T cells.
65
 
Recently, significant progress has been made in creating protein conjugates using SrtA to 
facilitate covalent attachment. Harrenga et. al. were able to covalently link antibody Fab 
fragments to a small molecule fluorophore using SrtA at μM concentrations. In this case, 
they linked the light chain of L19 Fab fragment, which is specific for fibronectinED-B 
and is a promising target for cancer therapies, to a small peptide containing the 
fluorophore DY-647. Additionally their work showed that ε-amino groups on lysines can 
also react causing undesirable protein aggregates. They found that these side reactions 
were dependent on both the position of the residue within the tertiary structure and on the 
pH of the reaction.
66
  Other examples of creating protein-molecule conjugates include  
 
Figure 1.5. Schematic representation of sortase-mediated ligation. First, sortase A 
recognizes a LPXTG sequence within a polypeptide and forms a covalent acyl-enzyme 
intermediate. Next, the thioester intermediate is attacked by the N-terminal amino group 
of a (G)3-containing probe and forms a native peptide bond between the two. 
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using sortagging to site-specifically PEGylate proteins,
67
 to create site-specific protein-
lipid conjugates,
68
 and to construct peptides and glycosylphosphatidylinositol chimeras.
69
  
Sortase has also been used in peptide synthesis to cyclize peptides to create macrocyclic 
peptides and glycopeptides.
70
 
In addition to small molecule-protein conjugates, other types of protein conjugates have 
also been designed. Buti et al. were able to immobilize a library of proteins from an 
Influenza virus onto glass plates using SrtA. In particular, they showed that the LPETG 
motif could be appended onto the C-terminal ends of proteins which could in turn be site-
specifically and covalently attached to the surfaces of glass slides that had been 
derivatized with a triglycine peptide. Once the proteins were immobilized on the glass 
plate, they were probed with H1N1 antiserum. Bound H1N1 antibodies were then 
visualized with a secondary antibody coupled to Alexa-647, whose fluorescence intensity 
could be quantified. By looking at the difference in fluorescence intensities, they were 
able to discern which proteins from the influenza virus were antigens for the H1N1 
antiserum. 
71
  This not only demonstrates that proteins can be efficiently conjugated to 
surfaces using sortase but also that these protein arrays can then be used for probing 
specific biological interactions. 
Another application of sortagging is for the creation of protein-protein conjugates. Witte 
et al. showed that N-to-N and C-to-C protein conjugates could be made using a variation 
of sortagging. By expressing a protein with triglycine N-terminus and then incubating 
that protein with SrtA and a small LPETGG peptide incorporating either an azide or 
alkyne, a bioorthogonal handle was added to the N-terminus of proteins. To create N-to-
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N protein-protein conjugates they reacted two complimentary handles to prepare the 
desired dimer. To create C-to-C protein conjugates, the target protein was expressed to 
contain a C-terminal LPETGG sequence that was then reacted with an azide- or alkyne-
functionalized triglycine peptide.  Using this method Witte et al. prepared homodimeric 
N-to-N fusions of ubiquitin vinylmethylester (UbVME). They were able to show that 
UbVME was able to still bind its target protein, in this case ubiquitin carboxyl-terminal 
hydrolase isozyme L3 (UCHL3). Because the dimer UbVME was able to bind two 
UCHL3 proteins, this confirmed that the UbVME retained its biological activity. 
Similarly they also constructed C-to-C fusions using a heavy chain antibody, VHH, 
which binds to GFP. They created this protein conjugate as described above and were 
able to confirm that it retained biological activity based on the ability of the dimer to bind 
two GFP proteins. This method demonstrates how sortagging can be used to create 
protein dimers without comprising the biological activity of the proteins being 
conjugated.
72
 
One of the problems with using sortase as a labeling catalyst is that the reaction is 
reversible; the glycine residue that is released in the first step can act as nucleophile to 
reform the original species. This means that an excess of nucleophile is needed to drive 
the reaction toward product formation. This is especially problematic if the nucleophile is 
costly or labor intensive to prepare. To address this problem, Williamson et al. developed 
a depsipeptide, where the amide bond between the threonine and the glycine of the 
LPETG sequence was replaced with an ester. Their hypothesis was that the peptide would 
still be a substrate for the enzyme but that the alcohol product could not efficiently 
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undergo the reverse reaction. They used this peptide first to label a small peptide with the 
sequence GGSEFG and showed they were able to get almost 100% conversion to product 
using a 1:1 ratio of the two peptides. They were then able to use this method to 
fluorescently label both human mannose binding protein and mouse pumilio-2 Puf RNA-
binding domain at the N-terminus containing a glycine. Significantly, it was possible to 
achieve quantitative labeling of the protein using only 1.5 equivalents of the 
corresponding LPETG-dansylated peptide.
73
 This strategy overcomes one of the 
limitations of using sortagging in that proteins can be labeled at their N-termini without 
having to use excess amounts of the protein to obtain sufficient levels of labeling. 
In summary, sortagging offers a versatile and powerful tool for the site-specific labeling 
and modification of proteins. Sortagging can be accomplished by directly conjugating 
proteins to surfaces or other biologically relevant molecules or it can be used to attach 
bioorthogonal functional groups which can then be used to perform a secondary reaction. 
As research continues to enhance and refine sortagging, its utility will undoubtedly 
increase. 
Transglutaminase. Transglutaminases are a family of enzymes that catalyze acyl 
transfer reactions between the carboxamide groups of glutamine residues (present in 
flexible loops in proteins) to a wide variety of unbranched primary amines, commonly the 
-amino group of lysine.  Due to their promiscuity with regard to the primary amine 
substrate, transglutaminases are attractive catalysts for generating protein conjugates 
(Figure 1.6).
5
  
 24 
 
One of the ways in which transglutaminases can be used to create therapeutic proteins is 
through the preparation of antibody-small molecule conjugates. Jeger et al. were able to 
use a bacterial transglutaminase to covalently link antibodies generated against tumor 
antigens with small molecular chelators that can deliver metals for use as imaging agents. 
Specifically they conjugated anti-L1-CAM mAb chCE7 antibody and a commercially 
available anti-CD20 antibody, rituximab. Initial experiments to label the antibodies using 
transglutaminase failed even though both antibodies had glutamine residues which should 
have reacted with the enzyme. It was not until the authors employed a mutant form of the 
antibodies that conjugation was observed. When this was investigated, it was concluded 
that since the mutation changes the ability of the antibody to be glycosylated and since 
antibody glycosylation caused the loop containing the targeted glutamine to be in a less 
accessible conformation, the efficiency of modification is highly dependent on the  
 
Figure 1.6. Schematic representation of site-specific labeling of proteins using 
transglutaminase (TGase) catalyzed ligation of cadaverine-functionalized probes (green 
star) to cell surface proteins recombinantly fused to a Q-tag (yellow rectangle). TGase 
site-specifically incorporates a probe into the protein by ligating the glutamine of the Q-
tag to the amine probe and forms a new amide bond between the two while releasing 
ammonia into solution. 
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accessibility of the  glutamine which is modified by the enzyme. They were able to 
follow-up on these findings by treating the antibody with a deglycosylase enzyme, N-
glycosidase F, and showed that once the antibodies were deglycosylated, they would then 
react with transglutaminase. In this way they were able to generate site-specific 
conjugates of the antibodies.
74
 
In addition to creating small molecule-protein conjugates, another area of intense 
research has been in using transglutaminases to create protein polyethylene glycol (PEG) 
conjugates. One of the drawbacks to using transglutaminase to PEGylate proteins is that 
the promiscuity of the enzyme toward glutamine residues makes it difficult to predict the 
site(s) of modification. This requires using MS method to determine the site of 
conjugation which can be laborious although progress is being made in this field.
75
 
Additionally efforts to lipidate proteins using transglutaminase have been reported. 
Recently Abe et al. reported a new substrate for a Streptomyces mobaraensis 
transglutaminase which can be used to attach lipids to proteins. This substrate consists of 
an eight amino acid sequence (GGGSLLQG) that is then also attached an alkyl chain. 
This small peptide-alkyl chain molecule can then act as one of the substrates for the 
enzyme and be attached to a lysine residue via the enzymatic reaction. In this way a lipid-
like modification can be introduced onto various proteins. They used this new substrate to 
create lipid conjugated eGFPs. The eGFP contained the enzyme recognition sequence 
MRHKGS, where the lysine acted as the acyl donator, and the lipid substrates ranged 
between 14 and 18 carbons long. They were then able to show that these protein 
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conjugates could anchor into the cellular membrane and that the degree on membrane 
anchoring increased with the length of the alkyl chain.
76
 In this way they were able to 
effectively create protein lipid conjugates using transglutaminase and employ these 
conjugates to study cellular systems.
76
 
Beyond the creation of protein-small molecule conjugates, work has also been performed 
to create site-specific protein conjugates. Nagamune et al. used a transglutaminase from 
Streptomyces mobaraensis to create eGFP-dihydrofolate reductase(DHFR) protein 
conjugates. This was accomplished by including a pentaglycine linker at the N-terminus 
of eGFP and adding a myc tag, which contained the glutaminase recognition sequence, to 
DHFR. They were then able to show that they could create a covalent linkage between 
the glycine residue of the N-terminus of eGFP and a glutamine residue near the N-
terminus of DHFR.  This shows that transglutmaninase can be used to create hetrodimeric 
protein conjugates. .
77
 
Transglutaminase can also be used to covalently attach proteins to a solid support. 
Tominaga et al. were able to conjugate  Escherichia coli alkaline phosphatase (AP) to 
casein-grafted agarose beads. They were able to do this site-specially by adding the 
TGase recognition tag at the N terminus of AP. Importantly they found that immobilized 
AP had a very similar specific activity when compared to the soluble enzyme.
78
 
Finally, transglutaminases can be used for ex vivo labeling as well. Lin et al. used this 
enzyme to label proteins within living cells. Of particular significance, they used a guinea 
pig transglutaminase (gpTGase) because it exhibits a high specificity for its glutamine 
containing protein substrate but also a high promiscuity for the amine substrate. In this 
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way they could specifically label proteins with what was termed as a Q-tag. Three 
different amino acid tags were examined including PNPQLPF, PKPQQFM, and 
GQQQLG, and all were found to be efficiently labeled by gpTGase with a cadaverine-
biotin or Alexa568-containing analogue. They showed that this labeling could also be 
accomplished ex vivo by labeling cyan fluorescent protein containing a cell surface 
targeting sequence using their transglutaminase method. Finally they examined how this 
method could be used to create an assay for difficult to assay targets. They chose to assay 
for the presence of the NF-κB homodimer, which can form in the presence of DNA 
damage but is difficult to easily quanitify. They showed that they could use their 
transglutaminase method to label NF-κB with a benzophenone spermine analogue, which 
acts as a photoaffinity reagent, creating a covalent bond between the protein subunits 
upon photolysis. The presence of the homodimer was easily detected using via SDS-
PAGE. This work highlights the utility of transglutaminase for protein labeling since it 
can be used in a site-specific manner to function in both in vitro and ex vivo 
environments.
79
 Overall, transglutaminase manifests high potential for use as a site-
specific labeling agent. While these enzymes can be somewhat non-selective, ways to 
overcome this limitation have been developed. 
Protein farnesyl transferase (PFTase). In nature, numerous proteins are 
posttranslationally modified on a sulfur atom present in a cysteine residue at the C-
termini of proteins by protein farnesyl transferase (PFTase). PFTase employs farnesyl 
pyrophosphate (FPP) as its natural substrate to transfer a farnesyl group to the cysteine of 
a “CaaX-box” tetrapeptide sequence (C is cysteine, a is an aliphatic amino acid, X is one 
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of a variety of amino acids) (Figure 1.7A&B). The reaction can also be performed in 
vitro. PFTase is promiscuous in the nature of its substrates, in that it can tolerate a variety 
of CaaX sequences as well as some modifications to the FPP structure. Recently, a 
number of groups have used this feature to site-specifically modify proteins using 
analogues of FPP. Various isoprenoid surrogates containing azide,
80
 alkyne,
81
 
aldehyde,
40,82
 or 1,3-diamino-phenyl groups have been synthesized and shown to be 
successfully used by PFTase. The PFTase-catalyzed transfer of synthetic alkyne- or 
azide-functionalized farnesyl analogues in combination with the Huisgen [3+2] 
cycloaddition or Staudinger ligation has been used for site-specific fluorophore labeling 
and oriented immobilization of proteins.
80
 Interestingly, CaaX-box sequences such as  
 
Figure 1.7. (A) Structures of farnesyl diphosphate (FPP), farnesyl dihydro azide 
diphosphate (FPP-dihydro azide) farnesyl aldehyde diphosphate (FPP-aldehyde) and 
farnesyl-aldehyde-alkyne diphosphate (FPP-bifunctional) as examples of FPP analogs. 
(B) Schematic representation of prenylation of a protein containing a CaaX-box 
positioned at its C-terminus with aldehyde-containing analog (FPP-aldehyde) to yield the 
prenylated product. (C) Chemoenzymatic site-specific tagging of proteins by FPP-
aldehyde using PFTase followed by capture of the aldehyde-functionalized protein in the 
crude cell lysate via hydrazide functionalized beads. The immobilized protein is then 
released into solution using aminooxy-containing reagents to yield fluorescently labeled 
or PEGylated protein.  
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CVIA, or CVIM can be genetically encoded to the C-termini of many proteins making 
them efficient substrates for PFTase. 
In early work, Poulter and coworkers used this strategy to immobilize protein on solid 
surfaces.
7
  They synthesized alkyne-functionalized FPP and incorporated the alkyne 
moiety into the proteins (GFP and GST) at their C-termini using PFTase. A glass-slide 
was functionalized with an azide group and covalent immobilization of the proteins to the 
slide was subsequently achieved using copper (I)-catalyzed [3+2] cycloaddition. In 
subsequent work they synthesized a collection of FPP analogues containing either alkyne 
or azide moieties and analyzed their kinetic parameters (KM and kcat) as substrates for 
PFTase.
83
 Out of the eleven synthetic analogs, two of them gave steady-state kinetic 
parameters (KM and kcat) very similar to those of the natural substrate FPP. 
Waldmann and coworkers used the PFTase strategy to modify proteins including H-, N-, 
and K-Ras GTPases, which are important in cellular signaling and are among the human 
oncogene products, at their C-termini with a farnesyl group. Subsequently they used thiol 
functionalized surfaces to react photochemically with the alkenes present in the farnesyl 
groups introduced into proteins as noted above. In this way, proteins were covalently 
immobilized in a site-specific manner under mild conditions in about 10 minutes.
84
  
In other work, they developed several azide-, biotin- and diene-functionalized analogues 
of FPP. After kinetic analysis of the enzymatic reactions with PFTase, they concluded 
that all of these new substrates, except the biotin-containing analogue, can be transferred 
onto proteins that possess a CaaX box.
85
 Subsequently, proteins functionalized with azide 
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or diene groups were successfully modified by Staudinger ligation or Diels–Alder 
cycloaddition.  
Distefano and coworkers have exploited the PFTase-catalyzed reaction for a number of 
applications. In early work, they synthesized an analogue of geranyl diphosphate 
containing an azide group at C-8 and showed that PFTase could transfer that shorter 
isoprenoid onto a peptide containing a CaaX box.
86
  The resulting peptide was further 
modified by selective Staudinger ligation between the peptidyl azide and a suitable 
triphenylphosphine derivative; they also found that a longer azide-containing analogue 
based on FPP could be similarly transferred and reacted.
87
 One problem with these azide-
containing analogues is that they undergo thermal rearrangements to produce a mixture of 
isomers due to the allylic azide moiety. Thus, proteins modified with these reagents can 
potentially produce similar mixtures abrogating one of the advantages of site-selective 
modification. To avoid this problem, Xu et al. synthesized a dihydroazide analogue based 
on geraniol that replaces the allylic azide with an aliphatic one and demonstrated that the 
resulting molecule is an alternative substrate for PFTase.
88
 That work was extended by 
synthesizing a similar analogue based on FPP. In this latter case, the analogue was used 
to tag GFP appended with a CaaX box with an azide that was subsequently used to 
immobilize the protein onto alkyne-functionalized agarose beads. Importantly, this two-
step enzymatic modification/immobilization sequence was accomplished with both 
purified protein as well as target present in crude E. coli extract at levels as low as 1% of 
total protein.
80
  The versatility of the proteins functionalized with azides incorporated via 
PFTase was further demonstrated in a subsequent publication where protein-DNA 
 31 
 
conjugates were prepared.
89
  In that case, a simple GFP-DNA species was first generated 
by Cu-catalyzed click reaction between GFP-azide and an oligonucleotide equipped with 
an alkyne. Upon hybridization with a second complementary oligonucleotide containing 
a Texas Red fluorophore, FRET was observed confirming the production of the desired 
product. That was extended to the preparation of a more complex protein-DNA 
tetrahedron composed of four oligonucleotides and four GFP molecules assembled in an 
analogous manner which was characterized by a combination of electrophoretic and 
single molecule techniques. The ability to create nanoscale sized protein-based objects 
with defined architecture highlights the utility of this approach. Recently this approach 
for preparing protein-DNA assemblies has been extended by using the related strain-
promoted azide-alkyne cyclization reaction. By incorporating a dibenzocyclooctyne 
moiety into the oligonucleotide, a number of proteins were conjugated to DNA including 
GFP, mCherry, GIP and HIV NC.
90
  GFP-mCherry heterodimers were also prepared 
using this strategy by conjugating complementary alkyne-modified DNA 
oligonucleotides to the two respective protein-azides followed by hybridization. 
In performing the Cu-catalyzed click reaction, it has been noted that lower levels of 
background reaction are often obtained when the azide component is the one used in 
excess.
91
 Accordingly, Distefano and coworkers prepared an alkyne-containing analogue 
using a GPP scaffold and showed that it was a good alternative substrate for PFTase.
81
  
They then showed that more nonspecific immobilization occurred when unfunctionalized 
GFP was reacted under typical click reaction conditions with alkyne functionalized 
agarose beads compared to a similar experiment with azide-containing beads. Based on 
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those results, GFP-alkyne, produced via PFTase-catalyzed incorporation of the alkyne-
containing analogue noted above, was labeled with excess Texas Red azide in high (81%) 
yield. FRET experiments allowed a distance of 37 Å between the GFP and Texas Red 
fluorophores to be measured which was in good agreement to the distance determined 
from computer modeling. These experiments highlight the utility of this approach for 
selective labeling for biophysical experiments. Additional work with a longer alkyne-
containing isoprenoid diphosphate based on FPP showed that this new compound was an 
efficient substrate for both PFTase and the related enzyme protein 
geranylgeranyltransferase opening up the possibility for transferring larger probes.
92
  
Conversely, one problem concerning the addition of isoprenoids to proteins is that this 
modification increases the hydrophobicity of the protein and thereby decreases its 
solubility. Accordingly, Wollack et al. prepared a more polar PFTase substrate analogue 
consisting of a single isoprenoid unit linked to an alkyne.
93
 While this analogue was 
incorporated significantly less efficiently (relative to the natural substrate, FPP), it was 
still possible to achieve essentially quantitative modification of mCherry and Hcp using 
higher amounts of enzyme. Interestingly, modification of Hcp with the C15-alkyne 
analogue resulted in a protein that was insoluble; in contrast, the C5-alkyne modified 
protein was completely soluble highlighting the utility of this less lipophilic modification. 
In that same report, the authors also demonstrated that the three C-terminal residues 
following the cysteine residue of the CaaX box could be proteolytically removed by 
treatment with carboxypeptidase Y after a peptide or protein was modified with the C5 
analogue. This means that while PFTase-catalyzed protein modification is not traceless, 
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the size of the tag remaining in the final protein product can be limited to a single 
prenylated cysteine residue. This has important implications in the area of protein 
therapeutics where the antigenicity of any added element may prove deleterious. 
Recently, FPP analogues that incorporate aldehyde functionality have also been 
developed. Rashidian et al. showed that a simple aldehyde-containing analogue of FPP 
could be used to incorporate an aldehyde into GFP. The resulting aldehyde was used to 
either immobilize the protein or to label it with a fluorophore via oxime formation.
82
  A 
subsequent study demonstrated that such aldehyde-modified proteins could be prepared 
and captured from crude extract by incubation with a hydrazide resin. The hydrazone 
linkage, though stable, is not irreversible and can be converted to a more stable oxime 
linkage. The authors used this to release, and simultaneously label, the captured protein 
into the solution by elution with an aryl amine  catalyst and an alkoxyamine.
40
  Using this 
strategy, the fluorescently labeled or PEGylated GFP was obtained without prior 
purification of the starting protein (Figure 1.7C). A PEGylated form of glucose-
dependent insulinotropic polypeptide (GIP), a protein with potential as a therapeutic 
agent for diabetes, was also prepared in an analogous fashion. This approach for protein 
modification could be particularly useful for large-scale production of protein conjugates 
for therapeutic or industrial applications. 
Biotin ligase. Biotin ligases catalyze the attachment of biotin groups onto proteins 
and other biomolecules (Figure 1.8). These enzymes possess several useful attributes for 
protein labeling. They can be used to site-specifically modify proteins by genetic fusion 
of a ligase recognition domain onto the target protein of interest. Enzymatic labeling of 
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the protein with biotin allows for the subsequent use of avidin (and related proteins) 
resulting in the formation of very strong non-covalent conjugates because of the low 
dissociation constant between biotin and avidin (~10
-15
 M).
94
 
A number of different groups have used biotin ligase to site-specifically modify proteins. 
One common method is to use the Escherichia coli biotin ligase, BirA, to attach biotin to 
proteins. BirA is convenient to use because it attaches biotin onto the lysine of a small, 
15-residue, acceptor peptide (AP). This sequence, GLNDIFEAQKIEWHE, was 
specifically developed as the minimalist structural element that can be efficiently 
recognized by BirA. The Ting group has adapted this method for preparing a wide range 
of biotinylated proteins which can be used for a variety of applications. In one study the 
AP recognition site was attached to a cyan fluorescent protein (CFP) that contains a 
transmembrane domain (TM) which should traffic the protein to the cell surface of HeLa 
cells. They found that they could biotinylate the protein using BirA and then conjugate it  
 
Figure 1.8. Schematic representation of targeting different species such as quantum dots, 
fluorophors or antibodies to surface proteins in living cells using biotin ligase. The 
acceptor peptide (AP) tag is genetically encoded either at the C- or N- terminus of a 
protein. Biotinylation of AP is performed by adding recombinantly expressed biotin 
ligase (BirA), ATP and biotin (B) to the cell medium. After removing excess biotin by 
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washing, fluorescently labeled streptavidin is added to visualize the  biotinylated surface 
proteins.   
to either a stepavidin-Alexa568 dye or a streptavidin-quantum dot. They determined that 
the streptavidin-quantum dot gave a better signal then the Alexa568 dye did. They also 
found that they could label epidermal growth factor receptor using this same method and 
image it in a similar fashion. They also looked to see if this work would extend to 
primary cells as well. Hippocampal neurons were transfected an AP tagged GluR2 
protein which is a subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMPA) receptor. They were able to analysis AMPA receptor trafficking by monitoring 
for fluorescence.
95
  More recent work has focused on refining this method so that the 
quantum dots are smaller and only contain monovalent streptavidin attachments, which 
can then better label site-specific biotinylated proteins in cells.
96
  
Ting and coworkers also explored whether different biotin ligases could catalyze the 
attachment of biotin analogues that contain alternative functionality suitable for 
bioorthogonal reactions. A panel of eight different biotin ligases was screened for activity 
using an array of biotin analogues leading to the discovery that a biotin ligase from 
Pyrococcus horikoshii could act on analogues that contained either an azide or alkyne 
group. They were then able to label a domain of a biotin acceptor protein with an azide 
derivative of biotin and conjugate that protein to a FLAG peptide via the Staudinger 
ligation. In this way they were able to show that biotin ligases could be used to attach 
bioorthogonal handles to proteins.
97
 
Biotin ligase has also been used to prepare modified proteins suitable for studies of 
protein-protein interactions. In one example, an AP peptide with a high KM for BirA was 
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engineered and incorporated into FKBP. The interaction between that protein and a BirA-
FRB fusion was then examined. Consistent with the fact that FRB and FKBP interact 
only in the presence of rapamycin, they observed that labeling of the AP domain by the 
BirA-FRB fusion occurred only in the presence of both biotin and rapamycin but not in 
the absence of the rapamycin. These experiments were performed both in vitro and ex 
vivo emphasizing the utility of their approach for monitoring protein-protein interaction. 
To expand the utility of this method they also examined the interaction of Cdc25C with 
14-3-3ε phosphoserine/threonine binding protein. Cdc25C was produced as a AP fusion 
and 14-3-3ε was fused to BirA; both were expressed in HEK cells. Importantly, 
biotinylation was observed when a wild type-like Cdc25C was used. However, when a 
non-phosphorylatable Cdc25C mutant was employed, no biotinylation was seen, 
suggesting that the interaction between Cdc25C and 14-3-3ε is phosphorylation 
dependent.
98
   
Sueda et al. used a biotin ligase from Sulfolobus tokodaii to modify proteins for imaging 
applications.
99
  This enzyme biotinylates the lysine residue of a biotin carboxyl carrier 
protein (BCCP), and interestingly, upon biotinylation, forms a tight non-covalent 
complex between the ligase and BCCP. Sueda et al. used this unique property to modify 
proteins by creating fusion proteins between the target of interest and a truncated version 
of the BCCP protein. They found that the biotin ligase would accept a truncated 69-
residue polypeptide derived from BCCP. A fusion was then created between this tag and 
the bradykinin B2 receptor (B2R), which is a transmembrane protein. They then 
expressed this protein in HEK293 cells, and incubated these cells in the presence of 
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Sulfolobus tokodaii biotin ligase that had been labeled previously with four fluorescein 
molecules. Fluorescent labeling was observed around the cell membrane, confirming that 
the N-terminus is localized on the outer side of the plasma membrane. In a second 
experiment, a C-terminal B2R fusion protein with the BCCP tag was expressed in 
HEK293 cells together with a GFP-biotin ligase fusion protein and were again able to 
detect fluorescence at the cell membrane. In this case, fluorescent labeling occurred 
because the C terminus of the B2R protein positioned on the inner side of the membrane 
was accessible to the GFP-biotin ligase fusion produced intracellularly. As a final remark, 
it should be noted that while most of the research to date with biotin ligases has focused 
on ex vivo imaging, its site and substrate specificity makes it an attractive tool for 
creating site-specific protein conjugates for other applications as well. Examples of this 
will undoubtedly be reported in the future. 
Lipoic acid ligase. Lipoic acid ligase catalyzes the acylation of lysine residues of 
proteins  with lipoic acid(Figure 1.9). Significant effort has gone into the development of 
this enzyme for use in site-specific labeling. Fernández-Suárez et al. designed and 
synthesized ten different lipoic acid analogues functionalized with either an azide or 
alkyne and tested them as alternative substrates for  E. coli lipoic acid ligase (LplA). 
While all analogues exhibited some degree of activity, they focused on an azide-
containing analogue due to its superior activity. Additionally they sought to develop a 
smaller peptide substrate to minimize the size of the fusion that would have to be used to 
decrease the possibility of interference with the function of protein under study. By 
analyzing the structure of E2p, a naturally lipoylated protein, they were able to design a 
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series of small peptides, which mimicked the β-turn where the lipoylated lysine residue is 
located on the protein. After further refinement the tag was reduced to just  22 amino 
acids (LAP). They were then able to show that a CFP-LAP fusion could be labeled with a 
small fluorophore in human embryonic kidney (HEK) cell lysates. Additionally they 
added a transmembrane domain to the CFP-LAP protein and were able to show that they 
could label the protein in living HEK cells and get conjugation using a cyclo-octyne 
fluorophore, either Cy3 or Alexafluor568. Also a LAP tag was added to the low-density 
lipoprotein receptor (LDLR) and visualized using this lipoic acid labeling methodology. 
Finally they tested the cross compatibility of using both lipoic acid labeling and biotin 
ligase. They transfected one population of cells containing LAP-LDLR and a different 
population containing an AP fused epidermal growth factor receptor (AP-EGFR). Once 
the cells were transfected the population were mixed together and subjected to both lipoic 
acid ligase and biotin ligase conjugation conditions. They saw that only cells containing 
AP-EGFR showed streptavidin conjugation and cells expressing LAP-LDLR showed 
only Cy3 labeling. Finally cells were transfected with both types of proteins and it was 
shown that they could conjugate them with the different bioconjugation techniques.
100
 
The use of other lipoic acid analogues for selective protein labeling has also been 
investigated. Through analysis of the LplA  crystal structure, a tryptophan and a 
glutamate residue in the lipotate binding pocket of the enzyme were identified that when 
mutated to smaller residues allow the mutant enzymes to accept a wider range  of lipoic 
acid analogues. Using that strategy, it was possible to create a mutant of LplA that 
accepts lipoate analogues that incorporate fluorescent moieties including Pacific Blue or 
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7-hydroxycoumarin. Thus, fluorescently labeled proteins could be produced ex vivo 
without having to perform a secondary conjugation reaction.
101,102
 These mutant enzymes 
were also used to incorporate azide analogues containing longer spacers, which were then 
conjugated ex vivo to more red-shifted fluorophores, which have a higher signal to 
background ratio when compared to the other fluorescent moieties excited at lower  
 
Figure 1.9. Schematic representation of protein labeling using lipoic acid ligase (LplA). 
(A) Natural ligation reaction catalyzed by LplA. (B) Site-specific labeling of a cell-
surface protein performed by fusion of a 22 residue LAP domain on the protein of 
interest followed by enzymatic transfer of an azide-containing lipoic acid analogue. The 
azide can be used for further modification via a [3+2] azide-alkyne cycloaddition reaction 
or Staudinger ligation. (C) Engineered coumarin ligase produced by mutagenesis of LplA 
can be used to site-specifically modify a protein with a coumarin probe. This can be used 
to directly incorporate fluorophores to mammalian cells.   
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wavelengths. Overall, these developments improved the ability to image the locations of 
proteins within living cells. More recently, Ting and coworkers have applied this lipoic 
ligase tagging technique to examine protein-protein interactions in experiments similar to 
those described above with biotin ligase. A lipoic acid peptide tag was created with a 
high KM value such that the peptide would only bind when the enzyme was held in close 
proximity via non-covalent forces. This method is implemented by fusing the lipoic acid 
ligase enzyme to one target protein and then fusing the peptide tag to a putative binding 
partner. This technique was employed to study the rapamycin-dependent binding of 
FKBP and FRB as well as to probe the interaction between the transcription factors Jun 
and Fos. They also used this technique to study the interaction between neuroligin-1 and 
PSD-95, which is involved in excitatory synapse formation and maturation. These 
examples illustrate the versatility of the lipoic acid ligase method for labeling proteins for 
the analysis of many different types of protein-protein interactions ex vivo.
103
   
The lipoic acid ligase labeling method has also been adapted to work with lipoic acid tags 
that contain aryl aldehydes and aryl hydrazines.
104
  Ting and coworkers synthesized 
lipoic acid derivatives containing an aryl aldehyde and an aryl-hydrazine and screened 
these two analogues against a panel of lipoic acid ligase mutants each containing a 
mutation at a tryptophan residue at the position 37. They found that a tryptophan to 
isoleucine mutation significantly increased the extent of conversion when using these 
alternative substrates compared to that obtained with the wild type enzyme. This mutant 
enzyme was then used with the aforementioned analogues to label neurexin-1β and then 
react it with complementary aldehyde- and hydrazine-containing reagents, which contain 
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either a fluorophore or a chromophore. These reactions were performed ex vivo using 
HEK cells. In a final set of experiments, they used this method to image single low 
density lipoprotein receptors on the surface of COS7 cells.  
Overall lipoic acid ligase is a powerful tool for creating site-specific protein conjugates. 
As was noted above, in reference to biotin ligase, work using LplA has also centered 
around the creation of protein-fluorophore conjugates for monitoring cellular processes 
ex vivo and for probing protein-protein interactions. However, this enzyme has significant 
potential for use in creating other types of protein conjugates including protein-DNA, 
protein-drug, and protein-protein chimeras. It is likely that such applications will be 
reported soon. 
N-myristoylation. Protein N-myristoylation involves the acyl transfer of 
myristate from myristoyl-CoA to the amino group of an N-terminal glycine residue of a 
protein to form an amide bond; The enzyme that performs this modification, N-myristoyl 
transferase (NMT), recognizes the sequence GXXXS/T where X can be a variety of 
amino acids and is found in eukaryotes, and very recently it has been observed in 
prokaryotes as well. Approximately, 0.5% of proteins in eukaryotes are myristoylated. 
Protein N-myristoylation is thought to occur during protein translation although recent 
evidence indicates that it can also occur post-translationally. Some important examples of 
myristoylated proteins include the Src family of tyrosine kinases, HIV-1 matrix protein, 
HIV-1 Gag and the ADP-ribosylating factors (ARFs). Because of the involvement of 
these proteins in various diseases, NMT has considerable potential as a therapeutic target. 
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Tate and coworkers, used the substrate promiscuity of NMT to site-specifically label 
recombinant proteins with azide and alkyne derivatives of myristate-CoA both ex vivo 
and in vitro.
105,106
 They used a well-characterized and widely-used NMT cloned from 
Candida albicans to transfer alkyne- and azide-containing myristate analogues that 
incorporated the bio-orthogonal groups at the distal end of the lipid. First they evaluated 
the substrate efficiency using a model peptide substrate GLYVSRLFNRLFQKK-NH2 
containing a canonical N-terminal myristoylation motif. Incubation of the peptide with 
either of the two acyl-CoA analogs in the presence of a catalytic quantity of NMT for 2 h 
resulted in complete transfer of the acyl group to the target peptide.  
Next, Escherichia coli engineered to co-express NMT and a substrate protein, 
PfARF1, was used for ex vivo analysis. The bacteria cells were transfected with a pair of 
plasmids encoding the substrate protein and the NMT together with orthogonal antibiotic 
resistance genes. The cells were incubated with one of the aforementioned analogues and 
induced by addition of IPTG to express both proteins. Importantly, this strategy  
 
Figure 1.10. Schematic representation of ex vivo protein labeling via N-
myristoyltransferase (NMT) using an Escherichia coli co-expression system. Cells are 
incubated with a myristic acid analog and plasmids encoding NMT and a recombinant 
target protein. Within the cells, the analog is converted to its corresponding CoA 
derivative and incorporated into the desired target protein using NMT. Tagged proteins 
may then be captured using Staudinger ligation or [3+2] cycloaddition to introduce a 
secondary label for subsequent applications.   
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capitalized on endogenous Escherichia coli enzymatic activity to convert the myristate 
analogues to the corresponding -CoA derivatives. After metabolic incorporation, the cells 
were lysed and reacted with bio-orthogonal biotin reagents to detect the tagged protein 
including azide-, alkyne- and triarylphosphine-containg compounds. Analysis by SDS-
PAGE and subsequent detection with streptavidin-HRP showed that this method could 
specifically tag PfARF1 when labeling was performed under these conditions within the 
cell. Overall, this method provides a convenient and potentially general method for N-
terminal recombinant protein labeling.  
Conclusion.  
In summary, a number of enzymes have been studied and employed for site specific 
labeling of proteins. Each of these enzymes has advantages and disadvantages ranging 
from substrate specificity to size of the tag added, enzyme kinetics, and site of 
modification. While all these different factors need to be taken into account, this also 
gives researchers a number of different options when determining which type of site-
specific enzyme to use. Table 1.1 describes a very useful summary of a number of these 
different parameters for the various enzymes. These methods have been designed so that 
researchers can now choose between whether they want to label at the N-terminus, C-
terminus or somewhere in the middle of the protein. The methods offer a diverse array of 
labeling approaches that can be performed to modify proteins: everything from 
modification with small molecules all the way up to modification with a protein.  While 
there has been much progress in way of site specific labeling, there still remains much 
work to be done so that these processes can be more widely utilized. Many of these 
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methods have been used primarily in studies of in vitro and ex vivo processes but have yet 
to be used in biotechnological processes. The versatility and robustness of many of these 
reactions make them ideal for creating protein conjugates that can be used in a wide 
variety of medical and technological applications. Hopefully with these diverse and novel 
techniques researchers can begin to more fully understand many biological processes and 
unlock fundamental questions. These new site-specific labeling methods should also help 
in the development of more powerful and effective drugs against a host of conditions and 
diseases.  
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Table 1.1. Kinetic parameters of different enzymes used for protein labeling. 
 
Enzyme Encoded tag peptide kcat           KM         kcat/KM 
min
-1  
     µM      min
-1
 
µM
-1
 
Site of the 
peptide 
 
Formylglycine 
generating enzyme 
CxPxR or 13-mer 
LCTPSRGSLFTGR 
 
-              -                - C or N 
terminus 
Phosphopantetheinyl  
transferase 
ACP, PCP or ybbR tags (11 
mer: DSLEFIASKLA; 13 
mer: VLDSLEFIASKLA; 17 
mer: 
GSQDVLDSLEFIASKLA) 
 
(for 500 µM ybbR 13 mer 
and biotin-CoA) 
14.7       60.8         0.242 
C or N 
terminus or 
flexible loops 
Sortase LPXTG 
 
16.2      5,500           0.003 Any section 
Transglutaminase XXQXX 
 
45          7                  6 Any section 
Farnesyl trasferase CaaX (for yPFTase and 2.4 µM 
CVIA) for FPP: 
31.2      1.71     18.2 
for FPP-aldehyde: 
7.8       1.87      4.17 
 
 
Biotin ligase GLNDIFEAQKIEWHE (for Escherichia coli 
biotin ligase and biotin) 
9.6          4.2            2.3 
 
C or N 
terminus 
Lipoic acid ligase GFEIDKVWYDLDA 2.88              -             - C or N 
terminus or 
flexible loops 
     
 
  
 46 
 
Chapter 2. Selective Labeling of Polypeptides Using Protein Farnesyltransferase via 
Rapid Oxime Ligation 
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An aldehyde-containing alternative substrate for protein farnesyltransferase was 
prepared and shown to be enzymatically incorporated into a peptide and a protein. 
The protein was subsequently immobilized onto aminooxy-functionalized agarose 
beads or labeled with a fluorophore. This method for protein modification provides an 
alternative to the commonly employed Cu(I)-catalyzed click reaction. 
Introduction. Chemical modification of proteins is important for many applications 
in biology and biotechnology. Selective functionalization of proteins is challenging 
because of the large number of reactive functional groups typically present in 
polypeptides. Our laboratory and others have recently exploited the high specificity of 
the enzyme, protein farnesyltransferase (PFTase), to site-specifically modify peptides 
and proteins.
7-80
 In nature, PFTase, catalyzes the transfer of a farnesyl isoprenoid 
group from farnesyl pyrophosphate (FPP, 1, Figure 2.1) to a sulfur atom present in a 
cysteine residue. That residue must be located in a tetrapeptide sequence (denoted as a  
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Figure 2.1. Farnesyl pyrophosphate (1), farnesyl aldehyde pyrophosphate (FAPP, 2) and 
a farnesylated protein showing a CAAX-box (CVIA) positioned at the C-terminus of a 
protein. 
 
CAAX-box) positioned at the C-terminus of a protein or peptide to be a PFTase 
substrate. Interestingly, CAAX-box sequences such as CVIA can be appended to the 
C-terminus of many proteins rendering them efficient substrates for PFTase. Since 
PFTase can tolerate many simple modifications to the isoprenoid substrate,
107,108
 it 
can be used to introduce a diverse range of functionality into proteins at their C-
termini. Chemoselective reaction with the resulting protein can then be used for  a 
wide range of applications. Although a number of reactions have been developed,
32-11
 
to date, the Cu(I) catalyzed click reaction has been the most widely used 
bioorthogonal process.
29
 While useful, that reaction employs Cu(I) which is toxic to 
cells and can erode enzymatic activity.  
Ligation reactions between aldehydes or ketones with hydrazine derivatives or 
alkoxyamines  are  attractive alternatives but these reactions suffer from slow 
kinetics. Recently, Dawson and coworkers reported the dramatic acceleration of 
oxime formation in presence of aniline
13
; several applications of this reaction have 
subsequently been described.
14
  
Here, we describe the synthesis of an aldehyde-containing analogue of FPP denoted 
as FAPP (2) and demonstrate that it is efficiently incorporated by PFTase. Model 
reactions with peptide substrates were used to confirm the structure of the prenylated 
product and monitor the rate of oxime formation. To investigate the utility of 2 for 
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protein modification, a GFP variant incorporating a CAAX-box was employed. 
PFTase was used to incorporate the modified isoprenoid into the protein. The 
resulting aldehyde-modified polypeptide was then either immobilized onto 
alkoxyamine-containing agarose beads or further functionalized with a second 
fluorophore via oxime formation. 
Results and Discussion. Farnesyl aldehyde pyrophosphate (FAPP, 2) was prepared in 
six steps starting from farnesol (Scheme 2.S1). Tetrahydropyran (THP)-protected 
farnesol was initially regioselectively oxidized at C-12 to a terminal alcohol followed 
by further oxidation to the corresponding aldehyde. Removal of the THP group, 
conversion to an allylic bromide and displacement with [(nBu)4N]3HP2O7 followed by 
purification by ion-exchange chromatography and reversed-phase HPLC (RP-HPLC) 
yielded FAPP (2) whose structure was confirmed by 
1
H-NMR, 
31
P-NMR, and HR-
ESI-MS. 
 
Figure 2.2. Prenylation of a CAAX-box containing peptide with FAPP (2) and 
subsequent aniline-catalyzed oxime ligation with aminooxy alexaflour-488. Panel A) 
Structures of reactants and products. Panel B) RP-HPLC analysis of the PFTase catalyzed 
prenylation of 3 with 2 to yield 4. Chromatogram a: reaction mixture prior to the addition 
of enzyme; chromatogram b: reaction mixture after 40 min at 30 °C showing conversion 
to the prenylated peptide 4. Panel C) RP-HPLC analysis of the oxime ligation reaction. 
A                                                                             B                                                                                    C
0
0.8
1.6
2.4
3.2
4
4.8
28 30 32 34 36
F
lu
o
re
s
c
e
n
c
e
 /
 I
U
t / min
a
b
ESI LC-MS: :
Calculated: 1384.9
Found: 1384.6
0
2
4
6
8
10
20 24 28 32 36
F
lu
o
re
s
c
e
n
c
e
 /
 I
U
t / min
a
b
ESI LC-MS:
Calculated: 913.5
Found: 913.5
 50 
 
Reaction was initiated by the addition of aniline. Chromatogram a: reaction mixture prior 
to the addition of alexaflour-488 (5); chromatogram b: reaction mixture 40 sec after the 
addition of alexaflour-488 (5) and aniline to the reaction mixture at rt showing 
conversion to the oxime 6. LC/MS analysis of the prenylated peptide and oxime ligated 
product confirmed quantitative formation of 4 and 6. 
Compound 2, was first evaluated as a substrate for PFTase (Figure 2.2A) by 
employing a continuous fluorescence-based enzyme assay. Varying concentrations of 
2 were incubated with a constant concentration of the fluorescent peptide substrate, 
N-dansyl-GCVIA (3) and PFTase (see Figure 2.S1 and 2.S2). From those experiments 
KM and kcat were found to be 2.2 µM and 0.065 µM min
-1
, respectively. In 
comparison, similar experiments employing FPP (1) yielded values for KM and kcat of 
0.42 µM and 0.26 µM min
-1
, respectively. These values indicate a 5-fold increase in 
KM, a 4-fold decrease in kcat and an overall 20-fold drop in catalytic efficiency. While, 
significant, this attenuation can be limited to a 4-fold reduction in rate by performing 
preparative reactions at saturating substrate concentrations. To verify the results 
obtained from the kinetic analysis and confirm the structure of the prenylated peptide, 
the formation of peptide 4 was monitored by RP-HPLC analysis. The peptide 
substrate 3 (2.4 µM) was incubated with 2 (25 µM) and PFTase at 30 °C. Complete 
conversion was observed after 40 min (Figure 2.1B, chromatogram b). The reaction 
mixture was concentrated by solid phase extraction with a Sep-Pak cartridge and 
purified by RP-HPLC. LC-MS analysis of the purified material gave an [M+H]
+
 of 
913.5 consistent with the proposed structure of 4 (Figure 2.S3). Next the ligation 
reaction between aminooxy alexafluor 5 and aldehyde-functionalized peptide 4 was 
evaluated. Compound 4 (7.5 µM) was incubated with 5 (200 µM) in PB (0.1 M, pH 
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7.0) at rt and the reaction was initiated by addition of aniline (100 mM). To monitor 
the reaction, aliquots were withdrawn at 40 sec intervals and flash frozen. Subsequent 
RP-HPLC analysis showed that the ligation reaction was complete within the first 40 
sec which  is impressive for a coupling reaction at physiological pH in the µM 
concentration range of reagents (Figure 2.2C). LC-MS analysis of the reaction 
mixture gave an ion of 698.2 as the predominant species, which is consistent with 
[M+2H]
2+
 for 6 (Figure 2.S3). Only a trace amount of unreacted starting aldehyde 4 
was observed suggesting an equilibrium constant of 10
8
 M for the ligation reaction. In 
contrast to the promising results noted above for oxime formation, attempts to achieve 
ligation via hydrazone formation between Texas-red hydrazine and 4 were not 
successful. RP-HPLC analysis of such a reaction mixture showed only a trace of 
possible product being formed. These results suggest that the equilibrium constant for 
hydrazone formation may not be sufficiently large to convert a significant percentage 
of aldehyde 4 when the reactants are present in µM concentrations. 
With the ability of 2 to be incorporated by PFTase and subsequently derivatized via 
oxime formation established, we next evaluated the utility of this alternative substrate  
 
 
  
Scheme 2.1. Prenylation of eGFP-CVIA with 
FAPP and subsequent immobilization on 
aminooxy functionalized agarose beads or 
labeling with aminooxy alexaflour-488 by 
oxime ligation.   
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for selective protein modification. Accordingly, 2 was incubated with eGFP-CVIA 
(7), in the presence of PFTase for 2 h at 30 °C (Scheme 2.1). The reaction time was 
based on our earlier observation that the peptide substrate 3 could be prenylated in 
less than 40 min. Concentration by ultracentrifugation followed by size exclusion 
chromatography to remove unreacted 2 yielded aldehyde-functionalized eGFP-CVIA 
(8). 
To determine the efficiency of prenylation, thiol titration was performed on both 
unmodified protein 7 and the prenylated product 8. DTNB titration of 7 revealed the 
presence of 2.8 thiols/protein in good agreement with the expected value of 3. A 
similar titration of 8 indicated the presence of 1.7 thiols/protein. These results 
indicate the loss of 1.1 thiols/protein after reaction and are consistent with complete 
modification of the cysteine residue present within the CVIA sequence after 
prenylation with 2. Next, we examined two possible applications for the aldehyde- 
 
 
Figure 2.3. Immobilization of aldehyde-labeled eGFP-CVIA (8) onto aminooxy-
functionalized agarose beads (9) to yield (10): Panel A) Reaction mixture in the presence 
of aniline (100 mM). Panel B) Reaction mixture in the absence of aniline. Panel C) 
Control immobilization reaction containing unmodified eGFP-CVIA (7) in the presence 
of aniline (100 mM). All reactions were carried out in the presence of protein (20 µM), 
and PB (100 mM, pH 7.0). Bright-field images are above and fluorescent microscope 
images below. Scale bars in the lower right-hand corners represent 200 µm.   
A                                    B                                    C                  
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modified protein produced above. First, its utility for protein immobilization was 
examined (Scheme 2.1). Aminooxy-functionalized agarose beads (9) were prepared 
by coupling a bifunctional aminooxy-PEG azide with alkyne-agarose beads via click 
chemistry. Beads (9) were incubated with aldehyde-functionalized eGFP-CVIA (7) at 
rt in the presence of 100 mM aniline. The reaction was vortexed and the fluorescence 
of supernatant was measured as a function of time. Results show that equilibrium is 
reached in less than 15 min. In that time, the beads became highly fluorescent (Figure 
2.3A); less fluorescent beads were observed in the absence of aniline catalyst (Figure 
2.3B) and no fluorescent beads were seen using GFP lacking the aldehyde moiety 
(Figure 2.3C). Based on the amount of 8 remaining in the supernatant, the efficiency 
of covalent immobilization (Figure 2.S5) was estimated to be ~30%. 
 
Figure 2.4. Selective labeling of aldehyde-labeled eGFP–CVIA (8) with alexaflour-488 
(5) to yield 11. Compound 8 (25 µM) was incubated with 5 (125 µM) and aniline (100 
mM). After incubation at 25 °C for 30 min, samples were dialyzed against PB to remove 
unreacted 5. Samples were then adjusted to contain equal protein concentration (17 µM) 
and the UV spectra were obtained. Panel A) Dashed line: Spectrum of 11 obtained from 
the treatment of 8 with 5; Solid line: Spectrum of 8. Panel B) Dashed line: Difference 
spectrum (Spectrum of 11 – Spectrum of 8); Solid line: Spectrum of 5 (10 µM).    
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Finally, oxime ligation was used to site-specifically label eGFP-CVIA with a second 
fluorophore. Aminooxy alexafluor-488 (5) (125 µM) was treated with 8 (25 µM) in 
presence of 100 mM aniline for 30 min at rt. Labeled protein (11) was purified from 
excess 5 by extensive dialysis at 4 °C. The UV spectrum obtained for coupled product 
(11) showed a significant increase in absorbance near 500 nm when compared to the 
unmodified protein 8 (Figure 2.4A). The difference spectrum for this pair matches 
closely the spectrum of alexafluor-488 (5) thereby confirming successful ligation 
(Figure 2.4B). Quantitative comparison of the UV difference spectrum with the 
spectrum of alexafluor-488 suggests an efficiency of 60% for oxime ligation in this 
case. 
Conclusions. In this report, we demonstrate that PFTase can be used to introduce an 
aldehyde group near the C-terminus of a polypeptide and that the resulting protein can 
be immobilized or further functionalized via aniline-promoted oxime formation. 
Given that CAAX-box sequences can be appended to the C-termini of almost any 
protein, the method reported here should be useful for a wide range of applications in 
protein chemistry. This copper free labeling approach may be particularly useful for 
live cell studies or for applications where enzymatic activity must be preserved. It 
should also be noted that this labeling chemistry and the Cu(I)-catalyzed click 
reaction are orthogonal. This opens up the possibility of performing multiple 
modifications on proteins using different, bioorthogonal chemistries. 
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Supporting Information 
General: All synthetic reactions were carried out at 25 C and stirred magnetically unless 
otherwise noted. TLC was performed on precoated (250 mm) silica gel 60 F-254 plates 
(Merck). Plates were visualized by staining with KMnO4 or hand-held UV lamp.  Flash 
chromatography silica gel (60–200 mesh, 75–250 µm) was obtained from Mallinckrodt 
Inc. CH2Cl2, CH3CN, and THF were dried by using a Mbraun solvent purification 
system. Deuterated NMR solvents were purchased from Cambridge Isotope Laboratories, 
Inc. 
1
H NMR spectra were obtained at 300 or 500 MHz; 
13
C NMR spectra were obtained 
at 125 MHz; 
31
P NMR spectra were obtained at 121 MHz. All NMR spectra were 
acquired on Varian instruments at 25°C. Chemical shifts are reported in ppm and J values 
are in Hz. Fluorescence assay data were obtained by using a Varian Cary Eclipse 
Fluorescence Spectrophotometer. Analytical HPLC was performed on a Beckman model 
125/166 instrument, equipped with a diode array UV detector, ABI Analytical 
Spectroflow 980 fluorescence detector, and a Varian C18 column (Microsorb-MV, 5 µm, 
4.6x250 mm). Preparative HPLC separations were performed by using a Beckman model 
127/166 instrument, equipped with a UV detector and a Phenomenex C18 column (Luna, 
10 µm, 10x250 mm). MS spectra for synthetic reactions were obtained on a Bruker 
BioTOF II instrument. MS and LC/MS spectra of modified peptides were obtained with 
an Applied Biosystems/MDS SCIEX QSTAR® Elite Hybrid LC-MS system. Sep-Pak 
cartridges were purchased from Waters (Milford, MA). Yeast PFTase was prepared as 
previously described.
1
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Scheme 2.S1. Syntheses of Farnesyl Aldehyde Pyrophosphate (FAPP, 2). 
 
 
(2E,6E,10E)-2,6,10-trimethyl-12-O-THP-dodeca-2,6,10-trienal (S4): Compound S2 
and S3 were prepared as previously described.
2
 Alcohol S3 (1.00 g, 3.94 mmol) was 
dissolved in 20 mL anhydrous CH2Cl2 in a 50 mL flask and the solution was cooled to 0 
°C in ice bath. DMSO (3.1 mL, 43 mmol) was added dropwise to the solution mixture 
followed by addition of 2.75 mL triethylamine (197 mmol). Sulfur trioxide pyridine 
complex (SO3·Py, 2.52 g, 15.75 mmol) was added slowly over 10 min to the reaction 
mixture. The reaction was stirred at 0 °C for an additional h where TLC analysis showed 
almost complete conversion to the product. The reaction was stopped by addition of 100 
mL CH2Cl2 and washed with 5 M HCl (2 x 10mL) until the aqueous phase remained 
acidic (via pH paper) which shows there is no more base left the in reaction mixture. 
S2
S3
S4
S6
S5
S1
2
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Next solution was washed with 15 mL NaHCO3 followed by 2 x 10 mL brine. The 
solution was dried over Na2SO4 and solvent was removed in vacuo. Compound S4 was 
purified by silica gel column chromatography using a step gradient of solvent 
(Hexane:EtOAc) starting from 1:0 (v/v) going to 3:1 (v/v) to afford 0.5 g of compound 
S4 as a pale yellow oil (50% yield).
 1
H NMR (500 MHz, CDCl3) δ 1.55 (m, 5H), 1.63 (s, 
3H), 1.67 (s, 3H), 1.74 (s, 3H), 1.82 (m, 1H), 2.0-2.25 (m, 6H), 2.46 (m, 2H), 3.51 (m, 
1H), 3.89 (m, 1H), 4.02 (dd, J = 7.3 Hz, J = 12 Hz, 1H), 4.24 (dd, J = 6.3 Hz, J = 12 Hz, 
1H), 4.62 (dd, J = 3.0 Hz, J = 4.5 Hz, 1H), 5.16 (t, J = 6.2 Hz, 3 H), 5.36 (dd, J ) 6.3 Hz, 
J = 7.3 Hz, 1H), 6.46 (t, J ) 7.2 Hz, 1H), 9.37 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 
195.38, 154.53, 139.95, 133.71, 125.33, 121.75, 120.86, 97.91, 63.70, 62.35, 39.51, 
38.01, 30.77, 27.45, 26.25, 25.55, 19.69, 16.47, 15.97, 9.28. HR-ESI-MS calcd for 
C20H32O3Na [M+Na]
+
 343.2249, found 343.2246. 
 
 
(2E,6E,10E)-12-hydroxy-2,6,10-trimethyldodeca-2,6,10-trienal (S5): Protected 
aldehyde S4 (0.66 g, 2.6 mmol) was dissolved in 15 mL CH3OH in a 25 mL flask. PPTS 
(40 mg) was added as catalyst. The reaction was then refluxed at 55 °C for 3 h. It was 
then quenched by adding 10 mL sat. NaHCO3 and 100 mL EtOAc. The organic layer was 
separated and dried over Na2SO4. Early 
1
H NMR analysis revealed deprotection of THP 
group in high yield but also protection of the aldehyde to a acetal with two methoxy 
groups as was expected. The product was dissolved in 15 mL of CH3CN and 1.5 mL of 
 58 
 
H2O. PPTS (25 mg) was then added and the reaction was stirred overnight at rt. 100 mL 
EtOAc was added to the reaction which was then washed with 10 mL sat. NaHCO3 
followed by 2 x 10 mL brine. The organic phase was collected and dried over Na2SO4. 
Solvent was evaporated in vacuo and the product was further purified by silica gel 
column chromatography with gradient elution (hexane:EtOAc) from 10:1 (v/v) going to 
2:1 (v/v) to afford 0.22 g of compound S5 as a pale yellow oil (38% yield). It should be 
mentioned that aldehyde deprotection was only 50% achieved when THF was used 
instead of CH3CN as solvent. 
1
H NMR (500 MHz, CDCl3) δ 1.64 (s, 3H), 1.68 (s, 3H), 1.74 (s, 3H), 2.0-2.25 (m, 6H), 
2.45 (t, J = 7.5, 2H), 4.143 (t, J = 7 Hz, 1H), 5.16 (t, J = 7 Hz, 3 H), 5.41 (t, J = 4.5 ), 
6.48 (t, J = 7.5 Hz, 1H), 9.37 (s, 1H). 
13
C-NMR (75 MHz, CDCl3) δ 195.352, 154.618, 
139.262, 133.602, 125.160, 123.718, 117.303, 63.569, 39.334, 38.084, 27.336, 26.174, 
16.203, 15.851, 9.163. HR-ESI-MS calcd for C15H24O2Na [M+Na]
+
 259.1674, found 
259.1669. 
 
 (2E,6E,10E)-12-bromo-2,6,10-trimethyldodeca-2,6,10-trienal (S6): PPh3 (polymer-
supported beads, 167 mg, 0.5 mmol) was added to a solution of S5 (107 mg, 0.454 mmol) 
in CH2Cl2 (15 mL), and the reaction was stirred for 20 min at room temperature to let the 
beads swell in the solution. CBr4 (165 mg, 0.5 mmol) was added slowly to the reaction 
mixture and the reaction was stirred for 15 min when TLC analysis showed most of 
starting material was converted to product. The reaction mixture was filtered to separate 
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beads, and solvent was evaporated in vacuo. The product was further purified by silica 
gel flash chromatography to yield 120 mg of S6 as a pale yellow liquid. (86%). 
1
H NMR (500 MHz, CDCl3) δ 1.628 (s, 3H), 1.723 (s, 3H), 1.738 (s, 3H), 2.0-2.25 (m, 
6H), 2.45 (t, J = 7.5, 2H), 4.013 (t, J = 8.5 Hz, 2H), 5.125 (t, J = 7 Hz, 1 H), 5.520 (t, J = 
4.5, 1H ), 6.462 (t, J = 7.5 Hz, 1H), 9.382 (s, 1H). 
13
C-NMR (75 MHz, CDCl3) δ 
195.288, 154.450, 141.242, 134.066, 124.679, 121.644, 120.763, 39.329, 38.076, 37.940, 
27.392, 26.951, 15.995, 15.947, 9.259. 
 
(2E,6E,10E)-3,7,11-trimethyl-12-oxododeca-2,6,10-trien-1-yl dihydrogen 
diphosphate (2): 
Compound S6 (100 mg, 0.317 mmol) and [(nBu)4N)]3HP2O7 (902 mg, 1.0 mmol) were 
mixed in dry CH3CN (1 mL) and stirred at rt for 3 h, after which the solvent was removed 
in vacuo. Bio-Rad AG 50W-X8 ion-exchange resin (100–200 mesh, H+ form) was used 
to convert the product to its ammonium form. The resin was packed and washed with 
three column volumes of H2O/conc. NH4OH (2:1, v/v) until the elution solvent became 
basic. The resin was then equilibrated with four volumes of NH4HCO3 (25 mm)/iPrOH 
(49:1, v/v; solvent A). The crude product was dissolved in 1 mL of solvent A and applied 
to the column and eluted with additional solvent A (20 mL), lyophilized, and purified by 
RP-HPLC with a semipreparative column using the following conditions: detection: 214 
nm; flow rate: 5.0 mL min
-1
; 2 mL injection loop; gradient 0–30% solvent B in 30 min, 
60–100% in 5 min; solvent A: 25 mm NH4HCO3, solvent B: CH3CN. Compound 2 eluted 
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from 20–25% solvent B. Fractions containing pure 2 were collected and lyophilized to 
yield 0.7 mg (0.54%) of a white powder. 
1
H NMR:
 
(500 MHz, D2O) δ 1.488 (s, 3H), 1.545 (s, 6H), 1.917 (t, J = 7 Hz, 2H), 1.996 
(t, J = 7 Hz, 2H), 2.067 (t, J = 7 Hz, 2H), 2.377 (t, J = 7 Hz, 2H), 4.302 (t, J = 6 Hz, 2H), 
5.081 (t, J = 6 Hz, 1H), 5.293 (t, J = 7 Hz, 1H), 6.613 (t, J = 7.5 Hz, 1H), 9.108 (s, 1H). 
31
P NMR: (121 MHz, D2O) δ -5.971 (d, J = 22.6, 1P), -10.013 (d, J = 22.6, 1P). HR-ESI-
MS calcd for C15H26O8P2 [M-H]
-
 395.1025, found 395.0907. 
Enzymatic studies of FAPP (2) using a continuous fluorescence assay: Enzymatic 
reaction mixtures contained 50 mM Tris·HCl, pH 7.5, 10 mM MgCl2, 10 μM ZnCl2, 5.0 
mM DTT, 2.4 μM N-dansylGCVIA, 0.040 % (w/v) n-dodecyl-ß-D-maltoside, 80 nM 
PFTase, and varying concentrations of 2 (0-10 μM), in a final volume of 450 μL. The 
reaction mixtures were equilibrated at 30 °C for 5 min, initiated by the addition of 
PFTase, and monitored for an increase in fluorescence (λex = 340 nm, λem = 505 nm, slit 
widths = 10 nm for both) for approximately 10 min. The initial rates of formation of 
products were obtained as slopes in IU/min using least squares analysis. Correction was 
applied to all rate calculation based on the difference of intensity of fluorescence of 
product and starting peptide. The difference corresponds only to the fluorescence of total 
amount of the product. The slope was then divided to the difference followed by 
multiplying to the total concentration of peptide which then gives the relative rate of 
formation of product. It should be noted that the KM values reported here are actually 
apparent KM values since the measurements were performed at only a single peptide 
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concentration. The data were fit to a Michaelis-Menten model using KaleidaGraph, a 
nonlinear regression program, to determine KM.  
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Figure 2.S1. Fluorescence-based PFTase enzyme assay for prenylation of 3 using 
varying concentrations of 2.  
 
To compare the catalytic efficiency of incorporation of FPP and 2, enzymatic reactions 
were performed as described above with the exception of the isoprenoid substrates, FPP 
or 2, which were included at 10 or 30 µM, respectively. Reaction mixtures were 
monitored spectrofluorometrically for 1 h to insure the endpoint was reached. The rate of 
reaction was then determined from the initial slope. 
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Figure 2.S2 Continuous fluorescence assay for PFTase catalyzed peptide prenylation of 
peptide 3 with 4 μM FPP or 10 μM FAPP at same concentration of enzyme (80 nM). a: 
Reaction of 2 (30 μM). b: Reaction of FPP (10 μM). 
 
 
Enzymatic synthesis of 4: Enzymatic reactions (26 mL) contained Tris-HCl (50 mM, pH 
7.5), MgCl2 (10 mM), ZnCl2 (10 mM), DTT (5.0 mM), 3 (2.4 µM), PFTase (80 nM), and 
2 (30 µM). To ensure complete disulfide reduction of the peptide, all reagents except 
FAPP and enzyme were premixed and incubated, for 2 h at 4 °C. With all reagents 
mixed, the reaction was initiated by the addition of enzyme and the resulting mixture was 
incubated at 30°C for 1 h. The reaction progress was monitored by fluorescence detection 
(λex=340 nm, λem=504 nm) using analytical RP-HPLC. The following conditions were 
employed: flow rate: 1 mL min
-1
; 100 mL injection loop; gradient 0–100% B in 40 min; 
b
a
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solvent A: NH4HCO3 25 mM in H2O; solvent B: CH3CN. After 1 h, the reaction was 
purified by using a Waters Sep-Pak Plus reversed-phase C18 Environmental Cartridge. 
The cartridge was first washed with solvent B (10 mL) followed by equilibration with 
solvent A (20 mL). The crude enzymatic reaction mixture was applied to the cartridge 
and a gradient elution was performed in the following sequence: 10 mL solvent A, 10 mL 
solvent C (20% solvent B, 80% solvent A), 10 mL solvent D (40% solvent B, 60% 
solvent A), 10 mL solvent E (60% solvent B, 40% solvent A). Fractions (1 mL) were 
collected and product elution was monitored by using a handheld UV lamp. The green-
fluorescent product was clearly visible and the brightest fraction was selected and its 
purity was confirmed by HPLC. 
LC-MS analysis of the purified product gave an ion of 913.5 as the predominant species, 
which is consistent with [M+H]
+
 for 4 (Figure 2.S3A). 
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Oxime ligation between peptide-aldehyde 4 and aminooxy alexafluor-488 (5): 
 
 
Coupling reactions contained 7.5 µM 4, 200 µM alexafluor-488 (5), 0.1 M PB, pH 7.0, 
and 100 mM aniline in final volume of 500 µL. Reactions were performed at rt and were 
initiated by addition of aniline (100 mM). To monitor the reactions, aliquots were 
withdrawn at 40 sec intervals and flash frozen by liquid nitrogen. LC-MS analysis of the 
reaction mixture gave an ion of 698.2 as the predominant species, which is consistent 
with [M+2H]
2+
 for 6 (Figure 2.S3B). 
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Figure 2.S3 ESI/LC-MS analysis of oxime ligation reaction between peptide aldehyde 4, 
and alexaflour-488 (5). Left panels are extracted ion chromatograms and right panels are 
corresponding MS spectra. A) Extracted ion chromatogram of starting peptide-aldehyde 4 
and corresponding MS spectrum. B) Extracted ion chromatogram of coupled product (6) 
superimposed on extracted ion chromatogram of starting aldehyde (4). Both 
chromatograms are extracted from the total ion chromatogram of the reaction mixture 
after 1 h of reaction. Relative intensity of peaks shows completion of oxime ligation to 
99% conversion. Corresponding MS spectrum of the oxime product (6) confirms the 
formation of oxime bond.    
 
eGFP-CVIA: Protein was prepared as previously described with one modification.
3
 In 
the final phenyl sepharose chromatography step, after the protein was loaded onto the 
column and washed with buffer as explained in the original work, the protein was eluted 
from column by adding water (no buffer). Protein could not be eluted from the column by 
adding buffer only (as it was described in the original reference).  
[M+H]+1
[M+H]+1
[M+2H]+2
[M+2H]+2
MS
MS
A
B
Starting aldehyde (4)
ESI LC-MS
Calculated= 913.5
ESI LC-MS
Calculated= 692.96
Remaining aldehyde (4)
Oxime Product (6)
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Enzymatic incorporation of FAPP moiety into eGFP-CVIA: Enzymatic reactions (10 
mL) contained Tris-HCl (50 mM, pH 7.0), MgCl2 (10 mM), ZnCl2 (10 µM), DTT (5.0 
mM), eGFP–CVIA (2.0 µM), 2 (30 µM), and PFTase (80 nM). After incubation at 30°C 
for 3 h, the reaction mixture was concentrated using an Amicon Centriprep centrifugation 
device (10,000 MW cutoff), and excess 2 was removed by using a NAP-5 column 
(Amersham). The subsequent protein concentration was calculated based on volume 
change assuming 100% recovery. 
Thiol titration of eGFP for determining efficiency of prenylation: KHPO3 (0.1 M, pH 
7.4, KPB) was used as buffer; 5 mM DTNB solution was prepared by dissolving 99 mg 
of DTNB in 50 mL of KPB. Dissolution of DTNB is slow and requires vortexing for a 
few minutes to become completely clear. Protein free of exogenous thiols (15 µL, 
prepared by NAP-5 desalting) was added to a solution of 75 µL of 6 M Guanidine•HCl 
and 10 µL of above DTNB solution. The final mixture was vortexed and the absorbance 
at 412 nm was measured after 5 min. Each measurement was repeated 3 times. A 
standard curve was prepared using cysteine as a standard. All measurements were 
repeated in triplicate.  
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Figure 2.S4.  Thiol titration of prenylated and unprenylated eGFP-CVIA by DTNB. 
 
Aminooxy agarose beads (11): Alkyne beads were prepared as previously described.
3
 
Aminooxy beads were prepared by treating aminooxy-PEG azide (S9) with alkyne 
agarose resin under click chemistry conditions. Aminooxy-PEG azide was synthesized 
from amine-PEG azide (S7) by coupling to N-Boc-aminooxy-acetic acid (S8) followed 
by Boc removal with TFA.  
 
PEG S7 (100 mg, 0.29 mmol) was added to a solution of 360 mg HCTU (0.87 mmol), 
268 µL of collidine
4
 (2.03 mmol) and 166 mg S8 (0.87 mmol) in 1 mL of DMF. The 
reaction was allowed to proceed for 2 h. TFA (3 mL) dissolved in CH2Cl2 (4 mL) was 
added to mixture and the reaction was allowed to proceed for an additional h. Solvent 
was removed in vacuo to give S9 which was used without further purification. 
1
H NMR 
+
Yellow
ε=13700 M-1cm-1
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(500 MHz, CDCl3) δ 3.177 (m, 4H), 3.381 (b, 24H), 4.425 (s, 2H), 8.090 (s, 1H). HR-
ESI-MS calcd for C16H34O8N5 [M+H]
+
 424.2407, found 424.2435. 
1
H NMR and MS 
analysis show ~complete conversion of starting amino-PEG S7 to final aminooxy-PEG 
S9.   
 
 
 
One tenth of the product solution of S9 (0.03 mmol PEG) was removed and the pH was 
adjusted with a mixture of PB and NaOH to neutrality. Alkyne beads S10 (1 mL) in PB, 
0.1 M, pH 7 was added to this solution. CuSO4 (1 mM), TCEP (1 mM), TBTA (100 µM) 
were added and the reaction was allowed to proceed for 2 h. Beads were centrifuged 
down and the overlaying solution was exchanged for PB.  The beads were centrifuged 
and the buffer exchanged again. This was repeated 5 times. Beads were stored in PB 
solution at 4 °C for future use. 
 
Immobilization of eGFP onto aminooxy agarose beads: To immobilize the protein 
onto the agarose beads, aldehyde-functionalized eGFP–CVIA (8, 50 µL, 40 µM stock in 
PB) was added to beads (9) in PB (20 µL). The ligation reaction was initiated by the 
addition of 100 mM aniline. 
For control reactions, eGFP-CVIA (7) was added instead. GFP fluorescence of the 
supernatant was measured as a function of time. Beads were centrifuged and 5 µL of 
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supernatant was removed, diluted into 445 µL of PB and the fluorescence was measured 
(λex=488 nm, λem=510 nm). 
 
 
Figure 2.S5. Immobilization efficiencies of aldehyde-labeled eGFP 8 onto aminooxy 
agarose beads (9). To determine the immobilization efficiencies and background labeling, 
eGFP-CVIA and aldehyde functionalized eGFP–CVIA (30 µM) were incubated with or 
without 100 mM aniline. At the appropriate times, beads were centrifuged and the 
fluorescence remaining in the supernatant was determined by spectrofluorimetry.  
 
Coupling reaction between aldehyde-labeled eGFP-CVIA and alexafluor-488: 
Alexafluor-488 (5) (7 µL of 1.9 mM solution in DMSO was added to 100 µL of eGFP-
C(FA)VIA (8) (stock solution of ~30 µM in PB). The reaction was initiated by adding 
100 mM aniline and was allowed to proceed for 30 min at rt. The mixture was then 
transferred to a micro dialysis cassette (10,000 MWCO, Pierce) and dialyzed against PB 
(15 mL) at 4°C for 3 days. The control reaction contained 7 µL of DMSO instead of the 
5. After dialysis, the final volume of sample was measured to be 165 µL. The control 
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reaction solution was also diluted to 165 µL and UV spectra were obtained. The 
concentrations of eGFP in both samples were determined by Bradford assay to be 17.1 
µM for the control and 17.9 µM for the coupling reaction. 
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Chapter 3. Chemoenzymatic Reversible Immobilization and Labeling of Proteins 
without Prior Purification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mohammad Rashidian, Mark D. Distefano 
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Site-specific chemical modification of proteins is important for many applications in 
biology and biotechnology. Recently, our laboratory and others have exploited the high 
specificity of the enzyme protein farnesyltransferase (PFTase) to site-specifically modify 
proteins through the use of alternative substrates that incorporate bioorthogonal 
functionality including azides and alkynes. In this study, we evaluate two aldehyde-
containing molecules as substrates for PFTase and as reactants in both oxime and 
hydrazone formation. Using green fluorescent protein (GFP) as a model system, we 
demonstrate that the purified protein can be enzymatically modified with either analogue 
to yield aldehyde-functionalized proteins. Oxime or hydrazone formation was then 
employed to immobilize, fluorescently label or PEGylate the resulting aldehyde-
containing proteins. Immobilization via hydrazone formation was also shown to be 
reversible via transoximization with a fluorescent alkoxyamine. After characterizing this 
labeling strategy using pure protein, the specificity of the enzymatic process was used to 
selectively label GFP present in crude E. coli extract followed by capture of the 
aldehyde-modified protein using hydrazide-agarose. Subsequent incubation of the 
immobilized protein using a fluorescently labeled or PEGylated alkoxyamine resulted in 
the release of pure GFP containing the desired site-specific covalent modifications. This 
procedure was also employed to produce PEGylated glucose-dependent insulinotropic 
polypeptide (GIP), a protein with potential therapeutic activity for diabetes. Given the 
specificity of the PFTase-catalyzed reaction coupled with the ability to introduce a 
CAAX-box recognition sequence onto almost any protein, this method shows great 
potential as a general approach for the selective immobilization and labeling of 
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recombinant proteins present in crude cellular extract without prior purification. Beyond 
generating site-specifically modified proteins, this approach for polypeptide modification 
could be particularly useful for large scale production of protein conjugates for 
therapeutic or industrial applications. 
Introduction. 
Site-specific chemical modification of proteins is important for many applications in 
biology and biotechnology. It can facilitate studies of proteins with respect to their 
structure, folding, and interaction with other proteins in both biochemical and cellular 
investigations. In particular, in many biotechnology applications, the oriented (i.e. site-
specific) covalent attachment of proteins to surfaces is important because it ensures 
homogeneous surface coverage and accessibility to the active site of the protein.
11,109–115
  
Protein immobilization is an important first step for many applications including the 
construction of biosensors and protein microarrays, development of immunoassay 
methods, and employment of enzymes in biotechnology procedures.
13,116,117
 Similarly, 
site-specific protein labeling is essential for a variety of applications ranging from the 
introduction of fluorophores for biophysical studies to the preparation of protein-polymer 
conjugates for medical applications.
49,118–122
 
Importantly, the structural sensitivity of polypeptides calls for chemical transformations 
that proceed under mild conditions and that are compatible with all functional groups 
present therein. However, such modification is challenging because of the large number 
of reactive functional groups typically present in polypeptides. Although many existing 
chemical reactions are applicable in principle, the development of new methods for site-
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specific modification of proteins that function under mild conditions is an area of intense 
research.
123
 While a number of reactions suitable for protein modification have been 
developed,
29,31,124,125
 to date, the Cu(I) catalyzed click reaction has been the most widely 
employed bioorthogonal process.
29
 Although highly useful, that reaction employs Cu(I) 
which is toxic to cells and can in some cases erode biological activity. To address those 
issues, copper-free variations of the click reaction have been developed that function 
based on the inclusion of electron withdrawing substituents and/or ring strain into alkyne-
containing reagents. While highly promising, these new reagents are not generally 
commercially available, are difficult to synthesize and manifest low aqueous 
solubility.
126–128
  
As an alternative, oxime and hydrazone-based reactions have found wide application in 
the conjugation of biomolecules on account of the absence of aldehyde or ketone groups 
in proteins and their orthogonal reactivity with aminooxy or hydrazine derivatives to give 
stable hydrazones or oximes.
26–33
 While reactions between aldehydes and ketones with 
alkoxyamines or hydrazides are generally slow, they can be significantly accelerated by 
the addition of aniline.
38,129
 This has resulted in a number of exciting applications ranging 
from the site-specific glycosylation of proteins
130
 to the fluorescent labeling of bacteria 
and mammalian cells.
131
 Given the utility of oxime and hydrazone formation, a number 
of methods have been developed to introduce aldehydes and ketones into proteins. 
Chemical approaches include transamination in the presence of sodium glyoxylate and 
copper sulfate
132
 or using pyridoxal-5-phosphate;
133
 while these have proved to be 
powerful methods, they are not applicable to all N-termini and cannot always be driven to 
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completion.  Enzymatic methods include the action of formylglycine-generating 
enzyme
44
 or nonsense suppression approaches that permit the incorporation of aldehydes 
into internal positions within proteins.
134
 
Recently, our laboratory and others have exploited the high specificity of the enzyme 
protein farnesyltransferase
135
 (PFTase) to site-specifically modify peptides and 
proteins.
32,41–43
 In nature, PFTase catalyzes the transfer of a farnesyl isoprenoid group 
from farnesyl diphosphate (FPP, Figure 3.1) to a sulfur atom present in a cysteine 
residue. That residue must be located in a tetrapeptide sequence (denoted as a CAAX-
box) positioned at the C-terminus of a protein or peptide to be a PFTase substrate. 
Interestingly, CAAX-box sequences such as CVIA can be appended to the C-termini of 
many proteins rendering them efficient substrates for PFTase. Since PFTase can tolerate 
many simple modifications to the isoprenoid substrate,
3,44–48
 it can be used to introduce a 
diverse range of functionality into proteins at their C-termini. Chemoselective reaction 
with the resulting functionalized protein can then be used for a wide range of 
applications. Since the “AAX” residues from a CAAX-box sequence can be removed by 
treatment with carboxypetidase after prenylation, the net addition to the protein in this 
labeling method can be limited to a single prenylcysteine residue.
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In an initial communication,
82
 we reported that compound 1, an aldehyde-containing 
analogue of FPP, can be incorporated into a purified protein substrate using PFTase and 
that the resulting aldehyde-functionalized protein can be immobilized or fluorescently 
labeled via oxime formation.  In this study, we have followed up on those initial 
observations by comparing the properties of ,-unsaturated aldehyde 1 with aryl 
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aldehyde 2 in terms of their efficiency as PFTase substrates and as reactants in both 
oxime and hydrazone formation. Using green fluorescent protein (GFP
136
) as a model 
system, we demonstrate that the purified protein can be enzymatically modified with 1 or 
2. Oxime or hydrazone formation was then employed to immobilize, fluorescently label 
or PEGylate the resulting aldehyde-functionalized proteins.  Immobilization via 
hydrazone formation was also shown to be reversible via transoximization with a  
 
 
Figure 3.1. A) Structures of  farnesyl diphosphate, farnesyl aldehyde diphosphate (1) and 
formylbenzoyl-oxy geranyl diphosphate (2). B) Schematic representation of prenylation 
of a protein contaning a CAAX-box positioned at its C-terminus (GFP-CVIA, 7) with 
aldehyde-containing analogue 2 to yield the prenylated product 9a. C) ESI MS analysis 
of 7 with the deconvoluted mass spectrum shown in the inset. D) ESI MS analysis of 9a 
with the deconvoluted mass spectrum shown in the inset.   
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fluorescent alkoxyamine. After characterizing this labeling strategy using pure protein, 
the specificity of the enzymatic process was used to selectively label GFP present in 
crude E. coli extract followed by capture of the aldehyde-modified protein using 
hydrazide-agarose. Subsequent incubation of the immobilized protein using a 
fluorescently labeled or PEGylated alkoxyamine resulted in the release of pure GFP 
containing the desired site-specific covalent modifications. This procedure was also 
employed to produce PEGylated glucose-dependent insulinotropic polypeptide
137
 (GIP), 
a protein with potential therapeutic activity for diabetes.
138
 
Experimental Section 
Enzymatic studies of FPP-analogues 1 and 2 using a continuous fluorescence assay. 
Enzymatic reaction mixtures contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl 
(20 mM), ZnCl2 (10 µM), 2.4 μM N-dansyl-GCVIA (3), 0.04 % (w/v) n-dodecyl-ß-D-
maltoside, 80 nM PFTase, and varying concentrations of either 1 or 2 (0-50 μM), in a 
final volume of 250 μL. The reaction mixtures were equilibrated at 30 °C for 5 min, 
initiated by the addition of PFTase, and monitored for an increase in fluorescence 
(λex=340 nm, λem=505 nm) for approximately 10 min. The initial rates of formation of 
products were obtained as slopes in IU/min using least squares analysis. Corrections were 
applied to all of the rate calculations based on the difference between the fluorescence 
intensity of the prenylated product and the starting peptide. Assuming 100% conversion, 
the difference corresponds only to the fluorescence of the total amount of the product. 
The slope was then divided by the fluorescence difference followed by multiplying by the 
total concentration of peptide (2.4 μM) which then gives the rate of formation of product 
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in μM/s. It should be noted that the KM values reported here are actually apparent KM 
values, since the measurements were performed at only a single peptide concentration. 
The data were fit to a Michaelis-Menten model using a nonlinear regression program, to 
determine kcat and KM. 
Enzymatic synthesis of 4a and 5a. Enzymatic reactions (26 mL) contained Tris·HCl (50 
mM, pH 7.5), MgCl2 (10 mM), KCl (20 mM), ZnCl2 (10 µM), DTT (5.0 mM), 3 (2.4 
µM), PFTase (80 nM), and either 1 or 2 (30-50 µM). To ensure complete disulfide 
reduction of the peptide, all reagents except substrates and enzyme were pre-mixed and 
incubated, for 2 h at 4 °C. With all reagents mixed, the reaction was initiated by the 
addition of enzyme and the resulting mixture was incubated at 30°C for 1 h. The reaction 
progress was monitored by UV absorbance (λ=340 nm, absorbance of the dansyl 
chromophore) using analytical RP-HPLC. The following conditions were employed: flow 
rate: 1 mL·min-1; 500 µL injection loop; gradient 0–100% B in 30 min; solvent A: 
NH4HCO3 (25 mM in H2O); solvent B: CH3CN. After 1 h, the reaction was purified by 
using a Waters Sep-Pak Plus reversed-phase C18 Environmental Cartridge. The cartridge 
was first washed with solvent B (10 mL) then equilibrated with solvent A (20 mL). The 
crude enzymatic reaction mixture was applied to the cartridge and a gradient elution was 
performed in the following sequence: 10 mL solvent A, 10 mL solvent C (20% solvent B, 
80% solvent A), 10 mL solvent D (40% solvent B, 60% solvent A), 10 mL solvent E 
(60% solvent B, 40% solvent A). Fractions (1 mL per tube) were collected and the 
product elution was monitored using a handheld UV lamp. The green-fluorescent product 
was clearly visible and the brightest fraction was selected and its purity was confirmed by 
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RP-HPLC. LC-MS analysis of the purified products gave ions of 913.5 and 979.4 as the 
predominant species, which are consistent with [M+H]
+
 for 4a and 5a, respectively. 
Oxime ligation between peptide-aldehyde 4a and 5a and aminooxy alexafluor-488 
(6c). Coupling reactions contained 3-5 µM 4a or 5a, 200 µM alexafluor-488 (6c), PB (0.1 
M, pH 7.0), and aniline (100 mM) in a final volume of 500 µL. Reactions were 
performed at rt and were initiated by addition of aniline (100 mM). LC-MS analysis of 
the reaction mixture after 3-4 h gave ions of 1384.6 and 1450.6 as the predominant 
species, which are consistent with [M+H]
+
 for 4c and 5c, respectively. 
Hydrazone ligation between peptide-aldehydes 4a and 5a and Texas red hydrazide 
(6b). Coupling reactions contained 3-5 µM 4a or 5a, 200 µM Texas red (6b), PB (0.1 M, 
pH 7.0), and aniline (100 mM) in final volume of 500 µL. Reactions were performed at rt 
and were initiated by addition of aniline (100 mM). LC-MS analysis of the reaction 
mixture after 1 h gave ions of 758.46 and 791.45 as the predominant species, consistent 
with [M+2H]
2+
 for hydrazones 4b and 5b, respectively. 
Enzymatic incorporation of compounds 1 and 2 into GFP-CVIA (7).
80
 Enzymatic 
reaction mixtures (10 mL) contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl 
(30 mM), ZnCl2 (10 µM), DTT (5.0 mM), 7 (2.4 µM), either 1 or 2 (30-50 µM), and 
PFTase (80-200 nM). After incubation at 30°C for 2 h for 1, and overnight for 2, the 
respective reaction mixtures were concentrated using an Amicon Centriprep 
centrifugation device (10,000 MW cut-off). Next, excess of 1 or 2 was removed through 
a NAP-5 (Amersham) column using Tris·HCl (50 mM, pH 7.5) as the eluant. The 
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subsequent protein concentration was calculated by UV absorbance at 488 nm (ε=55,000 
M
-1·cm-1). 
Coupling reaction between aldehyde-labeled GFP-CVIA (8a and 9a) with 
alexafluor-488 (6c). Alexafluor-488 (6c) (3.2 µL of 3.2 mM solution in DMSO) was 
added to 42 µL of 8a or 9a (stock solution of 60 µM in PB). PB (2 M, pH 7.0, 2.5 µL) 
was added and the reaction was initiated by adding aniline (100 mM) and was allowed to 
proceed for 3-5 h at rt. The mixture was then purified by a NAP-5 column to remove 
excess dye. LC-MS analysis of the sample showed only oxime ligated protein and no free 
aldehyde was detected indicating a complete reaction in both cases. 
Immobilization of 9a onto hydrazide agarose beads. Hydrazide agarose beads 
(Thermo Scientific, hydrazide loading: 16 µmol/mL) (300 µL) were washed with PB (0.1 
M, pH 7.0, 3x500 µL). PB (30 µL, 1 M, pH 7.0) was added to the beads followed by 
addition of 9a (200 µL, 87 µM). Immobilization was initiated by adding aniline (2 µL, 
100 mM). For controls, GFP-CVIA (7) was added instead of 9a. The solution was 
centrifuged, then the GFP UV-absorbance of the supernatant was measured as a function 
of time (488 nm, ε=55,000 M-1 ·cm-1). After 2 h, the solution was centrifuged and the 
beads were washed thoroughly with PB (0.3 M, pH 7.3, 3x300 µL) and KCl (1 M, 3x300 
µL) to remove non-specifically bound proteins and were stored in pH 7.5 Tris buffer at 4 
°C. 
Release of immobilized GFP from beads using hydroxylamine. The GFP-beads were 
incubated in PB (0.3 M, pH 7.0) with hydroxylamine (200 mM) and aniline (100 mM) 
and the resulting mixture was vortexed. The solution was centrifuged and then the UV-
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absorbance of the GFP in the supernatant was measured as a function of time (488 nm, 
ε=55,000 M-1 ·cm-1). 
Coupling reaction between aldehyde-labeled GFP-CVIA (8a and 9a) with 
alexafluor-488 (6c). Alexafluor-488 (6c) (3.2 µL of 3.2 mM solution in DMSO) was 
added to 42 µL of 8a or 9a (stock solution of 60 µM in PB). PB (2 M, pH 6.7, 2.5 µL) 
was added and the reaction was initiated by adding 100 mM aniline and was allowed to 
proceed for 5-6 h at rt. The mixture was then purified using a NAP-5 column to remove 
excess dye. LS-MS analysis of the sample showed only oxime-ligated protein and no free 
aldehyde was detected indicating a complete reaction in both cases. 
Coupling reaction between aldehyde-labeled GFP-CVIA (8a and 9a) with Texas red 
hydrazide (6b). Texas red hydrazide (6b) (7 µL of 1.9 mM solution in DMSO) was 
added to 100 µL 8a and 9a (stock solution of 40 µM in PB). The reaction was initiated by 
adding 100 mM aniline and was allowed to proceed for 1 h at rt. The mixture was then 
purified using a NAP-5 column to remove excess of 6b. LC-MS analysis of the sample 
showed the presence of both hydrazone ligated proteins 8b and 9b, and the free 
aldehydes 8a and 9a. The ratios of free aldehydes to their respective hydrazone products 
were ~4, indicating only ~20% completion within this range of reactant concentrations. 
The mass spectrum in Figure 3.2E which corresponds to conversion of compound 8a to 
8b was made by superimposing the two separate mass spectra of both the free aldehyde 
protein 8a and the hydrazone ligated protein 8b present in the product mixture, based on 
their relative intensities. The aldehyde- and hydrazone-functionalized proteins have 
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different retention times and thus show two different peaks in the corresponding LC 
chromatograms. 
FRET studies between GFP-aldehyde 9a and Texas red hydrazide (6b). Texas Red 
hydrazide (6b) (7 µL of 1.9 mM solution in DMSO) was added to 90 µL of 9a (stock 
solution of 60 µM in PB, 0.1 M, pH 6.7). The reaction was initiated by adding 0.9 µL 
aniline (100 mM) followed by vortexing the solution and allowing it to proceed for 1 h at 
rt. The mixture was then purified using a NAP-5 column to remove excess of 6b.  The 
protein solution was diluted to 1 nM and its fluorescence was measured. For the first 
control, the same amount of GFP-CVIA (7) fluorescence was measured and compared 
with that of 9b. As a second control, the ligated protein (9b) was heated for few minutes 
to denature the protein and the resulting fluorescence was measured to verify that FRET 
required both the protein and the Texas red fluorophores.  
FRET studies between GFP-aldehyde 9a and aminooxy-TAMRA (6d). Aminooxy-
TAMRA (6d) (100 µM) was added to 90 µL of 9a (stock solution of 50 µM in Tris·HCl 
(100 mM, pH 7.0). The reaction was initiated by adding 0.9 µL aniline (100 mM) 
followed by vortexing the solution and allowing it to proceed for 3 h at rt. The mixture 
was then purified using a NAP-10 column to remove excess of 6d. The collected solution 
appeared red and not green suggesting that efficient FRET was occurring between the 
GFP and TAMRA fluorophores. The fluorescence of the solution was measured and 
compared with two other controls. For the first control, the same amount of GFP-CVIA 
(7) fluorescence was measured and compared with that of 9e. As a second control, the 
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same amount of TAMRA fluorescence was measured. The two controls confirmed that 
FRET was occurring between the protein and the TAMRA fluorophores. 
Crude prenylation, immobilization and subsequent labeling and release of GFP-
CVIA. A pellet of cells expressing GFP-CVIA were suspended in buffer (20 mM 
Tris·HCl pH 7.5, 1 mM EDTA), sonicated and clarified by centrifugation. The GFP 
concentration present in the crude soluble protein mixture was calculated by UV 
absorbance at 488 nm. Next, prenylation was performed by adding PFTase (200 nM), 2 
(50 µM), Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl (30 mM), ZnCl2 (10 µM) and 
DTT (5.0 mM) to a solution of 7, to achieve a final concentration of 2.0 µM in the crude 
mixture. After overnight incubation at 30°C, the reaction mixture was filtered and 
concentrated using an Amicon Centriprep centrifugation device (10,000 MW cut-off). 
Next, excess 2 was removed through a NAP-5 (Amersham) column using Tris·HCl (50 
mM, pH 7.5) as the eluting solvent. The subsequent GFP concentration in the crude 
mixture was calculated by UV absorbance at 488 nm and was determined to be 30 µM. 
Immobilization was performed as described above. The beads were washed thoroughly 
with PB (0.3 M, pH 7.3) and KCl (3x300 µL, 1 M) to remove non-specifically bound 
proteins followed by incubation with aminooxy fluorophore 6c (1 mM) and aniline (100 
mM) overnight with constant agitation. The supernatant was then analyzed via SDS-
PAGE and in-gel fluorescence analysis to confirm the labeling and release of the protein 
from the beads.  
Coupling reaction between aldehyde-labeled GFP-CVIA (9a) with aminooxy PEG 
(10). Aminooxy PEG (10) (1.5 mg, MW 10 kDa) was added to 100 µL 9a (stock solution 
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of 10 µM in 50 mM Tris·HCl). PB (pH 7) was added to a final concentration of 0.1 M. 
The reaction was initiated by adding 100 mM aniline and was allowed to proceed for 1 h 
at rt. SDS-PAGE analysis of the sample was used to confirm covalent attachment of the 
PEG 10 to aldehyde 9a. Excess 10 and PB were removed using a zip-tip protocol 
followed by MALDI MS analysis of the sample to characterize the product and 
demonstrate that no free aldehyde was present indicating complete reaction.  
PEGylation from immobilized GFP-beads. Immobilization was performed as described 
above. Beads were washed thoroughly with PB (0.3 M, pH 7.3, 3x300 µL) and KCl (1 M, 
3x300 µL) to remove non-specifically bound proteins. Next, the beads were incubated 
with aminooxy PEG 10 (2 mM) and aniline (100 mM) overnight while vortexing the 
solution. SDS-PAGE analysis of the supernatant indicated the successful PEGylation and 
release of the aldehyde-GFP from the hydrazide-beads. 
Enzymatic prenylation of GIP-CVIM (12a) with aldehyde substrate 2. Enzymatic 
reaction mixtures (10 mL) contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl 
(30 mM), ZnCl2 (10 µM), DTT (5.0 mM), 12a (2 µM), 2 (50 µM), and PFTase (200 nM). 
After incubation at 30°C overnight, significant precipitate was present in the solution, 
suggesting possible precipitation of GIP was occurring upon prenylation. The precipitate 
was separated from the solution by centrifugation at 12,000xg for 15 min, washed with 
25 mM (NH4)2CO3 buffer to remove excess 2, and centrifuged again. MALDI-MS 
analysis of the precipitate (dissolved in H2O, 0.5% TFA, v/v) confirmed the prenylation 
of GIP with 2, while the solution showed neither starting GIP 12a nor the prenylated 
material 12b. 
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Coupling reaction between aldehyde-labeled GIP (12b) with aminooxy PEG (13).  A 
small amount of the precipitate 12b was dissolved in H2O containing 0.5% TFA (v/v) and 
aminooxy PEG  (13) was added to a final concentration of 200 µM. The reaction was 
allowed to proceed for 2 h at rt. Excess 13 was removed using a zip-tip protocol. 
MALDI-MS analysis of the sample was employed to characterize the product and to 
demonstrate that no free aldehyde was present indicating complete reaction.  
Prenylation of GIP (12a) in crude E. coli extract. E. coli extract containing GIP-CVIM 
(12a) was subjected to enzymatic prenylation by incubating it in the presence of PFTase 
(200 nM), 2 (50 µM), Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl (30 mM), ZnCl2 
(10 µM) and DTT (5.0 mM). After overnight incubation, the precipitate was separated 
from the solution by centrifugation at 12,000xg for 15 min, washed with 25 mM 
(NH4)2CO3 buffer to remove excess of 2, and then centrifuged again. MALDI-MS 
analysis of the precipitate, performed as described above, was used to confirm the 
prenylation of GIP with 2. 
Immobilization and subsequent PEGylation and release of resin-bound GIP. 
Immobilization was performed as described above for GFP except that GIP was dissolved 
in H2O containing 0.5% TFA (v/v). No aniline catalyst was added to the solution in this 
case. After incubation for 1 h, the beads were washed thoroughly with H2O (3x300 µL) to 
remove non-specifically bound proteins from the beads. Next, the beads were incubated 
with aminooxy PEG 13 (~400 µM) in H2O containing 0.5% TFA overnight with constant 
agitation of the solution. Excess 13 was removed using a zip-tip protocol. MALDI MS 
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analysis of the sample was employed to confirm the presence of the desired product and 
to assess the purity of the PEGylated GIP (14). 
General procedure for MALDI analysis of protein samples. A zip-tip (C4 column) 
was first washed with 10 µL solvent A (CH3CN containing 0.1% TFA; v/v) and then 
equilibrated with solvent B (H2O containing 0.1% TFA; v/v). The sample (10 µL) was 
then adsorbed onto the C4 matrix via repeated cycles of aspiration and ejection (5-10 
cycles) using a pipettor. Next, the zip-tip was washed 5x10 µL with solvent B and the 
proteins eluted with 2 µL of a mixture of solvent A and B (75:25). Next 0.7 µL of the 
eluted material was added to a MALDI plate and 0.7 µL of matrix was added on top of 
the sample plate to form crystals. A saturated solution of sinapinic acid (3,5-dimeth-oxy-
4-hydroxy-cinnamic acid) was used as the matrix. 
Results and Discussion. 
Comparison of alkyl and aryl aldehydes as substrates for PFTase. To examine the 
ability of PFTase to be used in a protein modification strategy employing oxime and 
hydrazone formation, we first wanted to explore the range of aldehydes that could be 
accepted as alternative substrates for PFTase.  Thus, compound 2, containing an aryl 
aldehyde was designed and synthesized in five steps from geraniol (Scheme 3.S2).  In 
brief, THP-protected geraniol was initially oxidized at C-8 to a terminal alcohol,
139
 
followed by acylation with formylbenzoic acid using EDC as the coupling reagent. The 
THP group was removed and the alcohol was converted to the corresponding allylic 
bromide using CBr4 and PPh3. Subsequent displacement with [(n-Bu)4N]3HP2O7 followed 
by purification via ion-exchange chromatography and RP-HPLC yielded product in 
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which the desired aldehyde was almost completely transformed to the corresponding 
carboxylic acid; therefore, a direct phosphorylation strategy using (HNEt3)2HPO4 and 
CCl3CN as the activating reagent was employed. Subsequent purification by RP-HPLC 
produced the desired aldehyde analogue 2 in 5.4% overall yield whose structure was 
confirmed by 
1
H-NMR, 
31
P-NMR,
140
 and HR-ESI-MS. Aldehyde 1 was prepared in six 
steps starting from farnesol as previously described
82
 with several modifications that 
significantly improved the overall yield to 1.3%. Despite these improvements, the 
synthesis of 2 was significantly more efficient primarily due to the selectivity in the SeO2 
oxidation step. The preparation of 1 proceeds via THP-protected farnesol whereas the 
synthesis of 2 uses THP-geraniol. Selective oxidation of the alkene at C-6 (over the 
electron poor C-2 alkene) in geraniol is facile compared to the preferential oxidation of 
the alkene at C-10 in farnesol due to competing reaction with the C-6 olefin which 
exhibits comparable reactivity. Hence, the reaction cannot be driven to completion 
resulting a significantly reduced yield (compare 56% for geraniol oxidation to 23% for 
farnesol oxidation).  
Initially, prenylation reactions containing N-dansyl-GCVIA (3), 2, and PFTase were 
monitored by HPLC and LC-MS/MS. As was observed previously with 1, a new species 
with longer retention time appeared in the reaction mixture containing 2. LC-MS analysis 
of that compound gave an [M+H]
+
 peak at 979.4 Da, consistent with the proposed 
structure of peptide 5a (Supporting Information). Next, a kinetic analysis of the 
incorporation of analogue 2 by PFTase was performed using a continuous fluorescence-
based enzyme assay as had previously been carried out with 1. Varying concentrations of 
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2 were incubated with the fluorescent peptide substrate, N-dansyl-GCVIA, and PFTase; 
the rates of those enzymatic reactions were determined and shown to obey saturation 
kinetics. Steady-state kinetic parameters for prenylation reactions with the two aldehyde 
analogues are summarized in Table 3.1 with additional details provided in the Supporting 
Information section (Figure 3.S2). Comparison of the catalytic efficiencies for these 
alternative substrates indicates that both compounds have reduced efficiency relative to 
FPP, manifesting kcat/KM values of 0.23 and 0.05, respectively (relative to FPP). We 
found that decreases in kcat constituted the major reason for the diminished catalytic 
efficiency of the analogues; kcat for aldehyde 1 was 4-fold lower while kcat for aldehyde 2 
was 35-fold lower (compared to kcat for FPP).  No significant differences were observed 
in the KM values for the different analogues. Thus, in summary, while 1 is the superior 
alternative substrate, 2 is easier to prepare making these two compounds functionally 
interchangeable.  
Preparation and reactivity of PFTase-mediated aldehyde-functionalized peptides. In 
our earlier work with 1, experiments with the aldehyde functionalized peptide 4a focused 
on oxime-forming reactions. Here, we sought to expand the scope of possible chemistry 
to include hydrazone formation as well. Accordingly, large scale (26 mL) reactions 
containing N-dansyl-GCVIA (3), 1 or 2, and PFTase were performed and the products 
isolated after purification via solid phase extraction. The resulting material was 
subsequently used to evaluate ligation reactions between Texas red hydrazide 
6b/alexafluor-488 aminooxy 6c and aldehyde-containing peptides 4a and 5a in the 
presence of aniline.
38
 Kinetic analysis of oxime formation showed that in the range of 2-4 
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µM of 4a and 5a, ligations at pH 7 were essentially complete within 3-4 h. LC-MS 
analysis of the reaction mixture resulted in [M+H]
+
 peaks being observed at 1384.6 and 
1450.6 Da, consistent with the production of oximes 4c and 5c, respectively (Supporting 
Information). In contrast, hydrazone formations with 4a and 5a in the same concentration 
range of reagents showed only 30-50% completion but within 30-60 min (a significantly 
shorter time frame). LC-MS analysis of the reaction mixtures resulted in [M+2H]
2+
 peaks 
observed at 758.46 and 791.45 Da, consistent with the formation of hydrazones 4b and 
5b, respectively (Supporting Information). Overall, these experiments with aldehyde-
containing peptides 4a and 5a suggest that hydrazone ligations have the advantage over 
oxime-forming reactions of reaching equilibrium at a higher rate but at the cost of lower 
conversion to the conjugated products due to their lower association constants.  
Preparation and reactivity of PFTase-mediated aldehyde-functionalized proteins. 
With the ability of aldehyde analogues 1 and 2 to be incorporated by PFTase and their 
subsequent derivatization via oxime and hydrazone ligations established in a peptide 
model system, we next evaluated the utility of the aldehyde analogues for selective 
protein modification. Accordingly, aldehydes 1 and 2 were incubated with GFP-CVIA  
Table 1. Steady-state kinetic parameters of substrates, and HPLC Retention times for 
prenylated peptide products. 
Compound
[a]
 kcat (s
-1
) KM (µM) (kcat/KM)rel
[a]
 Rt (min) 
FPP 0.52 1.71 1 -- 
1 
2 
N-dansyl-
GC(Far)VIA 
4a 
5a 
 
0.133±0.003 
0.015±0.001 
-- 
-- 
-- 
1.87±0.17 
1.02±0.16 
-- 
-- 
-- 
0.23 
0.05 
-- 
-- 
-- 
-- 
-- 
21.5 
18.9 
18.6 
[a] Vrel refers to kcat/KM with respect to FPP 
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(7) in the presence of PFTase for 2 h, and overnight, at 30 °C, respectively. Those 
reaction times were based on our earlier observations that peptide substrate 3 could be 
prenylated withaldehyde analogues 1 and 2 in less than 1 h, and 4 h, respectively.  
Figure 3.2. A) Schematic representation of oxime and hydrazone ligations of 8a to yield 
8b and 8c. B) Fluorescence (right) and Coomassie blue staining (left) images of a gel 
loaded with 8a labeled with alexafluor 6c and Texas red 6b via oxime and hydrazone 
ligations, respectively, showing covalent attachment of fluorophores to the protein. lane 
1: GFP-CVIA 7; lane 2: 8c; lane 3: 8b C, D and E) ESI MS spectra of 8a (spectrum C) 
and hydrazone/oxime ligation products 8b and 8c, showing full conversion for oxime 
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(spectrum D) and ~20% for hydrazone (spectrum E) ligations with the deconvoluted mass 
spectra shown in the insets.    
Concentration by ultracentrifugation followed by size-exclusion chromatography to 
remove unreacted substrates yielded aldehyde-functionalized GFP-CVIA 8a and 9a. 
Reaction completion was confirmed by LC-MS analysis (Figure 3.1C and 3.1D), in 
which none (in the case of 8a) or very small amounts (in the case of 9a) of free GFP-
CVIA (7) could be detected in comparison to the large peaks for prenylated GFPs. 
Deconvolution of the LC-MS data from the purified protein products showed species at 
27,559.0 Da and 27,625.5 Da, consistent with the structures of aldehyde-GFPs 8a and 9a. 
In general, LC-MS analysis of GFP and its congeners has proved to be quite powerful for 
studying these reactions. As noted above, in a preliminary communication,
82
 we had 
shown that aldehyde-GFPs 8a could be derivatized to produce oxime-linked products. 
Here, it was desired to expand those experiments to include hydrazone formation and to 
compare the relative reactivity between the two different aldehyde donors, 8a and 9a, 
containing ,-unsaturated- and aryl-aldehydes, respectively. To fluorescently label those 
aldehyde-functionalized proteins, we chose Texas red hydrazide (6b) and Alexaflour-488 
aminooxy (6c) for their excellent quantum yields and high visible light absorbtion. Thus, 
aldehyde-GFPs 8a and 9a were incubated separately with alkoxyamine 6c at pH 7 and rt. 
Kinetic analysis, performed via LC-MS measurements, showed that the reaction required 
3-4 h to proceed to completion. At that point, no detectable unmodified protein-aldehydes 
(8a and 9a) were observed. Gratifyingly, the deconvoluted MS data indicated the 
presence of species at 28,032.0 Da and 28,120.5 Da, consistent with the proposed oximes 
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8c and 9c. In-gel fluorescence analysis performed under denaturing conditions confirmed 
covalent attachment of aminooxy 6c to the aldehyde-containing proteins (Figure 3.2B). 
Unprenylated GFP-CVIA (7) failed to show any labeling with alkoxyamine 6c, further 
confirming that the ligations require the presence of the enzymatically introduced 
aldehyde functionality and that the ligation reaction is truly bioorthogonal. Overall, the 
oxime ligation reactions appear to be highly efficient since no unligated aldehyde-GFPs 
(8a or 9a) were observed upon LC-MS analysis (Figure 3.2C and 3.2D) of the ligation 
reaction mixtures. 
Aldehyde-functionalized GFPs 8a and 9a were also each incubated with hydrazide 6b at 
pH 7 and rt under the same conditions employed in the aforementioned oxime ligations. 
LC-MS analysis of aldehyde-functionalized GFP-containing reactions after 1 h showed 
approximately 20% conversion of aldehydes 8a and 9a to their respective hydrazones 8b 
and 9b (Figure 3.2C and 3.2E); more extensive reaction times did not result in the 
appearance of additional hydrazone product suggesting that the reaction had reached 
equilibrium within 1 h. These results are in good agreement with those from hydrazone 
ligations for aldehyde-functionalized peptides 4a and 5a described above. 
Application to FRET analysis of labeled GFP. To demonstrate the utility of this 
method for applications beyond simple protein labeling, we next investigated the ability 
of Texas red-labeled GFP (9b) to undergo fluorescence resonance energy transfer 
(FRET). After performing the ligation reaction between aldehyde 9a with Texas red 
hydrazide 6b at rt for 1 h, excess fluorophore was removed via size exclusion 
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chromatography. A strong fluorescent signal at 640 nm (emission wavelength of Texas 
red) was observed upon excitation at 488 nm (excitation wavelength of GFP), indicative 
 of FRET between Texas red and GFP due to their close proximity resulting from 
covalent attachment of the fluorophore to the protein (Figure 3.3). When the hydrazone-
ligated protein was denatured, no FRET was observed upon excitation at 488 nm (Figure 
3.3, red spectrum) and only a small background peak was observed upon excitation of 
GFP that had not been modified with Texas red (Figure 3.3, green spectrum), further 
confirming that FRET was occurring between the aldehyde- functionalized protein and 
the fluorophore. While the above results appeared promising, the FRET efficiency could 
not be calculated from the experimental data due to incomplete hydrazone ligation  
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Figure 3.3. A) Schematic representation of the fluorescent labeling of 9a via hydrazone 
ligation. The conjugated protein was expected to show FRET between Texas red and 
GFP-CVIA. B) Excitation spectra obtained by monitoring at 640 nm. Squares: 9b; 
Triangles: denatured 9b; Circles: 7; all three samples had equal concentrations of the 
chromophores.   
reaction. Hence, aminooxy-TAMRA 6d was ligated with aldehyde-protein 9a. As 
expected, LC-MS analysis of the oxime formation reaction mixture showed a peak at 
28,111 Da consistent with the structure of TAMRA labeled GFP 9d and showed no 9a, in 
good agreement with the high efficiency observed in previous oxime ligation reactions. 
Emission spectra of 9e, monitored at 488 nm excitation, showed FRET while the same 
amount of GFP-CVIA (7) and fluorophore 6d showed a substantially larger emission 
band at 510 nm and a smaller band at 580 nm, respectively. Energy was transferred from 
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donor (GFP) to acceptor (TAMRA) with an efficiency greater than >96% and the 
distance was calculated to be 37 Å (Figure 3.6B), consistent with a distance of 35 Å  
 
 Figure 3.4. A) Schematic representation of the fluorescence labeling of 9a via oxime 
ligation. The conjugated protein was expected to show FRET between TAMRA and GFP. 
B) Emission spectra obtained by excitation at 488 nm. Circles: 9e; Triangles: GFP-CVIA 
(7); Squares: 6d; all three samples had equal concentrations of the chromophores.  C) 
Molecular model of GFP–TAMRA 9e conjugate.  
 
calculated for the model GFP–TAMRA (Figure 3.6C) and measured from the GFP 
chromophore to the TAMRA fluorophore (See the Supporting Information for a 
description of the modeling). 
Reversible immobilization of purified aldehyde-functionalized GFP using 
hydrazide-modified agarose beads. Next, we examined two additional applications for 
the aldehyde-functionalized proteins described here. First, their utility in protein 
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immobilization was examined (Figure 3.5). Hydrazide- functionalized agarose beads 
were incubated with aldehyde-GFP 9a at rt in the presence of 100 mM aniline. The 
immobilization reaction was followed by monitoring the UV absorbance at 488 nm of the 
supernatant as a function of time. Results from those measurements showed that 
equilibrium was reached in approximately 45 min; in that time, the beads became highly 
fluorescent (Figure 3.6A); less fluorescent 
Figure 3.5. A) Schematic representation of immobilization of 9a onto hydrazide 
functionalized agarose beads to yield 9d. B) Kinetic analysis of immobilization of 9a 
onto hydrazide functionalized agarose beads. The reaction was carried out at rt, in the 
presence of 100 mM aniline and excess beads. UV absorbance of GFP in the supernatant 
was measured at different times showing >95% immobilization in ~45 min. The data was 
fit to a simple exponential process. 
beads were observed in the absence of aniline catalyst and no fluorescent beads were seen 
using GFP lacking the aldehyde moiety (Figure 3.6C). Based on the amount of aldehyde-
GFP 9a remaining in the supernatant, the efficiency of covalent immobilization was 
calculated to be greater than 95% (Figure 3.5B), an impressive result for site-specific 
protein immobilization. Next, oxime ligation using hydroxylamine in the presence of 
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aniline was employed to remove the covalently immobilized hydrazone-GFP 9d. 
Hydroxylamine (200 mM) was incubated with 9d in presence of aniline (100 mM) at rt 
and the UV absorbance at 488 nm of the supernatant was measured as a function of time. 
In this case, analysis of the results showed that in approximately 3 h, 80% of the 
immobilized GFP was released from the beads, and accordingly, the beads became 
significantly less fluorescent (Figures 3.6B and 3.7). For comparison, the hydrolytic 
 
Figure 3.6. Immobilization onto and subsequent release of 9a from hydrazide-
functionalized agarose beads: A) immobilization reaction mixture in the presence of 
aniline, B) release of 9d from agarose beads via oxime ligation with hydroxylamine in 
the presence of aniline for ~3 h, and C) control immobilization reaction containing 
unmodified GFP-CVIA 7. The immobilization reaction was carried out in the presence of 
protein (54 µM), aniline (100 mM) and PB (100 mM, pH 7). Release of hydrazone-GFP 
9d from agarose beads was carried out in the presence of hydroxylamine (200 mM), 
aniline (100 mM) and PB (200 mM, pH 7). Bright-field images are on the top and 
fluorescent microscope images are on the bottom. Scale bars in the lower right-hand 
corners represent 200 µm.   
A             B              C 
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Figure 3.7. A) Schematic representation of the release of immobilized GFP 9d to yield 
9e from agarose beads via oxime ligation with hydroxylamine. B) Kinetic analysis of the 
release of 9e from agarose beads by oxime ligation. The reaction was carried out at rt, in 
the presence of 100 mM aniline and 200 mM of hydroxylamine. UV absorbance of GFP 
in the supernatant was measured over time, which showed approximately 80% release of 
9e in 3 h. Analysis of the hydrolytic stability of 9d in the absence of hydroxylamine and 
aniline showed no detectable release of GFP on the same time scale. The data was fit to a 
simple exponential decay process. 
stability of immobilized GFP in the absence of hydroxylamine and aniline was also 
analyzed and the results showed that the hydrazone bond in pH 7.5 Tris buffer was 
completely stable for 48 h with no detectable release of GFP.
141
 This achievement 
highlights a significant advantage of this chemistry over click chemistry and other 
irreversible methods since it can be used to efficiently covalently immobilize proteins 
onto solid surfaces and then release them under mild conditions without protein 
denaturation. Addition of aniline catalyzes the hydrolysis of hydrazone to hydrazide and 
aldehyde. Since oxime formation has a larger equilibrium constant than hydrazone 
formation,
142
 the presence of hydroxylamine and aniline drives the equilibrium from 
hydrazone towards oxime formation and free hydrazide. 
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Enzymatic modification, immobilization and labeling in crude extract. An important 
feature of the labeling method described here is that it uses an enzymatic process for the 
introduction of aldehyde groups into proteins. Due to the specificity of that biocatalytic 
process and the fact that there are no endogenous proteins in E. coli that contain a C-
terminal CAAX box sequence, we reasoned that it should be possible to selectively 
functionalize proteins present in crude extract without purification. Additionally, once 
modified, it should also be possible to immobilize aldehyde-containing proteins and 
release them with an alkoxyamine that includes a fluorophore or PEG chain. In that way, 
a single protein present in E. coli crude extract could be modified, immobilized and 
labeled without purification. To explore this, E. coli cells expressing GFP-CVIA were 
grown, lysed, and subjected to enzymatic prenylation using PFTase and substrate 2. LC-
ESI/MS analysis of the reaction mixture was employed to confirm the introduction of the 
aldehyde functionality into GFP-CVIA 7 in the crude cell lysate. The reaction mixture 
was then concentrated and excess of 2 was removed via size exclusion column 
chromatography (NAP-5 column). Aldehyde-GFP 9a was then selectively immobilized 
from the crude cell lysate onto hydrazide-functionalized beads using aniline as the 
catalyst. Immobilization was followed by measuring the GFP absorbance present in the 
solution and was judged to be complete within 45 min at which time the beads became 
highly fluorescent and the supernatant solution became almost colorless. Next, the beads 
were washed to remove any non-specifically bound proteins and were then treated with 
aminooxy fluorophore  
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Figure 3.8. Chemoenzymatic site-specific tagging of proteins by aldehyde-FPP analogs 
by PFTase followed by capture of the aldehyde-functionalized protein in the crude cell 
lysate via hydrazide functionalized beads. Prenylation in the crude extract was confirmed 
by LC-MS analysis. The immobilized protein was then released into the solution or 
fluorescently labeled by addition of hydroxylamine or an aminooxy-fluorophore, using 
aniline as the catalyst. SDS-PAGE analysis: lane 1: crude E. coli lysate containing 9a 
visualized by Coomassie blue staining; lane 2: 9c released from hydrazide beads after 
treatment with 6c and visualized by Coomassie blue staining; lane 3: 9c released from 
hydrazide beads after treatment with 6c and visualized by in gel fluorescence analysis.  
 
6c in presence of 100 mM aniline overnight. SDS-PAGE analysis of the supernatant 
solution showed a single band (Figure 3.8, lane 2) migrating with an apparent mass of 29 
kDa slightly higher than that of the starting GFP (due to the addition of the aminooxy 
moiety) consistent with the release of GFP. In-gel fluorescence analysis (Figure 3.8, lane 
3) suggested that the released protein was labeled with the fluorophore 6c; LC-MS 
analysis of the released protein provided additional evidence for the formation of 9c. 
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Application to protein PEGylation. The attachment of polyethylene glycol (PEG) 
chains to proteins is the most widely used method for improving the pharmacokinetics of 
polypeptide-based therapeutic agents.
143–145
 Current methods for PEGylation are 
generally nonselective and can result in a mixture of protein-PEG positional isomers with 
variable biological activity.
146
 Site-specific methods offer a useful alternative approach 
for circumventing this problem of heterogeneity. Given our success in being able to 
incorporate a fluorescent label into a protein via the capture and release strategy 
described above, we decided to evaluate the utility of this approach for the preparation of  
 
 
Figure 3.9. A) Generation of site-specifically C-terminal PEGylated GFP from pure 9a. 
B) MALDI analysis of PEGylated GFP 11. The lower panel is the MALDI spectrum of 
pure PEG 10, the middle panel is the MALDI spectrum of pure 9a and the top panel is 
the MALDI spectrum of the oxime PEGylated GFP 11, which confirms complete 
conversion. The reaction was performed using 9a (10 µM) and 10 (100 µM) for 2 h. 
Excess of 10 was removed via a zip-tip protocol prior to MALDI analysis. 
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a PEGylated protein. Thus, aldehyde- functionalized GFP 9a was first prepared from 
purified GFP 7 using PFTase as described above and treated with aminooxy-PEG-10,000 
10, to produce the protein-PEG conjugate 11. Analysis of that material by MALDI-MS 
(Figure 3.9) showed an increase in molecular mass from 27.6 kDa (for 9a) to 38 kDa for 
11; the broader peak observed for 11 is consistent with the attachment of a polydisperse 
polymer to a monodisperse protein. It is also important to note that no species resulting 
from the addition of multiple PEG chains were observed, consistent with the selective  
 
 
Figure 3.10. Use of PFTase-catalyzed protein modification for site-specific PEGylation 
from purified protein or crude cell lysate. A) Generation of site-specific C-terminal 
PEGylated protein from pure 9a. B) PEGylation and release of immobilized 9d from 
hydrazide beads using PEG 10. C) SDS PAGE analysis of PEGylated GFP (11) from 
purified 9a or from immobilized protein 9d. In case of the crude cell lysate, 7 was 
chemoenzymatically and site-specifically tagged by aldehyde-containing analog 2 via 
PFTase catalyzed reaction, followed by capture of the resulting aldehyde-functionalized 
protein from the lysate using hydrazide functionalized beads. The immobilized protein 
was then released back into solution and simultaneously site-specifically PEGylated by 
addition of aminooxy-PEG 10, using aniline as a catalyst. SDS-PAGE analysis: lane 1: 
crude E. coli lysate containing 9a; lane 2: purified 9a; lane 3: 11 produced by PEGylation 
of pure 9a with 10; lane 4: 11 prepared from 9d (obtained using purified 9a) and 
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subsequently released with 10; lane 5: 11 prepared from 9d (obtained using 9a present in 
crude lysate) and subsequently released with 10.   
nature of the chemistry employed here. Analysis of the PEGylation reaction mixture by 
SDS PAGE revealed a decrease in electrophoretic mobility of 11 (Figure 3.10, lane 3) 
compared to the starting protein 9a (Figure 3.10, lane 2). As was noted in the MALDI 
MS, a wider band was observed for 11 relative to 9a, again consistent with the 
polydisperse nature of the protein-PEG conjugate. With the production of the PEGylated 
product clearly established, we next focused on generating the same material from 9a that 
had not been purified chromatographically. Thus, 7 was prenylated with 2 using PFTase 
in crude E. coli extract followed by capture using hydrazide-functionalized agarose. After 
washing the material to remove nonspecifically bound proteins, the desired PEGylated 
protein (11) was eluted via treatment with 10 in the presence of aniline. SDS PAGE 
analysis showed the presence of a single band (Figure 3.10, lane 5) that comigrated with 
the authentic product prepared from pure 9a (Figure 3.10, lane 3).  
PEGylation of glucose-dependent insulinotropic polypeptide (GIP). The incretin, 
glucose-dependent insulinotropic polypeptide (GIP), is secreted from intestinal K-cells in 
response to nutrient ingestion and acts to augment insulin secretion in the pancreas. GIP 
has been proposed as a potential therapeutic agent for the treatment of type 2 diabetes 
based on its stimulation of insulin secretion in the presence of elevated glucose 
levels;
147,148
 however, efforts to bring GIP forward as a drug have been hampered due to 
its short circulating half-life. Recently, a modified form of GIP functionalized with a C-
terminal mini-PEG group has shown resistance to proteolytic degradation while 
preserving biological activity in an obese rat model system.
138
 Accordingly, having 
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established the utility of our method for C-terminal site-specific modification described 
above with a model protein, GFP, we decided to demonstrate its utility for preparing a 
PEGylated form of GIP, a polypeptide with clear therapeutic potential. Thus, purified 
GIP-CVIM (12a), a form of GIP engineered to contain a C-terminal CAAX box (in this 
case CVIM
149
) was prenylated with analog 2 under conditions established above for GFP 
and subsequently PEGylated using a small aminooxy-functionalized PEG containing 
three ethylene glycol units (13). This shorter PEGylation reagent was employed since it is 
similar in length to what has previously been shown to be effective for increasing GIP 
stability in serum. MALDI MS analysis (Figure 3.11) confirmed the successful 
prenylation and PEGylation of GIP; as was noted above with GFP, both the enzymatic 
prenylation and subsequent chemical PEGylation proceed with essentially complete 
conversion. Next, we employed the capture and release strategy developed above for GFP 
to prepare PEGylated GIP without prior purification. GIP- CVIM (12a), present in crude 
E. coli  
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Figure 3.11. A) Schematic representation of prenylation of glucose-dependent 
insulinotropic polypeptide (GIP) containing a CAAX-box positioned at its C-terminus 
(GIP-CVIM, 12a) with aldehyde-containing analogue 2 to yield the prenylated product 
12b, which is then site-specifically PEGylated using a short chain aminooxy-PEG (13). 
B) MALDI MS analysis of prenylation and PEGylation of GIP 12a. MALDI MS spectra 
(from the top to the bottom) of oxime PEGylated GIP 14, the prenylated aldehyde labeled 
GIP 12b, and pure 12a, respectively.   
extract, was prenylated with 2 and the resulting aldehyde-functionalized polypeptide 12b 
was captured on hydrazide beads. The beads were washed extensively and then treated 
with aminooxy-PEG 13 resulting in oxime formation and release into solution. MALDI 
MS analysis of the eluted material showed only the presence of PEGylated-GIP (14), 
indicating a high degree of specificity in the capture and release (Figure 3.12). Thus, this 
general method allows facile and effective purification of site-specifically PEGylated GIP 
from the crude cell extract. Overall, these experiments conclusively demonstrate how a 
protein, present in crude extract, can be selectively modified, labeled with a fluorophore 
or PEG polymer and released in pure form via a simple process that requires no  
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Figure 3.12. Use of PFTase-catalyzed protein modification for site-specific PEGylation 
of GIP 12a from crude cell lysate. A) Chemoenzymatic site-specific tagging of GIP 12a 
by aldehyde-FPP analog 2 in the crude cell lysate via PFTase followed by capture of the 
aldehyde-functionalized polypeptide 12b via hydrazide functionalized beads. The 
immobilized polypeptide was then released back into the solution and simultaneously 
site-specifically PEGylated by addition of aminooxy-PEG 13. B) MALDI analysis of the 
released material confirmed the formation and release of the pure PEGylated GIP (14) 
into the solution.    
 
significant chromatographic steps. Given the specificity of the PFTase-catalyzed reaction 
coupled with the ability to introduce a CAAX-box onto almost any protein, this method 
shows great potential as a general approach for the selective immobilization and labeling 
of recombinant proteins present in crude cellular extract without prior purification. 
Beyond generating site-specifically modified proteins, this approach could greatly reduce 
the cost of producing PEGylated polypeptides for therapeutic applications due to the 
streamlined nature of the process. 
A    
B
4000 6000 8000 1 10
4
1.2 10
4
GIP-Prenylated-PEG (14)
Calculated: 7493
Found: 7495
In
te
n
s
it
y
 (
a
.u
.)
m/z
 109 
 
Conclusion.  
In this work, we have demonstrated that PFTase can be used to introduce aldehyde 
functionality near the C-terminus of a protein and that the resulting aldehyde-
functionalized proteins can then be modified in a plethora of ways via aniline-catalyzed 
hydrazone or oxime ligation under mild conditions. We show that if the concentration of 
the aldehyde–functionalized protein is relatively high (>50 µM), hydrazone ligation is 
more efficient compared with oxime ligation due to its faster kinetics, whereas if the 
protein concentration is in the low micromolar range, oxime ligation is more 
advantageous due to its larger equilibrium constant. An important feature of the 
chemistry reported here is its reversible nature that can be harnessed to permit efficient 
release of proteins; covalent immobilization using hydrazone ligation of an aldehyde-
containing protein can be followed by subsequent oxime formation to release the 
polypeptide without denaturation. Using synthetically modified alkoxyamines, a variety 
of new functionality ranging from fluorescent groups to PEG chains can be appended 
onto proteins. A second key feature of this approach concerns the enzymatic method for 
aldehyde incorporation. By capitalizing on the selectivity of the enzymatic process, the 
initial protein functionalization can be performed using unpurified protein substrates. The 
resulting modified protein can then be captured via hydrazone formation and released via 
oxime formation to produce a variety of pure, site-specifically modified protein 
conjugates. Such a streamlined approach for polypeptide modification could be 
particularly useful for large-scale production of protein conjugates for therapeutic or 
industrial applications. It should also be noted that the ligation chemistry described herein 
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and the Cu(I)-catalyzed click reaction are orthogonal. This opens up the possibility of 
performing multiple modifications on proteins using different bioorthogonal chemistries. 
Given that CAAX-box sequences can be appended to the C-terminus of almost any 
protein, the method reported here should be useful for a variety of applications in protein 
chemistry. 
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Supporting Information 
General. All synthetic reactions were carried out at rt and stirred magnetically unless 
otherwise noted. TLC was performed on precoated (250 mm) silica gel 60 F-254 plates 
(Merck). Plates were visualized by staining with KMnO4 or with a hand-held UV lamp. 
Flash chromatography silica gel (60–200 mesh, 75–250 µm) was obtained from 
Mallinckrodt Inc. CH2Cl2, CH3CN, and THF were dried by using a Mbraun solvent 
purification system. Deuterated NMR solvents were purchased from Cambridge Isotope 
Laboratories, Inc. 
1
H NMR spectra were obtained at 300 or 500 MHz; 
13
C NMR spectra 
were obtained at 125 MHz; 
31
P NMR spectra were obtained at 121 MHz. All NMR 
spectra were acquired on Varian instruments at 25°C. Chemical shifts are reported in ppm 
and J values are in Hz. Fluorescence assay data were obtained using a Varian Cary 
Eclipse Fluorescence Spectrophotometer. Analytical HPLC was performed on a Beckman 
model 125/166 instrument, equipped with a diode array UV detector, ABI Analytical 
Spectroflow 980 fluorescence detector, and a Varian C18 column (Microsorb-MV, 5 µm, 
4.6x250 mm). Preparative HPLC separations were performed by using a Beckman model 
127/166 instrument, equipped with a UV detector and a Phenomenex C18 column (Luna, 
10 µm, 10x250 mm). MS spectra for synthetic reactions were obtained on a Bruker 
BioTOF II instrument. MS and LC/MS spectra of modified peptides were obtained with 
an Applied Biosystems/MDS SCIEX QSTAR® Elite Hybrid LC-MS system. Sep-Pak 
cartridges were purchased from Waters (Milford, MA). Yeast PFTase was prepared as 
previously described.
1 
Protein LC/MS analyses were performed using a Waters Synapt 
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G2 Quadropole TOF mass spectrometer instrument. MALDI-MS analyses were 
performed with a Bruker MALDI TOF spectrometer Instrument. 
Materials and Methods. Alexa Fluor 488-aminooxy (6c) and Texas red hydrazide (6b) 
were from AnaSpec; hydrazide agarose beads were from Thermo Scientific. PEG 
aminooxy 10,000 MW was from NOF America Corporation. C18 Sep-Pak
®
 cartridges 
were purchased from Waters. Vydac 218TP54 and 218TP1010 columns were used for 
analytical and preparative RP-HPLC, respectively. All solvents were of HPLC grade. All 
other reagents were from Sigma Aldrich.  
Abbreviations.  
AF, Alexa-Fluoro488 aminooxy;  
TR, Texas red hydrazide; 
FPP, Farnesyl diphosphate; 
DTT, dithiothreitol; 
ESI-MS, electrospray ionization mass spectrometry; 
Far, farnesyl; 
RP-HPLC, reversed-phase high-pressure liquid chromatography; 
PB, phosphate buffer; 
PEG, polyethylene glycol;  
DMAP, 4-dimethylaminopyridine; 
HOBt, 1-hydroxybenzotriazole; 
HTCU, (2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate); 
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GIP, glucose-dependent insulinotropic peptide; 
DIEA, N,N-Diisopropylethylamine; 
 
Figure 3.S1. Structures of compounds 1 to 14. 
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General method used for synthesis of diphosphates from corresponding alcohols. 
Alcohol (1 eq) was added to CCl3CN (6 eq) in a 25 mL flask. In a separate 5 mL flask, 
(Et3NH)2HPO4 salt (2.8 eq) was added to dry CH3CN (1 mL per 50 mg of alcohol in the 
reaction), and placed in an oil bath at 30 °C for 5 min to dissolve the salt. This solution 
was added drop-wise to the mixture of alcohol and CCl3CN solution over 3 h at rt, and 
was left to stir for an additional 15 min at rt. The slow addition of salt solution to the 
reaction flask was critical to significantly increase the yield. The solvent was removed in 
vacuo and NH4HCO3 (25 mM, 8 mL per 50 mg of alcohol in the reaction) was added to 
the resulting solution and a white precipitate was formed. The solution was filtered and 
purified by RP-HPLC with a semi-preparative column under the following conditions: 
detection at 214 nm; flow rate at 5.0 mL·min-1; 5 mL injection loop; solvent A: 25 mM 
NH4HCO3 in H2O, solvent B: CH3CN. The specific HPLC method used and the yield 
obtained for each substrate is described in its respective section. 
Scheme 3.S1. Synthesis of farnesyl aldehyde diphosphate (1). 
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Synthesis of farnesyl aldehyde diphosphate (1) 
(2E,6E,10E)-2,6,10-trimethyl-12-O-THP-dodeca-2,6,10-trienal (S4). 
 
Compounds S2 and S3 were prepared as previously described.
2
 Alcohol S3 (1.00 g, 3.10 
mmol) was dissolved in anhydrous CH2Cl2 (20 mL) in a 50 mL flask and the solution was 
cooled to 0 °C in an ice bath. DMSO (3.1 mL, 43 mmol) was added drop-wise to the 
solution mixture followed by the addition of triethylamine (2.75 mL, 197 mmol). Sulfur 
trioxide pyridine complex (SO3·Py, 2.52 g, 15.8 mmol) was added slowly over 10 min to 
the reaction mixture. The reaction was stirred at 0 °C for an additional 1 h until TLC 
analysis showed almost complete conversion to the product. The reaction was stopped by 
the addition of 100 mL CH2Cl2 and washed with 5 M HCl (2 x 10 mL) until the aqueous 
phase remained acidic (tested via pH paper) indicating the absence of base in the reaction 
mixture. Next, the solution was washed with sat. NaHCO3 (1 x 15 mL) followed by brine 
(2 x 10 mL). The solution was dried over Na2SO4 and the solvent was removed in vacuo. 
Crude product was purified by silica gel column chromatography using a step gradient of 
solvent (Hex:EtOAc) starting from 1:0 (v/v) going to 3:1 (v/v) to afford 0.79 g of 
compound S4 (2.48 mmol) as a pale yellow oil (80% yield). 
1
H NMR (500 MHz, CDCl3) 
δ 9.37 (s, 1H), 6.46 (t, J = 7.2 Hz, 1H), 6.46 (t, J = 7.2 Hz, 1H), 5.36 (dd, J = 6.3 Hz, J = 
7.3 Hz, 1H), 5.16 (t, J = 6.2 Hz, 3 H), 4.62 (dd, J = 3.0 Hz, J = 4.5 Hz, 1H), 4.24 (dd, J = 
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6.3 Hz, J = 12 Hz, 1H), 4.02 (dd, J = 7.3 Hz, J = 12 Hz, 1H), 3.51 (m, 1H), 3.89 (m, 1H), 
2.0-2.25 (m, 6H), 2.46 (m, 2H), 1.74 (s, 3H), 1.82 (m, 1H), 1.63 (s, 3H), 1.67 (s, 3H), 
1.55 (m, 5H). 
13
C NMR (75 MHz, CDCl3) δ 195.38, 154.53, 139.95, 133.71, 125.33, 
121.75, 120.86, 97.91, 63.70, 62.35, 39.51, 38.01, 30.77, 27.45, 26.25, 25.55, 19.69, 
16.47, 15.97, 9.28. HR-ESI-MS calcd for C20H32O3Na [M+Na]
+
 343.2249, found 
343.2246. 
(2E,6E,10E)-12-hydroxy-2,6,10-trimethyldodeca-2,6,10-trienal (S5). 
 
Protected aldehyde S4 (1.30 g, 4.05 mmol) was dissolved in i-PrOH (20 mL) in a 50 mL 
flask. PPTS (30 mg) was added as catalyst. The reaction was then refluxed at 75 °C for 4 
h, when TLC analysis indicated complete conversion to the product. It was then 
quenched by adding sat. NaHCO3 (10 mL) and EtOAc (100 mL). The organic layer was 
then separated and dried over Na2SO4. The solvent was removed in vacuo and afforded 
0.87 g of compound S5 (91% yield) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 
9.37 (s, 1H), 6.48 (t, J = 7.5 Hz, 1H), 5.41 (t, J = 4.5 ), 5.16 (t, J = 7 Hz, 3 H), 4.14 (t, J = 
7 Hz, 1H), 2.45 (t, J = 7.5, 2H), 2.0-2.25 (m, 6H), 1.68 (s, 3H), 1.74 (s, 3H), 1.64 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 195.35, 154.62, 139.26, 133.60, 125.16, 123.72, 117.30, 
63.57, 39.33, 38.08, 27.34, 26.17, 16.20, 15.85, 9.16. HR-ESI-MS calcd for C15H24O2Na 
[M+Na]
+
 259.1674, found 259.1669. 
(2E,6E,10E)-3,7,11-trimethyl-12-oxododeca-2,6,10-trien-1-yl diphosphate (1). 
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Aldehyde S5 (0.18 g, 0.76 mmol) was used to synthesize compound 1 using the “General 
Method used for Synthesis of diphosphates.” The reagents used were CCl3CN (457 µL, 
4.56 mmol), (Et3NH)2HPO4 (0.57 g, 1.90 mmol) and CH3CN (3.6 mL). The RP-HPLC 
method used was a gradient of 0–30% solvent B in 30 min, 30–100% in 5 min; 
compound 1 eluted from 20–25% solvent B. Fractions containing pure 1 were collected 
and lyophilized. The resulting salt was dissolved in D2O and its concentration was 
measured following a previously established NMR-based quantification
3
 to yield 10 mL 
of 2.5 mM solution of 1 (36 mg, 12% yield). 
1
H NMR: (500 MHz, D2O) δ 9.11 (s, 1H), 
6.61 (t, J = 7.5 Hz, 1H), 5.29 (t, J = 7 Hz, 1H), 5.08 (t, J = 6 Hz, 1H), 4.30 (t, J = 6 Hz, 
2H), 2.38 (t, J = 7 Hz, 2H), 2.07 (t, J = 7 Hz, 2H), 2.00 (t, J = 7 Hz, 2H), 1.917 (t, J = 7 
Hz, 2H), 1.54 (s, 6H), 1.49 (s, 3H). 
31
P NMR: (121 MHz, D2O) δ -5.971 (d, J = 22.6, 1P), 
-10.013 (d, J = 22.6, 1P). HR-ESI-MS calcd for C15H26O8P2 [M-H]
–
 395.1025, found 
395.0907.  
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Scheme 3.S2. Synthesis of formyl benzoyl-oxy geranyl diphosphate (2). 
Synthesis of formyl benzoyl-oxy geranyl diphosphate (2). 
(2E,6E)-2,6-dimethyl-8-O-THP-octa-2,6-dien-1-yl 4-formylbenzoate (S9). 
 
Compounds S7 and S8 were prepared as previously described.
2
 Alcohol S8 (1.50 g, 5.90 
mmol) was dissolved in CH2Cl2 (20 mL) in a flame dried 50 mL flask. para-
Formylbenzoic acid (0.73 g, 7.87 mmol) and DMAP (0.43 g, 5.31 mmol) were added to 
the reaction flask, then left to stir for 10 min at 0 °C. 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (1.83 g, 11.8 mmol) was then added to the reaction flask, and stirred 
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at 0 °C for 1 h until TLC analysis (2:1 Hex:EtOAc v/v) indicated almost complete 
conversion to the product. The reaction was diluted in EtOAc (100 mL), and treated with 
5% HCl (1:10 v/v) until the aqueous layer remained acidic (tested via pH paper). The 
reaction was then washed with sat. NaHCO3 (2 x 10 mL) and brine (2 x 5 mL). The 
solvent was removed in vacuo and the crude product was further purified by silica gel 
column chromatography with gradient elution (Hex:EtOAc) from 10:1 (v/v) going to 2:1 
(v/v) to afford 1.86 g of compound S9 (4.84 mmol, 82% yield) as a pale yellow oil. 
1
H 
NMR (300 MHz, CDCl3) δ 10.11 (s, 1H), 8.21 (d, J = 8.0 Hz, 2H), 7.96 (d, J = 8.4 Hz, 
2H), 5.57 (t, J = 7.9 Hz, 1H), 5.39 (t, J = 7.3 Hz, 1H), 4.74 (s, 2H), 4.62 (m, 1H), 4.25 
(dd, J = 11.7, 6.4 Hz, 2H), 4.03 (dd, J = 11.8, 7.4 Hz, 1H), 3.95–3.83 (m, 1H), 3.51 (dd, J 
= 10.7, 4.8 Hz, 1H), 2.24 (m, 2H), 2.10 (t, J = 7.3 Hz, 2H), 1.76 (s, 3H), 1.70 (s, 3H), 
1.66–1.46 (m, 5H). 13C NMR (75 MHz, CDCl3) δ 191.50, 165.24, 139.32, 138.97, 
135.23, 130.06, 129.81, 129.65, 129.38, 120.98, 97.75, 96.82, 71.11, 63.49, 62.18, 38.79, 
30.58, 25.90, 25.36, 19.51, 16.31, 13.98. 
(2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dien-1-yl 4-formylbenzoate (S10). 
 
Protected alcohol S9 (1.26 g, 3.26 mmol) was dissolved in i-PrOH (20 mL) in a 50 mL 
flask. PPTS (30 mg) was added as a catalyst. The reaction was then refluxed at 80 °C for 
4 h when TLC analysis (2:1 Hex:EtOAc v/v) showed almost complete conversion to the 
product, and was quenched by adding sat. NaHCO3 (10 mL) and EtOAc (100 mL). The 
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organic layer was separated and dried over Na2SO4. Solvent was removed in vacuo to 
afford 0.87 g of compound S10 (2.90 mmol, 89% yield) as a pale yellow oil. 
1
H NMR 
(500 MHz, CDCl3) δ 10.10 (s, 1H), 8.21 (d, J = 8.1 Hz, 2H), 7.96 (d, J = 8.1 Hz, 2H), 
5.56 (t, J = 6.7 Hz, 1H), 5.43 (t, J = 6.5 Hz, 1H), 4.75 (s, 2H), 4.16 (d, J = 6.8 Hz, 2H), 
2.23 (m, 2H), 2.10 (t, J = 7.5 Hz, 2H), 1.76 (s, 3H), 1.68 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 191.71, 165.43, 139.09, 138.44, 135.30, 130.17, 129.91, 129.61, 129.52, 
124.06, 71.21, 59.18, 38.79, 25.91, 16.19, 14.06. HR-ESI-MS calcd for C18H22O4Na 
[M+Na]
+
 325.1415, found 325.1477. 
1-(((2E,6E)-8-((4-formylbenzoyl)oxy)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-1,3-
dihydroxy-3-oxido-1,3-dioxodiphosphoxane (2). 
 
Aldehyde S10 (0.52 g, 1.72 mmol) was used to synthesize compound 2 using the 
“General Method used for Synthesis of diphosphates.” The reagents used were CCl3CN 
(1.035 mL, 10.32 mmol), (Et3NH)2HPO4 (1.55 g, 5.16 mmol) and CH3CN (4 mL). The 
RP-HPLC method used was a gradient of 0–35% solvent B in 30 min, 35–100% in 5 min; 
compound 2 eluted from 25–30% solvent B . Fractions containing pure 2 were collected 
and lyophilized. The resulting salt was dissolved in D2O and concentration was measured 
following the previously established NMR-based quantification method
3
 providing 20 
mL of 8.72 mM of compound 2 (80 mg, 15% yield). The product was stored in Tris·HCl 
(50 mM, pH 7.5) at -80°C; 
1
H NMR (500 MHz, D2O): δ 9.81 (s, 1H), 7.90 (d, J = 6.5 Hz, 
2H), 7.78 (d, J = 7.2 Hz, 2H), 5.39 (t, J = 6.5 Hz, 1H), 5.27 (t, J = 6.5 Hz, 1H), 4.53 (s, 
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2H), 4.29 (t, J = 6.6 Hz, 2H), 2.04 (m, 2H), 1.94 (t, J = 6.9 Hz, 2H), 1.53 (s, 6H).   
31
P 
NMR (162 MHz, D2O) δ -5.91 (d, J = 22.4 Hz), -9.73 (d, J = 22.4 Hz). HR-ESI-MS calcd 
for C18H23O10P2 [M-H]
-
 461.0771, found 461.2021. 
Enzymatic studies of FPP-analogues 1 and 2 using a continuous fluorescence assay. 
Enzymatic reaction mixtures contained Tris·HCl (50 mM , pH 7.5) , MgCl2 (10 mM), 
ZnCl2 (10 μM), DTT (5.0 mM), 2.4 μM N-dansyl-GCVIA (3), 0.040 % (w/v) n-dodecyl-
ß-D-maltoside, PFTase (80 nM), and varying concentrations of either 1 or 2 (0-50 μM), 
in a final volume of 250 μL. The reaction mixtures were equilibrated at 30 °C for 5 min, 
initiated by the addition of PFTase, and monitored for an increase in fluorescence 
(λex=340 nm, λem=505 nm) for approximately 10 min. The initial rates of formation of 
products were obtained as slopes in IU/min using least squares analysis. Corrections were 
applied to all the rate calculations based on the difference between the fluorescence 
intensity of the prenylated product and the starting peptide. Assuming 100% conversion, 
the difference corresponds only to the fluorescence of the total amount of the product. 
The slope was then divided by the fluorescence difference followed by multiplying by the 
total concentration of peptide (2.4 μM) which then gives the rate of formation of product 
in μM/s. It should be noted that the KM values reported here are actually apparent KM 
values,  
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Figure 3.S2. Fluorescence-based PFTase enzyme assay for prenylation of model peptide 
3 using varying concentrations of 1 (left panel) or 2 (right panel). 
  
since the measurements were performed in only a single peptide concentration. The data 
were fit to a Michaelis-Menten model (  
[  ]     [ ]
   [ ]
) using a nonlinear regression 
program, to determine kcat and KM. 
Oxime ligation between peptide-aldehyde 4a and 5a and aminooxy alexafluor-488 
(6c). Coupling reactions contained 3-5 µM 4a or 5a, 200 µM alexafluor-488 (6c), PB (0.1 
M, pH 7.0), and aniline (100 mM) in a final volume of 500 µL. Reactions were 
performed at rt and were initiated by addition of aniline (100 mM). LC-MS analysis of 
the reaction mixture after 3-4 h gave ions of 1384.6 Da and 1450.6 Da  as the 
predominant species, which are consistent with [M+H]
+
 for 4c and 5c, respectively. 
Hydrazone ligation between peptide-aldehydes 4a and 5a and Texas red hydrazide 
(6b). Coupling reactions contained 3-5 µM 4a or 5a, 200 µM Texas red (6b), PB (0.1 M, 
pH 7.0), and aniline (100 mM) in final volume of 500 µL. Reactions were performed at rt 
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and were initiated by addition of aniline (100 mM). LC-MS analysis of the reaction 
mixture after 1 h gave ions of 758.46 Da and 791.45 Da as the predominant species, 
consistent with [M+2H]
2+
 for hydrazones 4b and 5b, respectively. 
 
Figure 3.S3. Schematic representation of oxime and hydrazone ligation reactions of 
aldehydes 4a and 5a with 6b and 6c to form 4b and 4c, and 5b and 5c respectively. 
 
GFP-CVIA. Protein was prepared as previously described with one modification.
4,5
 In 
the final phenyl sepharose chromatography step, after the protein was loaded onto the 
column and washed with buffer as explained in the original work, the protein was eluted 
from column by adding water instead of buffer.  
LC-MS analysis of GFP for determination of prenylation efficiency. Purified 
prenylated GFP was analyzed by LC-MS to ensure complete prenylation. The only peak 
observed was prenylated GFP in case of 1, and there was a small trace of remaining 
unprenylated GFP in case of 2. Proteins were stored in Tris·HCl (50 mM, pH 7.5) prior to 
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injection into the LC-MS instrument.  The LC-MS method used was gradient 0–100% 
solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 min. 
 
Figure 3.S4. ESI mass spectra of A) GFP-CVIA (7), B) GFP prenylated with aldehyde-
analogue 1 to yield 8a, and C) GFP prenylated with aldehyde-analogue 2 to yield 9a, 
showing succesful prenylation of GFP in both cases. The deconvoluted mass spectra are 
shown in the insets. 
 
Effect of prenylation on GFP fluorescence. Fluorescence of same concentration (9 µM) 
of GFP-CVIA (7) and GFP-aldehyde (9a) were measured and the result showed that 
prenylation does not affect the protein fluorescence characteristic. 
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Figure 3.S5. Comparison of the fluorescence intensity of GFP-CVIA (7) and aldehyde-
GFP (9a). The fluorescence of solutions containing 7 or 9a (9 µM) were measured to 
establish that prenylation does not affect the fluorescence properties of GFP (excitation at 
450 nm and emission at 535 nm). 
 
Molecular modeling of GFP-TAMRA. The model of GFP-TAMRA was based on the 
previously solved X-ray structure of GFP (PDB ID: 2Y0G) and subsequent modeling was 
performed using Maestro (Schrodinger, Portland, OR). The CVIA tag was first appended 
onto the C-terminus of GFP and the prenyl moiety containing the covalently coupled 
TAMRA was built onto the thiol side chain of the C terminal cysteine. The protein, the 
CVIA C-terminus and the prenyl-fluorophore group were then energy minimized using a 
truncated Newton algorithm. 
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Immobilization of 9a onto hydrazide agarose beads. Hydrazide agarose beads 
(Thermo Scientific, hydrazide loading: 16 µmol/mL) (300 µL) were washed with PB (0.1 
M, 3x500 µL, pH 7.0). PB (30 µL, 1 M, pH 7.0) was added to the beads followed by 
addition of 9a (200 µL, 87 µM). Immobilization was initiated by adding aniline (2 µL, 
100 mM). For controls, GFP-CVIA (7) was added instead of 9a. The solution was 
centrifuged, then the GFP UV-absorbance of the supernatant was measured as a function 
of time (488 nm, ε=55,000 M-1 ·cm-1). After 2 h, the solution was centrifuged and the 
beads were washed thoroughly with PB (0.3 M, pH 7.3, 3x300 µL) and KCl (3x300 µL, 1 
M) to remove non-specifically bound proteins and were stored in pH 7.5 Tris buffer at 4 
°C. 
 
Figure 3.S6. Kinetic analysis of immobilization of 9a onto hydrazide functionalized 
agarose beads. The reaction was carried out at rt, in the presence of 100 mM aniline and 
excess beads. UV absorbance of GFP in the supernatant was measured at different times 
showing >95% immobilization in ~45 min. Experiments were performed in duplicate. 
The data was fit to a simple exponential process. 
 
 127 
 
MALDI analysis of protein PEGylation. MALDI analysis was used to measure the Mn, 
Mw and PDI of the PEG 10 and GFP-PEG 11 using equations below: 
   
∑    
∑  
          
∑  
    
∑  
            
  
  
 
Where M is the mass of each species and N is the intensity of that specific peak. 
Calculations showed that for PEG 10: Mn=10,790, Mw=10,804 and PDI=1.0012. MALDI 
analysis for GFP-PEG 11 showed Mn=38,637, Mw=37,647 and PDI=1.0003. It should be 
noted that since PDI is, in part, related to the mass of the polymer, it is expected that 
addition of a monodisperse protein to a polydisperse polymer should result in a decrease 
in PDI of the protein-polymer conjugate as was observed.  
 
Figure 3.S7. MALDI analysis of PEG 10, GFP-aldehyde 9a and PEGylated GFP 11. The 
lower panel is the MALDI spectrum of pure PEG 10, the middle panel is the MALDI 
spectrum of pure 9a and the top panel is the MALDI spectrum of the oxime PEGylated 
GFP 11, which confirms complete conversion. Excess of 10 was removed via a zip-tip 
protocol prior to MALDI analysis of 11. 
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Scheme 3.3. Synthesis of PEG-aminooxy (13). 
 
Synthesis of PEG 13. 4,7,10-Trioxa-1,13-tridecanediamine (S11, 9.3 mmol, 2.049 g) 
was dissolved in anhydrous DMF (15 mL) in a 25 mL round bottom flask. Dansyl-
chloride (1.86 mmol, 500 mg) was added to the solution and the reaction mixture was 
stirred at rt for 3 h. The reaction was stopped by the addition of 100 mL CH2Cl2 and 
washed with 5 M NaOH (2 x 10 mL). Next, the solution was washed with brine (1 x 10 
mL) and was dried over Na2SO4. The solvent was removed in vacuo, the crude product 
was re-dissolved in 4 mL DMF, and then one fourth of the resulting solution was 
transferred to a 2 mL eppendorf tube. (Boc-aminooxy)acetic acid (0.5 mmol, 95 mg) was 
dissolved in 0.5 mL DMF. Collidine (1.1 mmol, 145 µL) and EDC (0.5 mmol, 88.5 µL) 
were added to the (Boc-aminooxy)acetic acid solution and the mixture was quickly added 
to the PEG containing solution. The reaction mixture was stirred for 2 h at rt. The 
reaction was stopped by the addition of 100 mL EtOAc and washed with 5 M NaOH (1 x 
5 mL), sat. NH4Cl (1 x 5 mL) and 5 M HCl (1 x 5 mL) respectively. Next, the solution 
was washed with brine (1 x 5 mL) and was dried over Na2SO4. The solvent was removed 
in vacuo, the crude product was dissolved in 1 mL CH2Cl2, and transferred to a 5 mL 
flask. CH2Cl2 (2 mL) and TFA (1.5 mL) were added to the crude product and the reaction 
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mixture was stirred for 2 h at rt. Next the solvent was removed in vacuo and the crude 
product was dissolved in 5 mL solution of H2O containing 0.1% TFA (v/v). The product 
PEG 13 was purified by RP-HPLC with a semi-preparative column under the following 
conditions: detection at 330 nm; flow rate at 5.0 mL·min-1; 1 mL injection loop; solvent 
A: H2O, solvent B: CH3CN. The RP-HPLC method used was a gradient of 0–35% 
solvent B in 30 min, 35–100% in 5 min; PEG 13 eluted from 23–28% solvent B. 
Fractions containing pure 13 were collected and lyophilized. HR-ESI-MS calcd for 
C24H39O7N4S [M+H]
+
 527.2534, found 527.2571. The compound was dissolved in 2 mL 
Tris·HCl (50 mM, pH 7.5) and stored at -20 °C. The concentration was measured using 
UV absorbance of dansyl-chromophore at 325 nm (ɛ=4200 M-1·cm-1, 4.3 mM,  4.5 mg, 
2% yield over three steps). 
Synthesis of GIP-CVIM. GIP-CVIM is a fusion of GIP
6
 and the 15 C-terminal residues 
from human K-Ras 4B.
7
  The sequence is shown below in Figure 3.S8. The protein was 
prepared by solid phase synthesis using a Protein Technologies PS3 synthesizer 
employing standard Fmoc procedures. The synthesis was performed on a 0.1 mmol scale 
starting with preloaded Fmoc-L-Met-PEG-PS resin (Applied Biosystems). Each residue 
was double-coupled in the presence of HCTU, HOBT and DIEA. Following completion 
of the synthesis, the material was treated with Reagent K for 2.5 h followed by 
precipitation with Et2O. The solid product was isolated by centrifugation and the pellet 
washed twice with Et2O. The resulting white solid was dissolved in H2O containing 0.1% 
TFA and half of it was purified by RP-HPLC. Yield 43.1 mg (13% from 50 µmol peptide 
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resin), purity by LC-MS analysis: 83%. LC-ESI-MS: calcd: 6700.8, observed 
(deconvoluted): 6700.0.  
 
 
YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQGKKKKKKSKTK
CVIM 
 
Figure 3.S8. Sequence of GIP-CVIM. The 15 C-terminal residues from human K-Ras 4B 
are underlined. 
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1
H-NMR for compound 1. 
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31
P-NMR for compound 1. 
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1
H-NMR of compound 2. 
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31
P-NMR of compound 2. Na2H2P2O7 is used as standard for quantification 
measurements.
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Imine-based reactions are useful for a wide range of bioconjugation applications. 
Although aniline is known to catalyze the oxime ligation reaction under physiological 
conditions, it suffers from slow reaction kinetics, specifically when a ketone is being used 
or when hydrazone-oxime exchange is performed. Here, we report on the discovery of a 
new catalyst that is up to 15 times more efficient than aniline. That catalyst, m-
phenylenediamine (mPDA), was initially used to analyze the kinetics of oxime ligation 
on aldehyde- and ketone-containing small molecules. While mPDA is only modestly 
more effective than aniline when used in equal concentrations (~ 2-fold), its much greater 
aqueous solubility relative to aniline allows it to be used at higher concentrations, 
resulting in significantly more efficient catalysis. In the context of protein labeling, it was 
first used to site-specifically label an aldehyde-functionalized protein through oxime 
ligation, and its kinetics were compared to reaction with aniline. Next, a protein was 
labeled with an aldehyde-containing substrate in crude cell lysate, captured with 
hydrazide-functionalized beads and then the kinetics of immobilized protein release via 
hydrazone-oxime exchange were analyzed. Our results show that mPDA can release and 
label 15 times more protein than aniline can in 3 h. Then, using the new catalyst, ciliary 
neurotrophic factor, a protein with therapeutic potential, was successfully labeled with a 
fluorophore in only 5 min. Finally, a protein containing the unnatural amino acid, p-
acetyl phenylalanine, a ketone-containing residue, was prepared and PEGylated 
efficiently via oxime ligation using mPDA. This new catalyst should have a significant 
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impact on the field of bioconjugation, where oxime ligation and hydrazone-oxime 
exchange are commonly employed. 
Introduction 
Imine-based reactions are widely used to link complex biomolecules due to their high 
chemoselectivity and reversibility.
150–152,123,153–156
 When there is an oxygen or nitrogen 
atom adjacent to a nitrogen as in the cases of hydrazines and alkoxyamines, the reaction 
favors imine formation;
157,141
 in the absence of such a substituent, the equilibrium favors 
formation of free amine and free aldehyde or ketone. Among all imine-based reactions, 
oximes are the most stable imines
141
 and as a result have found widespread use in 
applications such as protein labeling,
11–15
 analyzing protein-protein interactions and in 
vivo cell imaging.
9,158
 Although aniline is known to catalyze the oxime formation 
reaction, it suffers from relatively slow reaction kinetics, especially when a ketone is 
being used
11,18
 or when transoximization is conducted.
39
 In the case of ketones under 
physiological conditions, even in presence of aniline, it takes several hours for the 
reaction to be complete although faster rates can be achieved if higher reactant 
concentrations are employed. Moreover, in the case of hydrazone-oxime exchange, the 
reaction rates are orders of magnitudes slower. Therefore, discovery of an improved 
catalyst would significantly improve the utility and broaden the scope of this valuable 
bioorthogonal reaction. Here, we introduce a new catalyst, m-phenylenediamine (mPDA) 
that can accelerate oxime ligation several times faster compared with aniline-catalyzed 
oxime ligation. That feature, in concert with the substantially greater aqueous solubility 
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of m-phenylenediamine allows rate accelerations of approximately 15-fold to be 
obtained. 
Experimental Section 
Dansyl fluorescence assay. Reaction mixtures contained phosphate buffer (PB) (100 
mM, pH 7.0), varying concentrations (10 μM to 300 μM) of aminooxy-dansyl (1), 0.08 % 
(w/v) n-dodecyl-ß-D-maltoside, 50 μM aldehyde (citral or dodecanal) and varying 
concentrations of catalysts, in a final volume of 250 μL. The reaction mixtures were 
equilibrated at rt for 1 min, initiated by the addition of the aldehyde, and monitored for an 
increase in fluorescence (λex=340 nm, λem=505 nm) for approximately 50 min. 
Catalyst screening. m-Phenylediamine, o-phenylenediamine, p-phenylediamine, o-
aminophenol, m-aminophenol, p-aminophenol, o-aminobenzoic acid and aniline were 
analyzed for catalytic activity in the oxime ligation reaction. Reaction mixtures contained 
PB (100 mM, pH 7.0), 100 μM aminooxy-dansyl (1), 0.08 % (w/v) n-dodecyl-ß-D-
maltoside, 50 μM aldehyde (citral or dodecanal) and 25 μM catalyst, in a final volume of 
200 μL. The reaction mixtures were equilibrated at rt for 1 min, initiated by the addition 
of the aminooxy reagent, and monitored for an increase in fluorescence (λex=340 nm, 
λem=505 nm) for 50 min.  
Effect of the catalyst concentration on the kobs. Reaction mixtures contained PB (100 
mM, pH 7.0), 100 μM aminooxy-dansyl (1), 0.08 % (w/v) n-dodecyl-ß-D-maltoside, 30 
μM aldehyde (citral) and varying concentrations of catalysts (25 to 50 mM) in a final 
volume of 200 μL. The reaction mixtures were equilibrated at rt for 1 min, initiated by 
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the addition of the aldehyde, and monitored for an increase in fluorescence (λex=340 nm, 
λem=505 nm) for approximately 25 min. 
Kinetic analysis of oxime ligation between 2-pentanone and aminooxy-dansyl 1. 
Reaction mixtures contained Tris·HCl (50 mM, pH 7.5), aminooxy-dansyl 1 (150 μM), 
0.4 % (w/v) n-dodecyl-ß-D-maltoside, 5 mM ketone (2-pentanone) and varying 
concentrations of catalysts, in a final volume of 200 μL. The reaction mixtures were 
equilibrated at rt for 1 min, initiated by the addition of the aminooxy, and monitored for 
an increase in fluorescence (λex=340 nm, λem=505 nm) for approximately 4 h. 
Enzymatic incorporation of 2 into GFP-CVIA (3). Enzymatic reaction mixtures (50 
mL) contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl (30 mM), ZnCl2 (10 
µM), DTT (5.0 mM), GFP-CVIA (3, 2.4 µM), 2 (50 µM), and PFTase (200 nM). After 
incubation at rt overnight, the reaction mixture was concentrated using an Amicon 
Centriprep centrifugation device (10,000 MW cut-off). Next, excess 2 was removed with 
a NAP-5 (Amersham) column using Tris·HCl (50 mM, pH 7.5) as the eluent. The 
subsequent protein concentration was calculated by UV absorbance at 488 nm (ε=55,000 
M
-1·cm-1). 
Kinetic analysis of protein labeling via oxime ligation. Reaction mixtures contained 
PB (100 mM, pH 7.0), 10 μM GFP-aldehyde 4a, 50 μM aminooxy-dansyl 1 and varying 
concentrations of m-phenylenediamine or 100 mM aniline, in a final volume of 250 μL. 
The reaction mixtures were equilibrated at rt for 1 min, initiated by the addition of the 
catalyst, and monitored for an increase in fluorescence (λex=340 nm, λem=505 nm) for 
approximately 100 min. 
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Crude prenylation, immobilization and subsequent labeling and release of GFP-
CVIA. A pellet of cells expressing GFP-CVIA were suspended in buffer (20 mM 
Tris·HCl pH 7.5, 1 mM EDTA), sonicated and clarified by centrifugation. The GFP 
concentration present in the crude soluble protein mixture was calculated by UV 
absorbance at 488 nm. Next, prenylation was performed by adding PFTase (200 nM), 2 
(50 µM), Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl (30 mM), ZnCl2 (10 µM) and 
DTT (5.0 mM) to a solution of 3, to achieve a final concentration of 2.0 µM in the crude 
mixture. After overnight incubation at rt, the reaction mixture was filtered and 
concentrated using an Amicon Centriprep centrifugation device (10,000 MW cut-off). 
Next, excess 2 was removed through a NAP-5 (Amersham) column using Tris·HCl (50 
mM, pH 7.5) as the eluting solvent. The subsequent GFP concentration in the crude 
mixture was calculated by UV absorbance at 488 nm. Hydrazide agarose beads (Thermo 
Scientific, hydrazide loading: 16 µmol/mL) (300 µL) were washed with PB (0.1 M, 
3x500 µL, pH 7.0). PB (30 µL, 1 M, pH 7.0) was added to the beads followed by addition 
of 4a in the crude mixture (200 µL, 70 µM). Immobilization was initiated by adding 
aniline (100 mM) or m-phenylenediamine (40 mM). After 1 h with constant agitation, the 
beads were washed thoroughly with PB (0.3 M, pH 7.3) and KCl (3x300 µL, 1 M) to 
remove non-specifically bound proteins followed by incubation with aminooxy 
fluorophore 5 (0.7 mM) and either m-phenylenediamine (700 mM) or aniline (100 mM) 
with constant agitation. The supernatant was then analyzed via SDS-PAGE and in-gel 
fluorescence analysis to compare the amount of protein released from the beads with 
either catalyst. 
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LC-MS analysis of proteins for determination of prenylation and labeling efficiency. 
Purified prenylated GFP (4a) and pure GFP-CVIA (3) were analyzed by LC-MS to 
ensure complete prenylation. Proteins were stored in Tris·HCl (50 mM, pH 7.5) prior to 
injection into the LC-MS instrument. Crude reaction mixtures of GFP-aldehyde 4a and 
aminooxy 1 catalyzed by either aniline or m-phenylenediamine were analyzed by LC-MS 
to ensure complete ligation in both cases of the catalysts.  The LC-MS method used was a 
gradient of 0–100% solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 
min.  
Kinetic analysis of hydrazone-oxime exchange. The hydrazide beads containing 
immobilized GFP were incubated in PB (0.3 M, pH 7.0) with aminooxy-alexafluor-488 5 
(1 mM) and either aniline (100 mM) or m-phenylenediamine (750 mM) with constant 
agitation of the resulting mixtures at rt. The solutions were centrifuged at different time 
points (every 1 h for mPDA and every 2 h for aniline for a total of 8 h) and the amounts 
of released protein in the solutions were analyzed via SDS-PAGE. Gels were visualized 
by staining with Coomassie blue after being scanned via in-gel fluorescence imaging of 
alexafluor-488.  
PEGylation from immobilized GFP-beads. Immobilization was performed as described 
above. Beads were washed thoroughly with PB (0.3 M, pH 7.3) and KCl (3x300 µL, 1 
M) to remove non-specifically bound proteins. Next, the beads were incubated with 
aminooxy PEG 10 (5 mM) and m-phenylenediamine (200 mM) for 2 h with constant 
agitation of the solution at rt. MALDI-MS analysis of the supernatant indicated the 
successful PEGylation and release of the aldehyde-GFP from the hydrazide-beads. 
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Prenylation of CNTF-CVIA with aldehyde analog 2. Enzymatic reaction mixtures (20 
mL) contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl (30 mM), ZnCl2 (10 
µM), DTT (5.0 mM), CNTF-CVIA (2.4 µM), 2 (50 µM), and PFTase (200 nM). After 
incubation at rt for 90 min, the reaction mixture was concentrated using an Amicon 
Centriprep centrifugation device (10,000 MW cut-off). Next, excess 2 was removed with 
a NAP-5 (Amersham) column using Tris·HCl (50 mM, pH 7.5) as the eluent. Purified 
prenylated CNTF (9) and pure CNTF-CVIA were analyzed by LC-MS to ensure 
complete prenylation. Proteins were stored in Tris·HCl (50 mM, pH 7.5) prior to 
injection into the LC-MS instrument. 
Coupling reaction between aldehyde-labeled CNTF-CVIA (9) with alexafluor-488 
(5). Alexafluor-488 (5) (4.2 µL of 3.2 mM solution in DMSO) was added to 42 µL of 9 
(stock solution of 60 µM in Tris·HCl (50 mM, pH 7.5)). PB (2 M, pH 7, 2.5 µL) was 
added and the reaction was initiated by adding 50 mM m-phenylenediamine (stock 
solution of 1.5 M in 0.3 M PB, pH 7.0) and was allowed to proceed for 30 min at rt. LS-
MS analysis of the sample showed only oxime ligated protein and no free aldehyde was 
detected indicating a complete reaction in both prenylation and oxime ligation reactions. 
Rate analysis of the coupling reaction between aldehyde-CNTF 9 and aminooxy 5. 
Alexafluor-488 (5) (8 µL of 3.1 mM solution in DMSO) was added to 6 µL of PB (1 M, 
pH 7) and 2 µL of m-phenylenediamine (stock solution of 1.5 M in 0.3 M PB, pH 7.0) or 
2 µL water as the control reaction. Reactions were performed at rt and were initiated by 
adding 20 µL of 9 (stock solution of 60 µM in Tris·HCl (50 mM, pH 7.5)). To monitor 
the reactions, 15 µL aliquots were withdrawn at 5 min intervals, added to 15 µL of 
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loading buffer, flash frozen by liquid nitrogen and subjected to SDS-PAGE analysis. 
Samples were heated at 98 °C for 4 min prior to gel analysis. 
PEGylation of DHFR2 M174pAcF 11 protein with aminooxy-PEG 12 using mPDA. 
DHFR
2
 fusion protein with the unnatural amino acid p-acetyl phenylalanine (DHFR
2
 
M174pAcF) (7 µM) was reacted with aminooxy-PEG 12 (3 kDa) (5 mM) in PB (0.1 M, 
pH 7) in the presence of either 100 mM aniline, 500 mM mPDA or no catalyst at rt. The 
amounts of PEGylated protein in the solutions were analyzed at different time points via 
SDS-PAGE. Gels were visualized by staining with Coomassie blue. Densitometry 
analyses on the stained gels were performed using the program ImageJ v1.46. 
General procedure for MALDI analysis of protein samples. The sample was adsorbed 
onto a zip-tip (C4 column) via repeated cycles of aspiration and ejection (5-10 cycles of 
10 µL each) using a pipettor. Next, in order to remove excess buffer and reagents, the 
zip-tip was washed 5x10 µL with solvent A (H2O containing 0.1% TFA; v/v) and the 
proteins eluted with 2 µL of a mixture of A and B (25:75) (solvent B: CH3CN containing 
0.1% TFA; v/v). Next 0.7 µL of the eluted material was added to a MALDI plate and 
0.7 µL of matrix was added on top of the sample plate and both were mixed thoroughly 
to form crystals. A saturated solution of sinapinic acid (3,5-dimeth-oxy-4-hydroxy-
cinnamic acid) was used as the matrix. 
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Results and Discussion 
Development of an assay to analyse kinetic of the oxime ligation reaction. 
   In order to study catalysis of oxime ligation, a continuous fluorescence assay was 
developed that enabled easy monitoring of the reaction. The dansyl chromophore 
manifests environmentally sensitive fluorescence that increases in the presence of 
hydrophobic groups.
159
 Thus, it was postulated that reaction of an aminooxy dansyl 
compound with a hydrophobic aldehyde or ketone would result in an increase in dansyl 
fluorescence that could easily be used to monitor the kinetics of oxime ligation. 
Therefore, an aminooxy-derivatized dansyl-containing compound, 1, was designed and 
synthesized in three steps (Figure 4.1A). Incubation of 1 in the presence of citral, 
dodecanal or 2-pentanone resulted in a time dependent increase in fluorescence indicative 
of oxime formation. The formation of these products was confirmed by HPLC and MS 
analysis. 
Screening for a new catalyst suitable for oxime ligation reaction. 
   After validating the continuous fluorescence assay, a number of different compounds 
were examined to identify new putative oxime ligation reaction catalysts. Two key 
features were considered in screening for such catalysts. First, the basicity of the 
intermediate Schiff base imine formed
142
 should not be significantly lower than the 
original amine (catalyst) basicity. Second, the catalyst should have high water solubility. 
Aromatic amines that are conjugated, such as aniline, meet only the first requirement in 
that their Schiff bases have basicities close to their free amines.
160
 Based on the idea that 
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the presence of electron donating groups on an aromatic ring would render the 
corresponding Schiff base more basic, it was reasoned that such compounds would be 
 
 
Figure 4.1. A) Synthesis of dansyl-aminooxy 1. B) Schematic representation of dansyl-
fluorescence assay. When the dansyl moiety is in close proximity to a hydrophobic 
group, its fluorescence increases. “Hydrophobic moiety” represents the alkyl chain of 
the aldehyde- or ketone-containing reactants. C) Analysis of the reaction of 1 (100 µM) 
with citral (30 µM), a conjugated hydrophobic aldehyde, in presence of either 50 mM 
mPDA (squares) or 50 mM aniline (triangles) with kobs of 78.2 s
-1
M
-1
and 48.9 s
-1
M
-1
 
respectively. D) Analysis of the reaction of 1 (150 µM) with 2-pentanone (5 mM), a non-
conjugated ketone, in presence of either 100 mM mPDA (squares) or 100 mM aniline 
(triangles) with kobs of 0.20 s
-1
M
-1
and 0.082 s
-1
M
-1
 respectively.   
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more efficient reaction catalysts. Thus, o-, m- and p-aminophenols, o-aminobenzoic acid 
and o-, m- and p-phenylenediamines were examined. The latter three compounds have the 
advantage of having two amino groups that theoretically increases the probability of 
formation of an intermediate Schiff base that could result in higher catalytic efficiency. 
After using the fluorescence assay described above to screen all seven proposed catalysts, 
and fitting the data to the second order kinetic model previously employed by Dawson 
and coworkers,
142
 a range of results were obtained and are summarized in Table 4.1 and 
Figure 4.S1. Given the variations in rate observed with the different catalysts, it is likely 
that a complex interplay of factors including inductive, steric and resonance effects 
together with hydrogen bonding (in the case of ortho substituents) participate in 
controlling their reactivity. o-Aminophenol was found to have a solubility too low to be 
useful. o-Phenylenediamine, m-aminophenol, and o-aminobenzoate were found to be 
equal to or less efficient than aniline while p-aminophenol, m-phenylenediamine and p-
phenylenediamine were found to be more efficient compared with aniline. Of those latter 
three, m-phenylenediamine (mPDA) was the most efficient catalyst (1.7-fold compared to 
aniline) and had high water solubility. Hence mPDA was selected for further study.  
Kinetic analysis of oxime ligation reactions using aniline and  m-phenylenediamine 
(mPDA). 
   Next, the reactions between several aldehyde- and ketone-containing compounds and 
alkoxyamine 1 were studied using aniline and mPDA as catalysts. Two hydrophobic 
aldehydes compatible with the fluorescence-based assay, citral and dodecanal 
(conjugated and nonconjugated aldehydes, respectively) were selected for initial 
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experimentation. Analyses were performed using 50 mM catalyst (aniline or mPDA), 100 
µM 1 and 30 µM aldehyde in phosphate buffer at pH 7.3. Interestingly, analysis of those 
reactions showed that both aldehydes were labeled with dansyl-aminooxy 1 within a few 
minutes. An equal concentration of mPDA was almost twice as efficient (Figure 4.1C, 
blue squares) as aniline (black triangles) consistent with what was observed in the initial 
screening; when no catalyst was employed, oxime formation required more than 80 min 
to achieve comparable levels of conversion under the same conditions (Figure 4.S2-A, 
green circles). Significantly, citral, a conjugated aldehyde, reacted almost two times 
slower than dodecanal did (Figure 4.S2-B). Given the importance of ketone-containing 
compounds as targets for bioorthogonal reactions, 2-pentanone was also studied as an 
example and was found to react at a rate at least two orders of magnitude slower than 
either of the two aldehydes (kobs for oxime ligation of citral and 2-pentanone with 
aminooxy-dansyl 1 were 48.6 s
-1
M
-1
 and 0.082 s
-1
M
-1
 using 50 mM and 100 mM aniline 
as a catalyst, respectively; Table 4.1 and Table 4.3). This highlights the role of carbonyl 
group reactivity in oxime formation kinetics. Aldehydes react more rapidly than ketones 
and non-conjugated aldehydes are more reactive than conjugated ones. Dawson and 
coworkers originally established that the kinetics of oxime ligation reactions catalyzed by 
aniline fit a second order model that is first order in both aldehyde and alkoxyamine.
142
 
They also showed that the apparent second order rate constant for this process varied with 
aniline concentration. Wen-jun et al. extended those observations by demonstrating that 
the apparent second order rate constant varied linearly with aniline.
161
 Accordingly, we 
analyzed the rate data for the citral model reaction described here and confirmed that both 
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the aniline- and mPDA-catalyzed reactions vary linearly with catalyst concentration 
(Figure 4.S4 and 4.S5; Table 4.2). A linear dependence on reaction rate with catalyst 
concentration was also observed in the model reaction involving the ketone, 2-pentanone 
(Table 4.3 and Figure 4.S3). Overall, the results of these model studies indicate that the 
increase in reaction rate using mPDA is approximately 2-fold higher than that obtained 
with aniline when the catalysts are employed at equal concentrations. However, the fact 
that the rate of oxime formation is first order in catalyst, coupled with the much greater 
solubility of mPDA suggested that it should be possible to obtain much greater rate 
acceleration with mPDA by employing it at concentrations substantially above the 
solubility limit of aniline (~ 100 mM). That feature is apparent from the data shown in 
Table 4.3 for 2-pentanone and was investigated in more detail using aldehyde- and 
ketone-containing proteins as described below. 
Kinetic analysis of oxime ligation on proteins. 
   To examine the kinetics of oxime ligation on proteins, the enzyme protein 
farnesyltransferase (PFTase) was employed to introduce aldehyde functionality into 
proteins. In previous work, a number of groups have exploited the high specificity of 
PFTase to site-specifically modify proteins. PFTase catalyzes the transfer of an 
isoprenoid group from farnesyl pyrophosphate (FPP, Figure 4.2A) to a cysteineyl sulfur 
atom present in a tetrapeptide sequence (denoted as a CaaX-box) positioned at the C-
terminus of a protein. Importantly, CaaX-box sequences such as CVIA can be appended 
to the C-termini of many proteins rendering them efficient substrates for PFTase. Since 
PFTase can tolerate many simple modifications of the isoprenoid substrate, it can be used 
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to introduce a variety of different functional groups into proteins; chemoselective reaction 
with the resulting functionalized protein can then be used for a wide range of 
applications. We previously showed that aldehyde-containing FPP analogues could be  
 
Figure 4.2. Kinetic analysis of oxime ligation with an aldehyde-functionalized protein. 
A) Structures of FPP and compound 2. B) Schematic representation of a prenylation 
reaction with a protein containing a CaaX box at its C-terminus. C) Schematic 
representation of oxime ligation with an aldehyde-functionalized protein 4a using either 
aniline or mPDA as the catalyst. D) Kinetic analysis of oxime ligation between 4a (10 
µM) and 1 (50 µM) using either aniline or different concentrations of mPDA. Note: at 
high mPDA/aminooxy ratios, Schiff base formation is competitive with oxime ligation. 
Hence, the % labeling reported here for oxime formation is relative to the value at 
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equilibrium and not complete conversion (vide infra). The solubility limit for aniline is 
approximately 100 mM under these conditions. 
successfully incorporated into the proteins using this strategy and used such aldehyde-
modified proteins here. 
   GFP-CVIA (3) was employed as a model protein to perform oxime kinetic analysis 
(Figure 4.2C). The protein was tagged with analogue 2
40
 using PFTase to yield aldehyde-
labeled protein 4a that was used in subsequent ligation reactions. Dansyl-aminooxy 1 was 
added to a solution of 10 µM aldehyde-functionalized protein 4a and the reactions were 
initiated by the addition of either aniline or mPDA catalyst. As was observed with the 
simple aldehyde model compounds described above, oxime formation between 1 and 4a 
resulted in a significant increase in dansyl group fluorescence that was then used to 
measure the reaction rate; no fluorescence change was observed when unprenylated GFP-
CVIA (3) was treated with 1 (Figure 4.S7).  Additionally, analysis of the initial protein 3, 
aldehyde-functionalized protein 4a, and oxime-labeled protein 4b via LC-MS gave 
species at 27,335 Da, 27,619 Da, 27,926 Da, confirming that prenylation and the 
following oxime labeling were proceeding as expected (Figure 4.S6). Interestingly, 
examiniation of the reaction rates using 4a via the fluorescence assay showed that both 
catalysts were somewhat less effective with the protein aldehyde than they were with the 
simple model aldehydes (Figure 4.S7). That observation suggests that the reactivity of the 
aldehyde can be modulated by the protein to which it is attached and is consistent with 
previous observations reported by Dawson and Bertozzi where varying extents of 
acceleration by aniline were reported.
153,158
 Since mPDA, in contrast to aniline, has a high 
solubility in water at pH 7 (approximately 100 mM for aniline compared to >2 M for 
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mPDA), we decided to examine the effect of employing higher concentrations of the new 
catalyst on the oxime ligation reaction using a protein-aldehyde substrate. Consistent with 
the first-order kinetics observed in the model reactions discussed above, a plot of rate 
versus mPDA concentration for oxime-protein ligation was also linear (Figure 4.S8). 
Thus, the ability to employ higher concentrations of mPDA compared with aniline due to 
its greater solubility resulted in significant rate acceleration; for example inclusion of 
mPDA at 750 mM resulted in essentially complete labeling of the aldehyde-
functionalized protein 4a in about 90 s (Figure 4.2D), which is an impressive result 
compared with the minimal reaction (<7%) obtained with 100 mM aniline during that 
same time period. Kinetic analysis revealed that when aniline and mPDA were used at the 
same concentrations (100 mM), mPDA catalyzed the reaction ~2.5 times more efficiently 
than aniline (compare kobs of 10.3 M
-1·s-1 for aniline versus 27.0 M-1·s-1 for mPDA, Table 
4.S1). More importantly the rate was greater than 10 times higher when mPDA was 500 
mM and approximately 15 times higher when mPDA was 750 mM (Figure 4.S8 and 
Table 4.S1). 
 Capture and release strategy to purify and label proteins from crude cell extract 
using mPDA. For many protein labeling applications, the target polypeptide is not 
always pure or present in high abundance; therefore, specific modification strategies that 
function in a crude mixture are necessary. In previous work, we reported on a method for 
site-specifically functionalizing a protein in a crude cell mixture, and labeling and 
purifying the modified protein using aniline without any additional purification.
40
 
Although that process was successful, it required long reaction times to achieve 
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significant levels of conversion. Accordingly, we next re-evaluated our aforementioned 
method for protein labeling with the new, more effective, mPDA catalyst discovered  
 
Figure 4.3. Purification and selective labeling of a protein using mPDA. Target protein 
was site-specifically tagged by aldehyde-FPP analog via PFTase followed by capture of 
the aldehyde-functionalized protein in the crude cell lysate by hydrazide functionalized 
surfaces. Prenylation in the crude was confirmed by LC-MS analysis on the crude extract 
after prenylation. The immobilized protein was then released into the solution and 
fluorescently labeled by addition of aminooxy-fluorophore 5 (0.7 mM), using either 
mPDA (700 mM) or aniline (100 mM, its approximate solubility limit) as the catalyst. 
SDS-PAGE analysis (visualized by staining with Coomassie blue): Right lane (1): crude 
cell lysate, middle lane (2): released protein (after immobilization) obtained using aniline 
for 4 h; Left lane (3): released protein after immobilization obtained using mPDA for 3 h. 
 
 
here. Thus, E. coli cells expressing GFP-CVIA 3 were lysed and enzymatically 
prenylated using PFTase and substrate 2. LC-ESI/MS analysis of the reaction sample 
confirmed incorporation of the aldehyde functionality into the GFP-CVIA 3 in the crude 
cell lysate. The reaction mixture was then concentrated and excess 2 was removed via 
size exclusion column chromatography. Aldehyde-GFP 4a was then selectively 
immobilized from the crude cell lysate onto hydrazide-functionalized beads using either 
3        2         1
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100 mM aniline or 40 mM mPDA as the catalyst. Immobilization was complete in less 
than 45 min in both cases at which point the beads became highly fluorescent. Next, the  
 
 
Figure 4.4. Kinetic analysis of the release of the hydrazone immobilized protein into 
fluorescently labeled oxime protein via hydrazone-oxime exchange reaction. 
Immobilized protein was incubated with aminooxy fluorophore 5 (1 mM) and catalyst, 
followed by analysis of the amount of released protein in the solution via SDS-PAGE. In 
(A) and (B), the upper bands were visualized by staining with Coomassie blue while the 
lower bands were detected via in-gel fluorescence imaging of Alexafluor-488. A) Time 
course of protein release in 1-8 h using mPDA (750 mM) as the catalyst. B) Time course 
of protein release using aniline (100 mM, its approximate solubility limit). C) 
Comparison of protein release rates using aniline or mPDA obtained by densitometric 
analysis of the SDS-PAGE results shown in (A) and (B) using the Coomassie blue 
stained gels. 
 
beads were thoroughly washed to remove any non-specifically bound proteins and then 
treated with aminooxy-alexafluor-488 5 in the presence of 100 mM aniline or 700 mM 
mPDA and the amount of released and fluorescently labeled protein was measured. SDS-
PAGE analysis of the supernatant solution showed a single band attributable to the 
released, labeled GFP 4d (Figure 4.3). Qualitatively, from that data, it is clear that the 
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efficiency of protein release using mPDA is substantially greater than with aniline. A 
more thorough kinetic analysis revealed that mPDA, under these reaction conditions, can 
release immobilized protein from the beads with an initial velocity approximately 15 
times faster than aniline (compare kobs of 0.0159 h
-1
 for 100 mM aniline with 0.237 h
-1
 for 
750 mM mPDA, Table 4.S2, Figure 4.4). The in-gel fluorescence analysis further 
confirmed that the released protein was actually labeled with fluorophore 5 with either 
catalyst (Figure 4.4). Overall, this important result indicates that a protein can be 
enzymatically modified in a crude mixture, selectively immobilized onto hydrazide beads 
in the presence of many other proteins and then successfully labeled and released back 
into the solution in high yield using an aminooxy-fluorophore in less than 8 h. It is worth 
noting that when the mPDA/aminooxy reagent ratio is very high (>250), Schiff base 
formation (as an end product) is competitive with oxime ligation. Thus, we recommend 
that mPDA/aminooxy reagent ratios of less than 250 be used so that competitive Schiff 
base formation becomes negligible. 
Capture and release strategy to purify and PEGylate proteins from crude cell 
extract using the catalyst. The attachment of polyethylene glycol (PEG) chains to 
proteins is the most widely employed method for increasing the half-life of protein-based 
therapeutic agents in blood.
143,145
 Site-specific methods for protein PEGylation can 
minimize deleterious effects associated with nonselective PEGylation.
162
 In previous 
work, we described a method for site-specific protein PEGylation based on the capture 
and release strategy outlined above using aniline as a catalyst.
40
 In that work, PEGylation 
was achieved by releasing the captured protein (obtained by enzymatic aldehyde 
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incorporation in crude extract followed by immobilization via hydrazide formation) using 
an aminooxy-functionalized PEG polymer. Given the significant rate enhancement  
Figure 4.5. A) Use of PFTase-catalyzed protein modification for site-specific PEGylation 
from crude cell lysate using the mPDA. The target protein was prenylated, captured using 
hydrazide beads and then simultaneously released into the solution and PEGylated by the 
addition of aminooxy-PEG (6, 5 mM using 200 mM mPDA as a catalyst. B) MALDI 
analysis of the released material in less than 2 h confirmed the formation and release of 
the highly pure PEGylated GFP (7) into the solution. 
 
observed with mPDA, we elected to evaluate the utility of this new catalyst for rapid 
protein PEGylation. Thus, 3 was prenylated with 2 using PFTase in crude E. coli extract 
followed by capture using hydrazide-functionalized agarose. After washing the material 
to remove nonspecifically bound proteins, the desired PEGylated protein (7) was eluted 
via treatment with 5 mM aminooxy-PEG 6 in the presence of 200 mM mPDA (Figure 
4.5). Analysis of that material by MALDI-MS (Figure 4.5) showed a product with a mass 
of 38 kDa (and nothing else) consistent with the formation of highly pure PEGylated 
protein 7 from crude lysate in less than 2 h; the broad peak observed is consistent with 
the attachment of a polydisperse polymer to a monodisperse protein. It is also important 
to note that no species resulting from the Schiff base formation of mPDA or addition of 
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multiple PEG chains were observed, consistent with the selective nature of the chemistry 
employed here. 
 
Figure 4.6. Prenylation of CNTF-CVIA (8) with aldehyde analog 2 followed by 
fluorophore labeling of the prenylated protein (50 µM) via oxime ligation with 5 (250 
µM) for 5 min. A and B are SDS-PAGE analysis of the labeled protein. A) No catalyst 
was used for labeling. B) mPDA was used as the catalyst (80 mM) for labeling. Upper 
bands are detected via in-gel fluorescence analysis and lower bands are visualized by 
staining with Coomassie blue. The fluorescently labeled protein has a higher mass and 
hence shows a decrease in its electrophoretic mobility compared to the precursor 
prenylated protein. 
 
Rapid labeling of CNTF, a protein of biomedical importance, using mPDA. Having 
established the utility of this method for rapid C-terminal site-specific modification with 
a model protein, GFP, we decided to illustrate its use by modifying a protein of 
biomedical importance. Ciliary neurotrophic factor (CNTF) is a member of a class of 
proteins that stimulate neurite outgrowth and promote neuron survival during 
inflammatory events.
163
 Recently, CNTF has been studied extensively as a possible 
therapeutic agent for slowing retinal degeneration.
164,165
 Thus, we elected to investigate 
the preparation of a fluorescent form of CNTF using the new catalyst reported here. To 
accomplish this, purified CNTF−CVIA (8), a form of CNTF engineered to contain a C-
 157 
 
terminal CAAX box, was prenylated with analog 2 under conditions established above 
for GFP followed by labeling using aminooxy fluorophore 5 and mPDA as the catalyst. 
LC-MS analysis (Figure 4.S9) confirmed successful prenylation and subsequent labeling 
of CNTF; as expected, both the enzymatic prenylation and the subsequent oxime ligation 
proceed with essentially complete conversion. Next, we analyzed how fast the protein is 
indeed labeled when the new catalyst is used. The aldehyde-labeled protein 9 (50 µM) 
was incubated with alkoxyamine 5 (600 µM), with or without mPDA as the catalyst (80 
mM) and the reaction was monitored via SDS-PAGE as a function of time. In-gel 
fluorescence analysis of the resulting gel showed a substantially higher labeling 
efficiency when mPDA was used as the catalyst relative to when no catalyst was used 
(Figure 4.6). Inspection of the Coomassie blue stained gel revealed that the labeled 
protein manifests a decrease in electrophoretic mobility compared to the prenylated 
protein due to their mass difference allowing the two forms to be distinguished. 
Accordingly, Coomassie blue visualization of the gel showed that while almost all of the 
protein was labeled when mPDA was used, the amount of labeling that was obtained in 
the absence of mPDA was very small when the reaction was performed within the same 
time period (Figure 4.6).  
PEGylation of a protein containing a ketone using mPDA. 
In addition to aldehydes, ketone-containing proteins have also been used for a number of 
bioconjugation applications including protein PEGylation and spin-labeling.
166
 The 
incorporation of the non-natural amino acid p-acetyl phenylalanine into polypeptides via 
suppressor t-RNA technology is a versatile approach for site-selective introduction of 
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ketones into proteins.
25,134
 However, given the attenuated reactivity of ketones, oxime 
formation is typically carried out under conditions more extreme than those used for  
 
Figure 4.7. Kinetic analysis of PEGylation of the protein DHFR
2
 M174pAcF which 
contains the unnatural amino acid p-acetyl phenylalanine with aminooxy-PEG (3 kDa). 
Protein (7 µM) was incubated with aminooxy-PEG (5 mM) with either 100 mM aniline 
or 500 mM catalyst. Next the samples were analyzed via SDS-PAGE and the protein was 
visualized by staining with Coomassie blue. A) Time course of protein PEGylation in 1-
17 h using mPDA (500 mM) as the catalyst.  B) Time course of protein PEGylation using 
aniline (100 mM, its approximate solubility limit) as the catalyst. C) Comparison of 
protein PEGylation rates using aniline or mPDA obtained by densitometric analysis of 
the SDS-PAGE results shown in (A) and (B) using the Coomassie blue stained gels. 
 
comparable reactions with aldehydes.  For example, a recent report from Schultz and 
coworkers employed 100 µM of a ketone-containing antibody and 5 mM alkoxyamine at 
pH 4.5, 37 °C to achieve near completion in 24 h.
167
 To probe the utility of mPDA for 
catalyzing oxime formation with a ketone-containing protein, a p-acetyl phenylalanine-
containing protein, (DHFR
2
 M174pAcF, 11) was produced in E. coli and purified. 
Aminooxy-PEG 12 (3 kDa, 5 mM) was reacted with DHFR
2
 M174pAcF (11, 7 µM) in 
PB (0.1 M, pH 7) in the presence of either 100 mM aniline, 500 mM mPDA or no 
catalyst. The extent of PEGylation was analyzed at different times via SDS-PAGE and 
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the protein bands were visualized by staining with Coomassie blue. Densitometric 
analysis of the gels revealed that while aniline did not have a significant effect on the 
reaction rate (Figure 4.S10), approximately 2.5 fold increase in the rate was observed 
when mPDA was used as the catalyst (Figure 4.7). It should be noted that while the 
protein concentration in this experiment (7.0 µM) was comparable to that used in the 
work described above with aldehyde-containing proteins (10 µM), it was necessary to 
increase the concentration of the aminooxy-PEG reagent to compensate for the decreased 
reactivity of the ketone (compare 0.1-1.0 mM for the aldehyde with 5 mM for the 
ketone). The presence of elevated concentrations of the aminooxy compound increases 
the rate for uncatalyzed oxime formation thereby reducing the net effect of the catalyst. 
Nevertheless, using mPDA, it was still possible to obtain substantial oxime formation 
under conditions significantly milder (7 µM protein-ketone, 5 mM aminooxy-PEG, pH 
7.0, rt) than those reported by other groups.
166–168
  
Effect of mPDA on protein structure and function. Since the mPDA catalyst described 
here is typically employed at elevated concentrations (relative to aniline), we decided to 
study its effect on protein structure and enzymatic function using two different assays. In 
the first assay, GFP was treated with different concentrations of mPDA followed by gel 
filtration chromatography to remove the catalyst. Circular dichroism spectroscopy of the 
resulting samples showed no significant differences suggesting that exposure to mPDA 
does not cause substantial denaturation or irreversible protein unfolding (Figure 4.S12). 
In the second assay, the effect of mPDA on enzymatic activity was examined. PFTase 
was treated with various concentrations of mPDA followed by dilution (to reduce the 
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mPDA concentration by a factor of 20) and activity measurement using the 
aforementioned spectrofluorometric assay. Analysis of that data showed no significant 
loss of enzymatic activity following treatment with mPDA (Figure 4.S8). Overall, these 
results suggest that mPDA can be used to catalyze oxime-ligation reactions with proteins 
without deleterious effects on protein structure or enzymatic activity. 
Conclusion. In conclusion, an analysis of the oxime ligation reaction for 
bioconjugation purposes was performed and resulted in the discovery of several new 
catalysts for oxime formation and hydrazone-oxime exchange with, m-phenylenediamine 
(mPDA), being the most efficient. mPDA is a highly efficient catalyst that accelerates 
oxime formation by orders of magnitude under physiological conditions; compared with 
aniline, it can catalyze the reaction approximately two-fold faster when employed at 
equal concentrations. Importantly, mPDA has the advantage of being significantly more 
soluble than aniline. That feature, in concert with greater catalytic efficiency, allows 
oxime ligation and hydrazone-oxime exchange to be performed up to 15-fold faster with 
mPDA compared with aniline; this result is reminiscent of observations made in 
mechanistic studies of native chemical ligation where replacement of thiophenol with 4-
carboxymethyl thiophenol led to significant rate enhancement in transthioesterification 
due to the much greater solubility of the latter compound.
169
 The acceleration obtained 
with mPDA is particularly useful for bioconjugation where high concentrations of 
proteins cannot typically be obtained to increase the reaction rate. To showcase the utility 
of this new catalyst, we demonstrated that a protein can be enzymatically labeled with an 
aldehyde moiety in crude cellular extract, selectively immobilized onto hydrazide beads, 
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and released back into the solution as a fluorescently labeled or PEGylated protein via 
mPDA catalyzed hydrazone-oxime exchange in a few hours. The amount of protein 
released in 3 h from the beads was up to 15 times higher in the case of mPDA compared 
to aniline as the catalyst. While the decreased reaction times achievable with mPDA 
could be useful in many contexts, this catalyst may be particularly useful for the 
preparation of materials containing short half-life radionuclides employed for various 
biomedical imaging applications.
170–172
 Overall, this new catalyst should be useful for a 
wide range of bioconjugation applications that require rapid reactions under mild, 
biocompatible reaction conditions. 
 Funding Sources. This work was supported by the National Institutes of Health 
(GM058842 and GM084152), University of Minnesota Endowment Funding and the 
Minnesota Supercomputer Institute. We also thank Dr. Peter Schultz’s group at Scripps 
Research Institute for providing the plasmid pEVOL_pAcF. 
 
 
  
 162 
 
Table 4.1. Kinetic analysis of oxime ligation reactions between the aldehyde, citral, and 1 
with different catalysts. 
 
Catalyst
a
 
 
     
b
 
         
    
               
t1/2 
(min) 
Approximate 
Solubility
c
 
Aniline 24.4±0.5 - 5.54 100 mM 
o-Aminophenol - - - Insoluble 
m-Aminophenol 23.9±0.5 0.98 5.65 100 mM 
p-Aminophenol 33.5±0.9 1.37 4.04 50 mM 
o-Aminobenzoic 
acid 
24.8±0.8 1.01 5.45 very soluble 
(>2 M) 
o-Phenylene-
diamine 
18.1±0.3 0.74 7.47 very soluble 
(>1 M) 
m-Phenylene-
diamine 
41.5±1.2 1.70 3.26 very soluble 
(>2 M) 
p-Phenylene-
diamine 
29.2±0.7 1.20 4.63 very soluble 
(>1 M) 
 
a
Reactions were performed using citral (50 µM), aminooxy-dansyl 1 (100 µM) and 
catalyst (25 mM).  
bThe kobs values were obtained by fitting the experimental data to Equation S3 using 
Kaleidagraph v4.1.3. The values are provided ± the standard error obtained from the 
curve fit. 
c
Solubility in phosphate buffer  (0.1 M), pH 7.0, at rt. 
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Table 4.2. Kinetic analysis of oxime ligation reaction, between the aldehyde, citral, and 
1, with varying concentrations of catalysts. 
 
Aniline
a
 
     
b
 
         
     [    ] 
(       ) 
t1/2 
(min) 
25 mM 24.3±0.2 0.97 5.20 
35 mM 33.5±0.2 0.96 3.77 
42 mM 36.9±0.3 0.88 3.42 
50 mM 48.6±0.2 0.97 2.60 
 
 
 
mPDA
a
 
    
b
 
         
     [    ] 
(       ) 
t1/2 
(min) 
          
               
 
25 mM 38.7±0.1 1.55 3.26 1.59 
35 mM 58.3±0.3 1.66 2.17 1.74 
42 mM 65.6±0.6 1.56 1.92 1.78 
50 mM 78.2±0.7 1.56 1.62 1.61 
 
 
a
Reactions were performed using citral (30 µM), aminooxy-dansyl 1 (100 µM) and 
varying concentrations of catalysts (25 to 50 mM).  
bThe kobs values were obtained by fitting the experimental data to Equation S3 using 
Kaleidagraph v4.1.3. The values are provided ± the standard error obtained from the 
curve fit.    
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Table 4.3. Kinetic analysis of oxime ligation reaction between the ketone, 2-pentanone, 
and 1 at different catalyst concentrations. 
[Catalyst]
a
 
(mM) 
     
b
 
         
          
               
 
t1/2 
(min) 
100 aniline 0.082±0.0007 - 28.5 
100 mPDA 0.20±0.0016 2.41 11.2 
300 mPDA 0.36±0.0042 4.45 6.4 
500 mPDA 0.73±0.0071 8.89 3.2 
700 mPDA 1.17±0.013 14.3 2.0 
900 mPDA 1.69±0.022 20.7 1.4 
 
a
Reactions were performed using 2-pentanone (5.0 mM), aminooxy-dansyl 1 (150 µM) 
and the catalysts at the concentrations indicated.  
bThe kobs values were obtained by fitting the experimental data to Equation S3 using 
Kaleidagraph v4.1.3. The values are provided ± the standard error obtained from the 
curve fit.  
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Abbreviations. mPDA, m-phenylenediamine; PB, phosphate buffer; DHFR, 
dihydrofolate reductase; rt, room temperature; PFTase, protein farnesyl transferase; FPP, 
farnesyl pyrophosphate; PEG, poly ethylene glycol; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; pAcF, p-acetylphenylalanine; CNTF, ciliary 
neurotrophic factor; LC-MS, liquid chromatography-mass spectrometry; MALDI, matrix-
assisted laser desorption ionization. 
Supporting Information 
General. All synthetic reactions were carried out at rt and stirred magnetically unless 
otherwise noted. TLC was performed on precoated (250 mm) silica gel 60 F-254 plates 
(Merck). Plates were visualized by staining with KMnO4 or with a hand-held UV lamp. 
Flash chromatography was performed using a Biotage
® 
instrument. Deuterated NMR 
solvents were purchased from Cambridge Isotope Laboratories, Inc. 
1
H NMR spectra 
were obtained at 500 MHz; 
13
C NMR spectra were obtained at 125 MHz. All NMR 
spectra were acquired on Varian instruments at 25 °C. Chemical shifts are reported in 
ppm and J values are in Hz. Fluorescence assay data were obtained using a Varian Cary 
Eclipse Fluorescence Spectrophotometer. MS spectra for synthetic reactions were 
obtained on a Bruker BioTOF II instrument. Yeast PFTase was prepared as previously 
described.
173 
Protein LC/MS analyses were performed using a Waters Synapt G2 
Quadropole TOF mass spectrometer instrument. MALDI-MS analyses were performed 
with a Bruker MALDI TOF spectrometer instrument. Aminooxy alexafluor-488 (5) was 
from AnaSpec; hydrazide agarose beads were from Thermo Scientific. PEG aminooxy 
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10,000 MW was from NOF America Corporation. All solvents were of HPLC grade. All 
other reagents were from Sigma Aldrich.  
Abbreviations. 
mPDA, m-Phenylenediamine 
FPP, Farnesyl diphosphate 
DTT, Dithiothreitol 
ESI-MS, Electrospray ionization mass spectrometry 
RP-HPLC, Reversed-phase high-pressure liquid chromatography 
PB, Phosphate buffer 
PEG, Polyethylene glycol 
DMAP, 4-Dimethylaminopyridine 
PFTase, Protein farnesyl transferase 
DMF, Dimethylformamide 
DBU, 1,8-Diazabicycloundec-7-ene 
TEA, Triethylamine 
Tris, Tris(hydroxymethyl)aminomethane 
EDTA, Ethylenediaminetetraacetic acid 
GFP, Green fluorescent protein 
CNTF, Ciliary neurotrophic factor 
CD, Circular dichroism 
DHFR, Dihydrofolate reductase 
pAcF, p-Acetylphenylalanine 
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Synthesis of compound 1. 
O,O'-(ethane-1,2-diyl)bis(hydroxylamine) S2. 
 
Compound S2 was synthesized according to a modified literature procedure.
174
 To a 
solution of N-hydroxyphthalimide (20 g, 122.5 mmol) in DMF (120 mL), DBU (18.3 mL, 
122.5 mmol) was added dropwise with stirring to give a very deep red solution. To this 
solution was added 1,2-dibromoethane (5.37 mL, 61.2 mmol) and the mixture was heated 
at 85 °C for 1 h during which time the deep red color faded to produce a colorless 
solution. The resulting solution was poured into ice and the resulting precipitate was 
filtered and washed with cold H2O (50 mL) followed by cold CH3CN (30 mL). The crude 
1,2-diphthalimidooxyethane (S1) was recrystallized from n-butanol (3 L). A suspension 
of 1,2-diphthalimideooxyethane (16.0 g, 41.6 mmol) in glacial acetic acid/HCl (50 mL, 
30:20, v/v) was heated at 115 °C for 3 h to give a clear solution. All the solvent and 
reagents were removed in vacuo. H2O (10 mL) was added to the solid and the suspension 
was filtered and washed with HCl (6 M). The combined filtrate was collected and 
reduced to dryness. The crude product was recrystallized from EtOH/H2O (5:1, v/v) to 
give the compound 1 (C2H8N2O2·2HCl salt) as white crystals (3.7 g, 22.4 mmol, 37 % 
over two steps and two recrystallizations); mp 228 °C; 
1
H NMR (δ, DMSO): 11.16 (s, 
6H), 4.26 (s, 4H). 
13
C NMR (δ, DMSO): 72.21. 
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N-(2-(aminooxy)ethoxy)-5-(dimethylamino)naphthalene-1-sulfonamide (1). 
 
To a solution of S2 (61 mg, 0.37 mmol) in CH2Cl2 (3 mL), TEA (123 µL, 0.87 mmol) 
and DMAP (5 mg, 0.04 mmol) were added with stirring to give a clear solution. To this 
solution was added dansyl chloride (20 mg, 0.074 mmol) and the mixture was stirred at rt 
for 3 h. The solvent was removed in vacuo and the crude product was further purified by 
silica gel column chromatography with gradient elution (EtOAc:MeOH in 0.5% TEA)  
from 1:0 (v/v) going to 9:1 (v/v) to afford 14.2 mg of compound 1 (0.044 mmol, 59% 
yield) as a yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 8.600 (d, J = 8.0 Hz, 1H), 8.342 (d, 
J = 7.5 Hz, 1H), 8.298 (d, J = 9.0 Hz, 1H), 7.554 (m, 2H), 7.180 (d, J = 7.5 Hz, 1H), 
4.083 (t, J = 4.5 Hz, 2H), 3.774 (t, J = 4.5 Hz,1H), 2.886 (s, 6H), 
13
C NMR (125 MHz, 
CDCl3) δ 132.18, 131.73, 128.85, 123.23, 118.18, 115.31, 75.03, 72.56, 45.4. 
Kinetic analysis of oxime ligation reaction: rate constant analysis.  
Dawson and coworkers originally established that the kinetics of oxime ligation reactions 
catalyzed by aniline fit a second order model that is first order in both aldehyde and 
alkoxyamine.
142
 They also showed that the apparent second order rate constant for this 
process varied with aniline concentration.  Wen-jun et al extended those observations by 
demonstrating that the apparent second order rate constant varied linearly with aniline.
161
  
Accordingly, we analyzed the rate data for the model reactions described here and 
confirmed that both the aniline- and mPDA-catalyzed reactions vary linearly with 
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catalyst concentration. In order to obtain an equation to curve fit the data, we started with 
the previously reported rate equation for the aniline catalyzed oxime reaction
3
: 
Eq. S1    V=kobs•[aldehyde][aminooxy] 
Where V is the rate of the reaction which is the rate of formation of the oxime as the end 
product, and kobs is the observed rate constant of the reaction. 
In general, for a second order reaction between A and B as reactants, the equation below 
for the kinetics of the reaction can be derived: 
Eq. S2      
[ ]
[ ]
 = 
[ ] 
[ ] 
  [ ]  [ ]     
By substituting [A] with {[Aminooxy]o-[Oxime]} and [B] with {[Aldehyde]o-[Oxime]} 
and solving the equation for [Oxime] the following relationship is obtained:  
Eq. S3    [Oxime]= 
[        ]  [ 
 [        ]  [        ]      ]
[        ] 
[        ] 
[  [        ]  [        ]    ]  
 
where [Oxime] is the concentration of product, [Aminooxy]o is the initial concentration 
of aminooxy-dansyl 1 and [Aldehyde]o is the initial concentration of aldehyde.  
Fluorescence assay data analysis. Oxime-forming reactions were monitored by 
recording the increase in dansyl group fluorescence (λex=340 nm, λem=505 nm) over time 
that occurred upon product formation. Hence, the raw experimental data was obtained in 
“fluorescence intensity/time” units. In order to obtain that data in units of “µM/time”, it 
was necessary to convert the fluorescence values to concentrations. That was 
accomplished by first calculating the difference between the fluorescence intensity of the 
product and the starting reagents. Assuming complete reaction (100% conversion), that 
difference corresponds only to the fluorescence of the total amount of product. Thus, the 
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fluorescence of the starting reagents was subtracted from the raw fluorescence data 
followed by dividing by the fluorescence difference between the final product and 
starting material and then multiplied by the total concentration of the limiting reagent (in 
μM) which then gives the data in units of “μM/time”. That calculation is summarized in 
equation S4: 
Eq. S4    [     ] = 
[ ]  [ ] 
[ ]    [ ] 
 [                ]  
In that expression, [     ]  is the concentration of product at each given time, [ ]  is 
the fluorescence of the reaction mixture at each given time, [ ]  is the initial 
fluorescence of starting reaction mixture, [ ]    is the maximum fluorescence of the 
reaction mixture at the end of the reaction and [                ]  is the initial 
concentration of the limiting reagent. 
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Figure 4.S1. Kinetic analysis of oxime ligation reaction, using 50 µM aldehyde (citral), 
100 µM aminooxy-dansyl 1, and 25 mM of catalysts. The kobs values were obtained by 
fitting the experimental data to equation S3. 
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Figure 4.S2. A) Analysis of the reaction of aminooxy-dansyl 1 (10 µM) with citral (50 
µM), a conjugated hydrophobic aldehyde, in presence of either 50 mM mPDA (squares) 
or 50 mM aniline (triangles) or no catalyst (circles). B) Kinetic analysis of oxime ligation 
reaction, using 50 μM aldehyde (citral or dodecanal), 20 μM aminooxy-dansyl 1 and 50 
mM mPDA. 
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Kinetic analysis of oxime ligation between 2-pentanone and aminooxy-dansyl 1.  
Figure 4.S3. A) Kinetic analysis of oxime ligation between a ketone (2-pentanone) and 
aminooxy-dansyl 1. Reaction mixtures contained Tris·HCl (50 mM, pH 7.5), aminooxy-
dansyl 1 (150 μM), 0.4 % (w/v) n-dodecyl-ß-D-maltoside, 5 mM ketone (2-pentanone) 
and either 100 mM aniline or varying concentrations of mPDA, in a final volume of 200 
μL. The reaction mixtures were equilibrated at rt for 1 min, initiated by the addition of 
the aminooxy, and monitored for an increase in fluorescence (λex=340 nm, λem=505 nm) 
for approximately 4 h. B) Plot of ratio of rate constant of mPDA catalyzed oxime ligation 
over aniline (100 mM) catalyzed oxime reaction vs concentration of mPDA used. The 
kobs values were obtained by fitting the experimental data to equation S3. 
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Effect of the catalyst concentration on the kobs. In order to analyze the effect of the 
catalyst concentration on the kobs, reactions with different catalyst concentrations were 
performed (Figure 4.S4). After analyzing the kinetics of the reactions and curve-fitting 
the data to the second order kinetic equation described above (Eq. S3), we observed that 
in the cases of both aniline and mPDA as the catalyst, a good fit was obtained to the 
kinetic expression derived above. Additional analysis revealed that reaction rate is linear 
with respect to the catalyst concentration (Figure 4.S5) which is in agreement with 
previous reports.
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Figure 4.S4. Kinetic analysis of oxime ligation reaction, using 30 µM aldehyde (citral), 
100 µM aminooxy-dansyl 1, varying concentrations of either m-phenylenediamine or 
aniline (from 25 to 50 µM). The data was fit to the equation S3. 
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Figure 4.S5. Kinetic analysis of oxime ligation reaction to determine the relationship 
between the observed rate constant and the catalyst concentration. Experiments were 
performed using 30 µM aldehyde (citral), 100 µM aminooxy-dansyl 1 and varying 
concentrations of either m-phenylenediamine or aniline (from 25 to 50 µM). 
GFP-CVIA preparation. Protein was prepared as previously described with one 
modification.
136
 In the final phenyl sepharose chromatography step, after the protein was 
loaded onto the column and washed with buffer as explained in the original work, the 
protein was eluted from column by adding water instead of buffer. 
LC-MS analysis of proteins for determination of prenylation and labeling efficiency. 
Purified prenylated GFP (4a) and pure GFP-CVIA (3) were analyzed by LC-MS to 
ensure complete prenylation. Proteins were stored in Tris·HCl (50 mM, pH 7.5) prior to 
injection into the LC-MS instrument. Crude reaction mixtures of GFP-aldehyde 4a and 
aminooxy 1 catalyzed by either aniline or m-phenylenediamine were analyzed by LC-MS 
to ensure complete ligation in both cases of the catalysts.  The LC-MS method used was a 
gradient of 0–100% solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 
min. 
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Figure 4.S6. A) Structures of farnesyl diphosphate (FPP) and formylbenzoyl-oxy 
geranyl diphosphate (2). B) Schematic representation of prenylation of GFP-CVIA 3 with 
aldehyde-containing analog 2 to yield the prenylated product 4a and subsequent oxime 
ligation with 1 to yield oxime 4b. C, D and E) ESI MS analysis of 3, 4a and 4b with the 
deconvoluted mass spectra shown in the insets, respectively. 
 
Kinetic analysis of protein labeling via oxime ligation. Reaction mixtures contained 
PB (100 mM, pH 7.0), 10 μM GFP-aldehyde 3, 50 μM aminooxy-dansyl 1 and varying 
concentrations of m-phenylenediamine or 100 mM aniline, in a final volume of 250 μL. 
The reaction mixtures were equilibrated at rt for 1 min, initiated by the addition of the 
catalyst, and monitored for an increase in fluorescence (λex=340 nm, λem=505 nm) for 
approximately 100 min. 
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Figure 4.S7. Schematic representation of labeling of GFP-aldehyde 4a with aminooxy 1 
to yield oxime 4b. B) Kinetic analysis of oxime ligation reaction between 4a (10 µM) 
and 1 (50 µM) using 50 mM m-phenylenediamine (green circles), 50 mM aniline (blue 
squares) or no catalyst (black triangles). Gray triangles: GFP-CVIA 3 (10 µM, with no 
aldehyde attached to it) is treated with aminooxy 1 (50 µM) in presence of 50 mM m-
phenylenediamine to further confirm that reaction is truly bioorthogonal. 
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Figure 4.S8. A) Kinetic analysis of oxime ligation reaction between aminooxy 1 and 
aldehyde-GFP 4a to determine the relationship between the observed initial rate of the 
reaction and the catalyst concentration. Experiments were performed using 10 µM 
aldehyde-GFP 4a, 50 µM aminooxy-dansyl 1 and varying concentrations of m-
phenylenediamine. In this case when higher concentrations of the catalyst (>500 mM) 
were used (where the ratio [cat]/[aminooxy] was high), the Schiff base between the 
catalyst and aldehyde becomes a significant product, complicating the kinetic analysis; 
hence that data was omitted from this analysis. It should be noted if it is necessary to 
employ very high catalyst concentrations, Schiff base formation can be countered by 
raising concentration of the aminooxy reagent. B) Plot of ratio of rate constant of mPDA 
catalyzed oxime ligation over aniline (100 mM) catalyzed oxime reaction vs 
concentration of mPDA used. Extrapolation of the line shows that at 750 mM of mPDA 
reaction would be 15 times more efficient in case of mPDA relative to 100 mM aniline. 
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Table 4.S1. Kinetic analysis of oxime ligation reaction between aldehyde-GFP 4a and 
aminooxy-dansyl 1, using aniline or mPDA as catalysts. 
 
[Catalyst]
a
 
mM 
             
 µ       
              
                    
 
     
b
 
         
          
               
 
t1/2 
(min) 
100 aniline 0.226 - 10.35±0.05 - 23.7 
100 mPDA 0.539 2.38 27.04±0.33 2.61 9.06 
200 mPDA 0.878 3.87 48.45±0.74 4.68 5.18 
300 mPDA 1.228 5.42 71.84±1.53 6.94 3.41 
400 mPDA 1.586 7.00 78.11±1.01 7.54 3.14 
500 mPDA 2.343 10.34 107.36±2.13 10.37 2.3 
 
aReactions were performed using 10 µM aldehyde-GFP 4a, 50 µM aminooxy-dansyl 1, 
and the catalyst concentrations given.  
bThe kobs values were obtained by fitting the experimental data to Equation S3 using 
Kaleidagraph v4.1.3. The values are provided ± the standard error obtained from the 
curve fit. 
 
Table 4.S2. Kinetic analysis of the release of the hydrazone immobilized protein into 
fluorescently labeled oxime protein via hydrazone-oxime exchange reaction.  
 
 
 
aImmobilized protein was incubated with aminooxy fluorophore 5 (1 mM) and catalyst, 
followed by analysis of the amount of released protein in the solution via SDS-PAGE.  
bThe kobs values were obtained by fitting the experimental data to a pseudo first order 
reaction. The values are provided ± the standard error obtained from the curve fit. 
 
CNTF-CVIA preparation. The gene for Ciliary Neurotrophic Factor (CNTF) was 
purchased from DNA 2.0 on a pJexpress414 vector.  The sequence of this synthetic gene 
(Menlo Park, CA) is given below.  The CVIA portion of the protein was added using an 
Invitrogen QuikChange Site Directed Mutagenesis kit (catalogue #200523 Menlo Park, 
CA) following the manufacturer’s instructions. 
[Catalyst]
a
 mM 
      
     
b
 t1/2 
(h) 
                         
 
100 aniline 0.016±0.001 43.6 - 
750 mPDA 0.237±0.009 2.9 15 
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The forward primer was tatggtgcaaaagataaacaaatgtgcgtgattgcgtaactcgagccccctag, and the 
reverse primer was ctagggggctcgagttacgcaatcacgcacatttgtttatcttttgcaccata. A plasmid 
containing the CNTF-CVIA was transformed into BL21(DE3)pLysS E. coli cells.  
BL21(DE3)pLysS E. coli cells containing the CNTF-CVIA plasmid were plated on LB-
Agar plates containing 100 μg/mL ampicillin.  These plates were grown overnight at 37 
o
C.  Single colonies were then picked and used to innoculate 50 mL of LB media 
containing 100 μg/mL ampicillin.  These flasks were grown overnight with shaking at 
250 rpm at 37 
o
C.  10 mL of the overnight growth was added to 1 L of LB media 
containing 100 μg/mL of ampicillin and incubated at 37 oC with shaking at 250 rpm.  
This culture was grown to an OD600 of 0.8 at which time protein expression was induced 
by the addition of 1 mL of 1M IPTG.  Cultures were then incubated for an additional 4 h 
by shaking at 250 rpm at 37 
o
C followed by harvesting by centrifugation at 5,400g for 10 
min.  E. coli cell pellets were stored at -80 
o
C. A cell pellet corresponding to 1 L of cell 
growth was suspended in 50 mL of buffer containing 50 mM Tris•HCl, pH 7.5 and 5 mM 
2-mercaptoethanol.  This was then subjected to pulse sonication (10 sec sonication / 10 
sec off) at 50 W for a total sonication time of 5 min.  The sonicated solution was then 
centrifuged at 13,000g for 30 min.  The supernatant was removed and the insoluble 
protein pellet containing the CNTF-CVIA was suspended in 30 mL of buffer containing 
10 mM Tris•HCl, pH 7.5, 6 M guanidine•HCl, 5 mM 2-mercaptoethanol, 100 mM 
NaH2PO4, and 20 mM imidiazole.  To thoroughly suspend the protein, the solution was 
subjected again to pulse sonication (10 sec sonication / 10 sec off) at 50 W for a total 
sonication time of 5 min.   This solution was then added at 3 mL/h to 500 mL of refolding 
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buffer (50 mM Tris•HCl, pH 7.5, 0.5 M NaCl, 10 mM CHAPS, 2 mM DTT).  This 
solution was then left to stir overnight at 4 
o
C and then concentrated using an Amicon 
Centriprep centrifugation (10,000 MW cut-off) according to manufacturer’s instructions.  
This yielded 9.2 mL of a 6.5 mg/mL protein solution.  This solution was diluted in half to 
store in 40% glycerol at -80 
o
C.  
CNTF gene from DNA 2.0 containing N-terminal His-tag.  
Protein sequence:   
MHHHHHHLVP • RGSMAFAEQT • PLTLHRRDLC • SRSIWLARKI • 
RSDLTALMES • YVKHQGLNKN • INLDSVDGVP • VASTDRWSEM • 
TEAERLQENL • QAYRTFQGML • TKLLEDQRVH • FTPTEGDFHQ • 
AIHTLMLQVS • AFAYQLEELM • VLLEQKIPEN • EADGMPATVG • 
DGGLFEKKLW • GLKVLQELSQ • WTVRSIHDLR • VISSHQMGIS • 
ALESHYGAKD • KQM  
DNA sequence (with ATG start underlined): 
aggagatatctagaatgcaccatcatcatcaccacctggttccacgcggtagcatggcc
ttc 
   E  I  S  R  M  H  H  H  H  H  H  L  V  P  R  G  S  M  A  
F  
gctgaacaaaccccgctgacgctgcaccgtcgcgatctgtgctcccgtagcatctggct
g 
 A  E  Q  T  P  L  T  L  H  R  R  D  L  C  S  R  S  I  W  L  
gcccgcaagattcgtagcgacctgaccgcattgatggaatcttacgttaagcatcaagg
t 
 A  R  K  I  R  S  D  L  T  A  L  M  E  S  Y  V  K  H  Q  G  
ctgaacaaaaacattaatctggatagcgtggatggtgttccggtcgcgagcacggaccg
t 
 L  N  K  N  I  N  L  D  S  V  D  G  V  P  V  A  S  T  D  R  
tggagcgaaatgaccgaagcggagcgcctgcaggagaacctgcaggcatatcgtacctt
c 
 W  S  E  M  T  E  A  E  R  L  Q  E  N  L  Q  A  Y  R  T  F  
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caaggtatgctgaccaaactgctggaggatcaacgcgtgcactttacgccgaccgaagg
t 
 Q  G  M  L  T  K  L  L  E  D  Q  R  V  H  F  T  P  T  E  G  
gattttcatcaggcgatccacaccctgatgctgcaagttagcgcttttgcttaccagct
g 
 D  F  H  Q  A  I  H  T  L  M  L  Q  V  S  A  F  A  Y  Q  L  
gaagagctgatggtgttgttggaacagaagattccggagaatgaggccgacggtatgcc
g 
 E  E  L  M  V  L  L  E  Q  K  I  P  E  N  E  A  D  G  M  P  
gcgaccgtcggcgacggtggcctgttcgaaaagaagctgtggggcctgaaagttctgca
g 
 A  T  V  G  D  G  G  L  F  E  K  K  L  W  G  L  K  V  L  Q  
gagctgagccagtggacggtccgttccattcatgacctgcgtgtgattagcagccacca
a 
 E  L  S  Q  W  T  V  R  S  I  H  D  L  R  V  I  S  S  H  Q  
atgggtatcagcgcactggaatctcattatggtgcaaaagataaacaaatgtaactcga
g 
 M  G  I  S  A  L  E  S  H  Y  G  A  K  D  K  Q  M  -  L  E  
Primers for CVIA mutant construction (CVIA sequences underlined). 
Forward Primer 
5’tatggtgcaaaagataaacaaatgtgcgtgattgcgtaactcgagccccctag-3’ 
Translated 5’-3’ Frame 1  
tatggtgcaaaagataaacaaatgtgcgtgattgcgtaactcgagccccctag 
 Y  G  A  K  D  K  Q  M  C  V  I  A  -  L  E  P  P     
Reverse Primer 
5’-ctagggggctcgagttacgcaatcacgcacatttgtttatcttttgcaccata-3’ 
Translated 3’-5’ Frame 1  
tatggtgcaaaagataaacaaatgtgcgtgattgcgtaactcgagccccctag 
 Y  G  A  K  D  K  Q  M  C  V  I  A  -  L  E  P  P     
Coupling reaction between aldehyde-labeled CNTF-CVIA (9) with alexafluor-488 
(5). Alexafluor-488 (5) (4.2 µL of 3.2 mM solution in DMSO) was added to 42 µL of 9 
(stock solution of 60 µM in Tris·HCl (50 mM, pH 7.5)). PB (2 M, pH 7, 2.5 µL) was 
added and the reaction was initiated by adding 50 mM m-phenylenediamine (stock 
solution of 1.5 M in 0.3 M PB, pH 7.0) and was allowed to proceed for 2 h at rt. LS-MS 
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analysis of the sample showed only oxime ligated protein and no free aldehyde was 
detected indicating a complete reaction in both prenylation and oxime ligation reactions. 
 
 
Figure 4.S9. A) Schematic representation of prenylation following by oxime ligation of 8 
to yield 9 and 10 respectively. B and C) ESI MS spectra of prenylated-CNTF 9 (spectrum 
B) and oxime product 10 (spectrum C) with the deconvoluted mass spectra shown in the 
insets. 
 
Preparation of DHFR2 M174pAcF (11). The unnatural amino acid p-Acetyl 
phenylalanine was synthesized and characterized as described previously.
175
 The BL21 
(DE3) competent cells were purchased from Invitrogen™.  Experimental details of the 
plasmid encoding two cysteine free DHFR (DHFR
2
) fusion proteins connected with 13 
amino acid linker has been described previously.
176
 The site for the unnatural amino acid 
incorporation (M174TAG) was chosen on the basis of the surface accessibility of the 
residue. The site was mutated to an amber (TAG) stop codon with a Quick change® site 
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directed mutagenesis kit (Strategene). The primers used for the mutation were 
RS_M174TAG F and RS_M174TAG R as shown below.  To facilitate the isolation of the 
fully expressed DHFR
2
 M174 pAcF protein, a C-terminus 6xHis sequence was appended. 
The primers used for the His6 insertion were RS_M174TAG His6 F & RS_M174TAG 
His6 R as shown below. The plasmid pEVOL_pAcF encoding amino acyl-tRNA  
synthetase (MjTyrRS) and tRNACUA evolved from M. jannaschi was provided by Dr. 
Schultz group and has been described previously.
177
 
Primer Seuquence 
RS_M174TAG F GGT GGT TAG GTT CCG CGT GGT  
RS_M174TAG R ACC ACG CGG AAC CTA ACC ACC 
RS_M174TAG His6 F C GAA ATC CTC GAG CGT CGT TAG CAC 
CAC CAT CAC CAT CAT TAA GGA TCC 
TAA TTA ATT AAT TCA C 
 
RS_M174TAG His6 R G CTA ACG ACG CTC GAG GAT TTC GAA 
ACT ATA GCT ATG CGA G 
 
To express the DHFR
2
 fusion protein with p-acetyl phenylalanine, the plasmid encoding 
DHFR
2
 M174TAG was co-transformed with pEVOL_pAcF into BL21 (DE3) competent 
E. coli cells. 50 ml overnight cultures in LB (Luria-Bertani) media were used to inoculate 
500 mL of M9 minimal media containing chloramphenicol (34 mg/ml) and ampicillin (50 
mg/ml). Cultures were then grown at 37 °C until the O.D. reached 0.57 after which the 
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protein expression was induced by adding 0.3 mM IPTG, 0.04% arabinose and 1 mM 
pAcF. The cultures were then transferred to 30 °C and incubated with shaking for an 
additional 18 h. The cells were then harvested via centrifugation at 7,500 rpm for 10 min. 
The cells pellet was resuspended into lysis buffer containing 1 mg/ml of lysozyme, 20 
mM sodium phosphate, 300 mM NaCl, 10 mM imidazole with gentle shaking for 30 min. 
The partially lysed cells were then cooled and sonicated. The lysate was then centrifuged 
at 16,000 rpm for 45 min and the supernatant was then loaded onto a Ni-NTA agarose 
column. The column was washed with buffer A (20 mM sodium phosphate, 300 mM 
NaCl, 25 mM imidazole) and eluted with gradient buffer B (20 mM sodium phosphate, 
300 mM NaCl, 500 mM imidazole). The protein concentration and purity in the fractions 
was determined using Bradford assay and SDS PAGE, respectively. After pooling the 
fractions containing the desired protein, it was concentrated and exchanged into 0.1 M 
PB pH 7.0 using an Amicon ultrafilitration device equipped with a 30 kDa membrane.  
The final yield of the protein was 8 mg/L and was stored in  - 80 °C. The production of 
the final DHFR
2
 M174 pAcF protein was confirmed by ESI-MS (Calculated m/z 
38061.5, found 38062.6).  
PEGylation of DHFR2 M174pAcF (11) with aminooxy-PEG (12, 3 kDa) using 
mPDA. Aminooxy-PEG 12 (5 mM) was reacted with DHFR
2
 M174pAcF 11 (10 µM) in 
PB (0.1 M, pH 7) in presence of either 100 mM aniline, 500 mM mPDA or no catalyst. 
The amounts of PEGylated protein in the solutions were analyzed at different times via 
SDS-PAGE. Gels were visualized by staining with Coomassie blue. Densitometry 
analysis on the gels was performed using the program ImageJ v1.46.  
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Figure 4.S10. SDS-PAGE analysis of PEGylation of the protein DHFR
2
 M174pAcF 
which contains the unnatural amino acid p-Acetyl phenylalanine with aminooxy-PEG 12 
(3 kDa).  Protein (10 µM) was incubated with aminooxy-PEG (5 mM) with or without 
catalyst for 12 h. Next the samples were analyzed via SDS-PAGE. Lane 1: pure protein; 
lane 2: no catalyst was used; lane 3: 100 mM aniline was used as the catalyst; lane 4: 400 
mM mPDA was used as the catalyst. The bands were visualized by staining with 
Coomassie Blue. %PEGylation were obtained by densitometric analysis of the SDS-
PAGE using the Coomassie blue stained gel. 
Circular dichroism spectroscopy studies for analysis of the effect of mPDA on 
protein structure and function.  
GFP-CVIA 3 (from stock solution of 92 µM diluted to final concentration of 18 µM) was 
treated with different concentrations of mPDA for ~30 min following by gel filtration 
chromatography using Zeba spin desalting column according to the manufacturer’s 
instruction (Thermo Scientific), to remove the mPDA catalyst. Circular dichroism 
spectroscopy of the resulting samples showed no significant differences suggesting that 
exposure to high concentrations of mPDA does not cause substantial denaturation or 
irreversible protein unfolding.  
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Recovered GFP solutions from Zeba spin desalting columns were concentrated down 
using an Amicon Centriprep centrifugation device (10,000 MW cut-off). Assuming 100% 
recovery from Zeba spin desalting columns, concentrations were calculated based on the 
volume of recovered concentrated solutions: pure GFP (21 µM, 440 µL), GFP that has 
been treated with 100 mM mPDA (21.5 µM, 430 µL); GFP that has been treated with 200 
mM mPDA (22 µM, 410 µL); GFP that has been treated with 300 mM mPDA (17 µM, 
540 µL); GFP that has been treated with 400 mM mPDA (18 µM, 500 µL); GFP that has 
been treated with 500 mM mPDA (17 µM, 540 µL); GFP that has been treated with 600 
mM mPDA (17 µM, 540 µL). Spectra were normalized based on 21 µM as the 
concentration of GFP solutions. 
 
Figure 4.S11. Circular dichroism spectroscopy studies for analysis of the effect of mPDA 
on protein structure and function. Spectra were normalized to an equal concentration of 
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GFP-CVIA 3 (21 µM). Green line: pure GFP; blue line: GFP that has been treated with 
100 mM mPDA for 30 min; red line: GFP that has been treated with 200 mM mPDA for 
30 min; black line: GFP that has been treated with 300 mM mPDA for 30 min;  pink line: 
GFP that has been treated with 400 mM mPDA for 30 min; dark green line: GFP that has 
been treated with 500 mM mPDA for 30 min; gray line: GFP that has been treated with 
600 mM mPDA for 30 min. 
Effect of catalyst concentration on the enzyme activity.   
PFTase, as a model enzyme, was incubated with varying concentrations of either of the 
two catalysts, aniline or mPDA, for ~15 min, in PB (0.3 M, pH 7.0). Next, 10 μL of each 
of the PFTase solutions was added to a solution containing Tris•HCl (50 mM , pH 7.5) , 
MgCl2 (10 mM), ZnCl2 (10 μM), DTT (5.0 mM) and 2.0 μM N-dansyl-GCVIA in a final 
volume of 200 μL. The reaction mixtures were equilibrated at 30 °C for 5 min, initiated 
by the addition of FPP (10 μM), and monitored for an increase in fluorescence (λex=340 
nm, λem=505 nm) for approximately 25 min. The initial rates of formation of products 
were obtained as slopes in IU/s using least squares analysis. Corrections were applied to 
all the rate calculations based on the difference between the fluorescence intensity of the 
prenylated product and the starting peptide. Assuming 100% conversion, the difference 
corresponds only to the fluorescence of the total amount of the product. The slope was 
then divided by the fluorescence difference followed by multiplying by the total 
concentration of peptide (2.0 μM) which then gives the rate of formation of product in 
μM/s. The rates for the different reactions were normalized to the rate observed in the 
absence of any catalyst (set to 100%) to facilitate comparison.  
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Figure 4.S12. Effect of catalysts on the activity of PFTase. A) Schematic representation 
of the farnesylation reaction of N-dansyl-GCVIA using PFTase. B) Rate analysis of the 
enzymatic farnesylation reaction using varying concentrations of either aniline or mPDA. 
The rates for the different reactions were normalized to the rate observed in the absence 
of any catalyst (set to 100%) to facilitate comparison. Reactions were performed in 
duplicates. 
 
General procedure for MALDI analysis of protein samples. The sample was adsorbed 
onto a zip-tip (C4 column) via repeated cycles of aspiration and ejection (5-10 cycles of 
10 µL each) using a pipettor. Next, in order to remove excess buffer and reagents, the 
zip-tip was washed 5x10 µL with solvent A (H2O containing 0.1% TFA; v/v) and the 
proteins eluted with 2 µL of a mixture of A and B (25:75) (solvent B: CH3CN containing 
0.1% TFA; v/v). Next 0.7 µL of the eluted material was added to a MALDI plate and 
0.7 µL of matrix was added on top of the sample plate and both were mixed thoroughly 
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to form crystals. Saturated solution of sinapinic acid (3,5-dimeth-oxy-4-hydroxy-
cinnamic acid) was used as the matrix. 
 
NMRs. 
 
1
H NMR of compound 1 
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13
C NMR of compound 1. 
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Chapter 5. Macromolecular Protein Self-Assembly by Bioorthogonal Chemical 
Dimerization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mohammad Rashidian, Sidath C. Kumarapperuma, Kari Gabrielse,  Adrian Fegan,  Mark 
D. Distefano and Carston R. Wagner 
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Construction of heterofunctional proteins is emerging as an interesting and important tool 
in biopharmaceuticals and in fact there are examples like immunoglobulin G Fc domain 
fusions that are among the growing class and top-selling human biotherapeutics. 
Combining a protein with other proteins or molecules, such as a targeting element, a toxic 
protein or molecule, a fluorophore or PEG groups, can improve the specificity, 
functionality, potency, and pharmacokinetic profile of the protein construct. Herein, we 
have demonstrated that enzymatic protein modification and bis-MTX driven chemical 
dimerization can be used to prepare complex multi-protein assemblies. Modular nature of 
this method can reduce the problems associated with heterogeneity of the conjugates and 
add to the versatility of the technique. This strategy is demonstrated with a scFv as the 
targeting element, GFP molecule representing the effector (eg. toxin) and a small 
molecule dye to represent a secondary effector (cytotoxic drug or an imaging agent). An 
important feature of this method is that a protein can be simultaneously and site-
specifically labeled with two bioorthogonal functionalities. 
Introduction. Self-organization of protein molecules into higher order structures is an 
integral part of living cells. A vast array of essential cellular functions are carried out 
through well-orchestrated non-covalent protein assembly and disassembly. By 
incorporating unique evolutionarily selected structural features, the formation of higher 
order structures by self-assembly are programmed by nature at the genetic level.
178–181
 In 
principle, protein assemblies can be genetically engineered to form designed biomimetic 
macromolecular nanostructures 
182,183
 However, unlike DNA and RNA based 
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nanostructures,
184–187
 the rules governing protein self-assembly are only beginning to be 
defined. Much of the previous effort to construct biomimetic protein assemblies has been 
based on direct protein-protein interactions through the incorporation of complementary 
amino acid residue surface interactions.
188
 As an alternative, chemical biological 
approaches for macromolecular protein assembly based on metal coordination,
189
 
polymer conjugation
190
, enzyme-inhibitor interactions,
191
 supramolecular chemistry 
192,193
 
and chemically induced dimerization
194
 have begun to be explored. 
Over the course of the last decade, bioorthogonal chemical methods have been 
developed for the site-specific chemical modification of proteins. These approaches have 
been used to enhance the functionality of proteins.
195,196
 For example, fluorophores can 
be site-specifically attached to proteins as a biophysical or cellular localization tool, 
while protein-polymer conjugation is a well-established method for modulating the in 
vivo behavior of proteins.
49,118,119,121
 Recently, employing non-natural mutagenesis 
techniques, Schultz and co-workers have coupled two antibody FABs via an alkyne-azide 
cycloaddition click reaction.
167
 Bertozzi and coworkers, used formyl generating enzyme 
strategy to incorporate aldehyde moiety into proteins, then using bifunctional linkers that 
contain aminooxy and cyclooctyne or azide functionalities, they could synthesize 
heterobifunctional protein fusions.
197
 In other work, Ploegh and coworkers showed that 
N-to-N and C-to-C protein conjugates could be made using a variation of sortagging.  
They first incorporated either an azide or alkyne, to the N-or C-termini of proteins using 
sortase strategy. Next, they reacted the two complimentary handles to prepare the desired 
dimer.
72
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Herein, we describe an alternative modular method for protein self-assembly that 
combines bioorthogonal protein labeling via enzymatic farnesylation and chemically 
induced dimerization for the preparation of GFP-labeled single chain antibody chemically 
self-assembled nanostructures (CSANs) (Figure 5.1). An important advantage of our 
methodology is the fact that a protein can be enzymatically simultaneously and site-
specifically labeled with two bioorthogonal functionalities, an aldehyde and an alkyne 
group. 
 
Figure 5.1. Modular construction of high avidity “effector-antibody-fluorophore” 
conjugates for therapeutic cargo delivery and tracking. 
 
 
Harnessing the reversible high affinity binding of methotrexate (MTX) with 
dihydrofolate reductase (DHFR), we have demonstrated that recombinantly produced 
antiCD3 single-chain variable fragments (scFv) containing dimeric dihydrofolate 
reductase fusion proteins  (DHFR
2
antiCD3) can be induced to form macrocyclic rings 
with a bis-MTX dimerizer (bis-MTX) ligand.
198
 The size of the protein nanorings can be 
controlled by varying the length of the linker between the two DHFR units.
199
 Taking 
advantage of this observation, we have been able to construct bivalent (13 amino acid 
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linker, 13-DHFR
2
antiCD3) chemically self-assembled antibody nanorings (CSANs) that 
mimic the binding and internalization behavior of the parental mAb and octameric (1 
amino acid linker, 1-DHFR
2
antiCD3) CSANs with superior binding properties to CD3
+
 
HPB-MLT T-leukemia cells compared to the parental mAb.
200
 Further, to enhance the 
utility of this platform we have synthesized a novel bis-MTX dimerizer with an amine 
containing third arm. Using nucleic acid conjugates to this amino-bis-MTX trilinker, we 
demonstrated the targeted delivery of single and double stranded oligonucleotides to T-
leukemia cells.
201
  To expand the organizational and delivery capabilities of the CSANS 
approach beyond oligonucleotides to proteins, we have chosen to explore the utility of 
protein farnesyltransferase (PFTase) bioorthogonal protein labeling. Previously, our 
group and a number of other groups have exploited the high specificity of PFTase to site-
specifically modify proteins.
7,82,111
 PFTase catalyzes the transfer of an isoprenoid group 
from farnesyl diphosphate (FPP, Figure 5.2A) to a cysteineyl sulfur atom present in a 
tetrapeptide sequence (denoted as a CaaX-box) positioned at the C-terminus of a protein 
(Figure 5.2B). Importantly, CaaX-box sequences such as CVIA can be appended to the 
C-termini of many proteins rendering them efficient substrates for PFTase. Since PFTase 
can tolerate many simple modifications to the isoprenoid substrate,
40,83,108,202
 it can be 
used to introduce chemoselectively a variety of functional groups into proteins. 
Previously, we have showed that aldehyde-containing FPP analogs and alkyne-containing 
FPP analogs can be successfully incorporated into proteins using this strategy.
40,80,82
 
Consequently, we envisioned that the coupling of a protein modified with an alkyne-
containing FPP analog that could be coupled to an analogue of amino-bis-MTX, in 
 199 
 
which the amino group has been substituted with an azido group, would facilitate 
incorporation of functional proteins into antibody-nanorings by self-assembly. To achieve 
this objective, a bifunctional FPP analogue linker was designed with orthogonal 
reactivity. This linker (1) was comprised of an aldehyde group and an alkyne moiety 
suitable for protein modification (Figure 5.2A). The orthogonal functionalities in the 
linker could then be used to selectively assemble the antibody-protein nanostructure as 
illustrated in Figure 5.1. 
Experimental Section 
Enzymatic studies of FPP-analogue 1 using a continuous fluorescence assay. 
Enzymatic reaction mixtures contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), 
ZnCl2 (10 μM), DTT (5.0 mM), 2.4 μM N-dansyl-GCVIA (2), 0.040 % (w/v) n-dodecyl-
ß-D-maltoside, PFTase (80 nM), and varying concentrations of 1 (0-50 μM), in a final 
volume of 250 μL. The reaction mixtures were equilibrated at 30 °C for 1 min, initiated 
by the addition of PFTase, and monitored for an increase in fluorescence (λex=340 nm, 
λem=505 nm) for approximately 20 min. The initial rates of formation of products were 
obtained as slopes in IU/min using least squares analysis. Corrections were applied to all 
the rate calculations based on the difference between the fluorescence intensity of the 
prenylated product and the starting peptide. Assuming 100% conversion, the difference 
corresponds only to the fluorescence of the total amount of the product. The slope was 
then divided by the fluorescence difference followed by multiplying by the total 
concentration of peptide (2.4 μM) which then gives the rate of formation of product in 
μM/s. It should be noted that the KM values reported here are actually apparent KM 
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values, since the measurements were performed in only a single peptide concentration. 
The data were fit to a Michaelis-Menten model (  
[  ]     [ ]
   [ ]
) using a nonlinear 
regression program, to determine kcat and KM. 
Enzymatic incorporation of compound 1 into GFP-CVIA (3).
80
 Enzymatic reaction 
mixtures (10 mL) contained Tris·HCl (50 mM, pH 7.5), MgCl2 (10 mM), KCl (30 mM), 
ZnCl2 (10 µM), DTT (5.0 mM), 7 (2.4 µM), compound 1 (30-50 µM), and PFTase (80-
200 nM). After incubation at 30°C for 4 h, the reaction mixture was concentrated using 
an Amicon Centriprep centrifugation device (10,000 MW cut-off). Next, excess of 1 was 
removed through a NAP-5 (Amersham) column using Tris·HCl (50 mM, pH 7.5) as the 
eluant. The subsequent protein concentration was calculated by UV absorbance at 488 
nm (ε=55,000 M-1·cm-1). 
Simultaneous coupling reactions between bifunctional-GFP (4) with azide-
bisMTX (6) and aminooxy-TAMRA (5). Aminooxy-TAMRA (5) (7 µL of 2.2 mM 
solution in DMSO) and azide-bisMTX (6) (7 µL of 10 mM solution in DMSO) were 
added to 100 µL 4 (stock solution of 40 µM in PB). CuSO4 (1 mM), TCEP (1 mM), 
TBTA (100 M) and m-phenylenediamine (40 mM) were added to the mixture and the 
reaction was allowed to proceed for 15 h. LC-MS analysis of the sample showed >90% 
conversion of the click reaction and >99% of oxime ligation on the bifunctionalized-
protein 4. The mixture was then purified by a NAP-5 column to remove the excess of 
reagents. 
Evaluation of the chemically induced self-assembly of TAMRA-GFP-bisMTX  (7) 
with dimeric DHFR proteins by HP-SEC. TAMRA-GFP-bisMTX  (7) (final 
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concentration of 10 uM) and dimeric DHFR proteins (final concentration of 10 uM) were 
mixed and incubated at rt for 2 h. Next the samples were analyzed by HP-SEC. 
Confocal microscopy. 0.5 x 10
6
 HPB-MLT cells were treated with 7 (1 μM) for 
control experiments and with self-assembled nanostructures (TG-13DDCD3 or TG-
1DDCD3) at either 4 or 37 °C for 1 h in RPMI media. Cells were then pelleted by 
centrifugation (400 x g, 5 min). After being washed twice with PBS (phosphate buffer 
saline), cells were incubated on Poly-Prep slides coated with poly-L-Lysine (Sigma) at 4 
or 37 °C for 30 min. Cells were then fixed with 4% paraformaldehyde solution for 10 min 
and washed thrice with PBS. Finally, cells were treated with ProLong Gold Antifade 
reagent with DAPI (Invitrogen) and a cover slip was applied. After overnight incubation 
they were imaged by fluorescence confocal microscopy using an Olympus FluoView 
1000 BX2 upright confocal microscope. 
Flow Cytometry. 1 x 10
6
 HPB-MLT cells were treated with either TG-13DDCD3 or 
TG-1DDCD3 (1/0.5/0.1 μM) at 4 °C for 1 h in PBS buffer (containing 0.05 % BSA and 
0.1 % sodium azide). Cells were pelleted (400 x g, 10 min), washed twice, resuspended in 
the supplemented PBS and their fluorescence was analyzed with a FACS Calibur flow 
cytometer (BD Biosciences). For the positive control experiment, 1 x 10
6
 HPB-MLT cells 
were incubated with 40 nM UCHT-1 (anti-CD3 monoclonal antibody). After 2 h of 
incubation, cells were washed, resuspended and analyzed by flow cytometry. For cell 
specific experiments, 1 x 10
6
 CD3
-
 Daudi B lymphoma cells were incubated with the 
constructs. 
 202 
 
Results and Discussion 
Compound 1 was synthesized from commercially available compounds, geraniol and 
3,5-dihydroxybenzaldehyde in nine steps (Scheme 5.S1). In brief, THP-protected 
geraniol was initially oxidized at C-8 to a terminal alcohol, followed by bromination of 
the alcohol group using CBr4 and PPh3. The 3,5-alkyne-aldehyde functionalized phenol 
was made from 3,5-dihydroxybenzaldehyde via Sonogashira Pd–Cu catalyzed cross-
coupling reaction
203
 in three steps. The modified phenol was attached to the bromide via 
a substitution reaction using K2CO3 as the base. The THP group was removed and the 
alcohol was converted to the corresponding diphosphate via a direct phosphorylation 
strategy employing (HNEt3)2HPO4 and CCl3CN as the activating reagent. Subsequent 
purification by RP-HPLC produced the desired bifunctional aldehyde-alkyne analogue 1 
whose structure was confirmed by 
1
H-NMR, 
31
P-NMR, and HR-ESI-MS. 
Initially, prenylation reactions containing a model peptide, N-dansyl-GCVIA (2), 
analog 1, and PFTase were performed and the reaction was monitored via a continuous 
fluorescence-based enzyme assay, as previously reported,
159
 which demonstrated that 
compound 1 is in fact an alternative substrate for the enzyme. Next, a kinetic analysis of 
that reaction was performed using varying concentrations of 1 and N-dansyl-GCVIA (2) 
in the presence of PFTase showing that the enzymatic process obeyed saturation kinetics. 
Steady-state kinetic parameters for the prenylation reaction using the bifunctional 
aldehyde-alkyne analogue are provided in the Supporting Information section (Figure 
5.S3). This analysis revealed that the catalytic efficiency for alternative substrate 1 is 
reduced relative to that of FPP, with a kcat/KM value of 0.02 (relative to FPP). We found 
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that decrease in kcat constituted the major reason for the diminished catalytic efficiency of 
the analogue, with the kcat value for 1 (kcat=0.0123 s
-1
) observed to be 42-fold lower than 
the kcat for FPP (kcat=0.52 s
-1
), while no substantial difference was observed between the 
KM values for the analogue (KM=2.52 µM) and that of FPP (KM= 1.71 µM). 
With the ability of analogue 1 to be incorporated by PFTase demonstrated, we next 
evaluated the utility of the analogue for selective protein modification. Accordingly, 1 
was incubated with GFP-CVIA (3) in the presence of PFTase (5 h, rt). That choice of 
reaction time was based on our earlier work with the peptide substrate N-dansyl-GCVIA 
(2) where a 2 h reaction resulted in complete conversion. Concentration by 
ultracentrifugation followed by size-exclusion chromatography to remove excess 1 
yielded pure bifunctionalized GFP 4 (Figure 5.S5). Completion of the reaction was 
confirmed by LC-ESI/MS (Figure 5.2C and 5.2D) with the major peak corresponding to 
prenylated GFP (4) and a minor peak  corresponding to negligible amount of unreacted 
GFP-CVIA (3) (Figure 5.S5).  
In a previous study, we had shown that aldehyde-GFP and alkyne-GFP modified 
proteins could be derivatized to produce oxime-linked or clicked products, 
respectively.
40,80
 In this study we explored simultaneous oxime and click reactions on a 
single prenylated-protein. First, to demonstrate the orthogonality of the two reactions, we 
separately carried out either an oxime ligation or a click reaction on the bifunctionalized 
protein. Hence, oxime ligation on 4 was performed with an aminooxy-dansyl compound 
(S10) using m-phenylenediamine (mPDA) as the catalyst.
204
 LC-MS analysis of the crude 
ligation reaction mixture confirmed complete conversion to the oxime-linked product in 
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less than 1 h (Figure 5.S6). The click reaction was tested on 4 with TAMRA-azide (S11) 
using TCEP, TBTA and copper as the catalyst. LC-MS analysis revealed that >80% 
conversion was obtained within 12 h of reaction, using equimolar concentrations of 
prenylated-protein and the coupling reagent (TAMRA-azide) as used in the above oxime 
ligation reaction. Typically the oxime ligation reaction proved to be modestly more 
efficient than the click reaction (Figure 5.S8). When the oxime and click reactions were 
carried out simultaneously on the modified protein using equimolar concentrations of 
reagents (vide supra), quantitative conversion for the oxime reaction and ~90% 
conversion for the click reaction after 15 h (Figure 5.S8) was observed. 
After optimizing the conditions for the oxime and click reactions on the prenylated 
protein 4, we next prepared bis-MTX-GFP-TAMRA, 7. The previously reported amino-
bis-MTX trilinker was coupled to 5-azidopentanoic acid using standard peptide 
chemistry to obtain azido-bis-MTX, 6. Next, prenylated protein 4 was incubated with 
aminooxy-TAMRA, 5, and azido-bis-MTX, 6, for 15 h using the optimized reaction 
conditions (vide supra). Subsequent LC-MS analysis of the reaction mixture revealed the 
successful simultaneous conjugation of the protein with both aminooxy-TAMRA and 
azido-bis-MTX (Figure 5.2E). Overall, the conjugation reactions appear to be highly 
efficient, since little free starting material was observed by LC-MS. Bis-MTX-GFP-
TAMRA, 7, was further purified by HP-SEC.  
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Figure 5.2. A) Structures of FPP and compound 1. B) Schematic representation of 
farnesylation reaction with a protein containing a CaaX box at its C-terminus. C) 
Schematic representation of simultaneous oxime ligation and click reaction of the 
bifunctionalized prenylated protein 4 with azido-bis-MTX 6 and aminooxy-TAMRA 5. 
D and E) ESI MS analysis of 4 and 7 with the deconvoluted mass spectra shown in the 
insets, respectively. 
 
With the bis-MTX- and TAMRA-functionalized GFP-protein (7) in hand, we then 
evaluated the chemically induced self-assembly of this protein with dimeric DHFR 
proteins by HP-SEC.  After simple mixing of the two entities and incubation at rt for 2 h, 
the samples were analyzed by HP-SEC. The elution profiles of the HP-SEC traces 
indicated the predominant formation of the internal monomeric species with 13-DHFR
2 
and much higher order species with 1-DHFR
2 
(Figure 5.S10-11). Having confirmed the 
self-assembly with non-targeting DHFR proteins, we then moved to construct the 
TAMRA-GFP-DHFR
2
antiCD3 (TG-DDCD3) protein nanostructures by mixing 13-
DHFR
2
antiCD3 (13DDCD3) and 1-DHFR
2
antiCD3 (1DDCD3) with 7. The targeting 
proteins generated a similar pattern in the SEC profile (Figure 5.3).  
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Figure 5.3. Self-assembly of antibody nanorings observed by SEC (13-DHFR
2
antiCD3 
with 7). Blue curve: bis-MTX-GFP-TAMRA (7, Peak A).  Green curve: monomeric 13-
DHFR
2
antiCD3 (Peak B). Black curve: induced oligomerization of 13-DHFR
2
antiCD3 
with 7 indicating the major products as the internal monomer (Peak C) and dimer (Peak 
D); Shaded area indicates the collected peak for internalization studies. 
 
As expected, TAMRA-GFP-DHFR CSANs prepared with 13-DHFR
2
antiCD3, 
exhibited predominantly internal dimer, dimer and small amount of higher order species. 
The peaks eluting between 20 –22.5 min (TG-13DDCD3) were collected for cellular 
internalization studies (Figure 5.3). Similar experiments were performed with 1-
DHFR
2
antiCD3 as well (Figure 5.S13 and 5.S14). 
In order to confirm the functionality of the TAMRA-GFP anti-CD3 CSANs (TG-
DDCD3’s), we determined their ability to specifically deliver the protein nanostructure to 
CD3
+
 T-Leukemia cells.  The cells were treated with TG-13DDCD3 and incubated for 1 
h and 24 h (at 4 °C and 37 °C) and evaluated by confocal laser scanning microscopy for 
cellular internalization. Both the GFP and TAMRA chromophores were excited 
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individually to observe the GFP and TAMRA emission. Next, GFP was excited and 
TAMRA emission was observed by FRET between GFP and TAMRA. 
 
Figure 5.4. A) Internalization studies of TG-13DDCD3 with HPB-MLT T-leukemia 
cells at 37 °C. (A) HPB-MLT cells treated with bis-MTX-GFP-TAMRA (7) for 1 h 
(control, blue=DAPI nuclear stain); (B-D) TG-13DDCD3 incubated with CD3
+
 T-
leukemia cells for 1 h; (E-H) TG-13DDCD3 incubated with CD3
+
 T-leukemia cells for 
24 h. (D&H) FRET between GFP and TAMRA was observed by exciting the cells with 
488 nm laser and a BA560/620 nm emission filter. 
 
Confocal microscopy images confirmed the delivery of the nanostructures (TG-
13DDCD3 and TG-1DDCD3) into the cells via an energy dependent endocytosis process 
(Figure 5.4 and Figures S12-14). At 4 °C, both GFP and TAMRA  fluorescence was 
observed on the cell membranes, (Figure 5.S12) and at 37 °C distinct punctate structures 
(Figure 5.4B&C) were observed within the cells indicating the energy dependent uptake 
of both GFP and TAMRA.  Overlay of the GFP/TAMRA channels indicated that the two 
fluorophores resided in the same location, while the positive FRET signal was consistent 
with the GFP/TAMRA conjugate, 7, having remained intact in the cells during the time 
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period of the experiment (24 h) (Figure 5.4E-H). These results are consistent with our 
previous observations with antiCD3 scFv CSAN’s.200 As was noted in earlier studies with 
antiCD3 CSAN’s, flow cytometric analysis (Figures 5.S15,16), revealed that the 
nanostructure bind specifically to  CD3
+
 HPB-MLT cells but not CD3
-
 Daudi cells 
(Figure 5.S19). When compared, little difference by flow cytometry was observed 
between the binding by CSANs prepared from TG-13DDCD3 and TG-1DDCD3 to 
CD3
+
 HPB-MLT cells, despite the supposed higher valency of TG-1DDCD3 based 
CSANs (Figures S17-18). This discrepancy may result from a lack of significant 
differences in the size of CSANs prepared from either monomer. The observation that the 
hydrodynamic radii of CSANs prepared from TG-13DDCD3 and TG-1DDCD3 are 
similar supports this hypothesis. 
Conclusions 
In summary, we have demonstrated that enzymatic protein modification and bis-MTX 
driven chemical dimerization can be used to prepare complex multi-protein assemblies. 
Using these tools, we have prepared a defined assembly composed of three proteins; a 
bioorthogonally chemically modified protein and a fusion protein. As a model system, we 
chose to prepare CSANs by chemical dimerization from bis-MTX conjugated GFP and 
anti-CD3 single chain antibodies using a DHFR-DHFR fusion protein as a scaffold for a 
targeting protein (13DDCD3 and 1DDCD3). Confocal microscopy and Flow cytometry 
experiments  confirmed that the CSANs are fully capable of delivering labeled-GFP 
specifically to CD3
+
 cells and that the GFP-TAMRA conjugate remains intact once 
internalized. The multifaceted chemical approach reported here for protein assembly sets 
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the stage for future studies that will examine the ability of our self-assembly approach to 
be applied to the development of novel multivalent immunotoxins, as well as the 
construction of bispecific antibodies, in addition to the simultaneous monitoring of their 
in vivo activity by fluorescence or radiochemical methods. 
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Supporting Information 
General. All synthetic reactions were carried out at rt and stirred magnetically unless 
otherwise noted. TLC was performed on precoated (250 mm) silica gel 60 F-254 plates 
(Merck). Plates were visualized by staining with KMnO4 or with a hand-held UV lamp. 
Flash chromatography was performed using a Biotage
® 
instrument. Deuterated NMR 
solvents were purchased from Cambridge Isotope Laboratories, Inc. 
1
H NMR spectra 
were obtained at 500 MHz; 
13
C NMR spectra were obtained at 125 MHz. All NMR 
spectra were acquired on Varian instruments at 25°C. Chemical shifts are reported in ppm 
and J values are in Hz. Fluorescence assay data were obtained using a Varian Cary 
Eclipse Fluorescence Spectrophotometer. MS spectra for synthetic reactions were 
obtained on a Bruker BioTOF II instrument. Yeast PFTase was prepared as previously 
described.
173 
Protein LC/MS analyses were performed using a Waters Synapt G2 
Quadropole TOF mass spectrometer instrument. MALDI-MS analyses were performed 
with a Bruker MALDI TOF spectrometer Instrument. Preparative HPLC separations were 
performed by using a Beckman model 127/166 instrument, equipped with a UV detector 
and a Phenomenex C18 column (Luna, 10 µm, 10x250 mm). Vydac 218TP1010 column 
was used for preparative RP-HPLC. Size Exclusion Chromatography (SEC) was 
performed on a System Gold 126/168 HPLC system (Beckman-Coulter, Fullerton, CA, 
USA) connected to a Superdex G75 or G200 column (GE Healthcare Life sciences) with 
P500 buffer (0.5 M NaCl, 50 mM KH2PO4, 1 mM EDTA, pH 7) as the mobile phase 
(flow rate 0.5 mL/min). All solvents were of HPLC grade. All other reagents were from 
Sigma Aldrich.  
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Abbreviations. 
 
GFP, green fluorescent protein; 
PFTase, protein farnesyl transferase; 
Bis-MTX, bis-methotrexate; 
mPDA, m-phenylenediamine; 
FPP, Farnesyl diphosphate; 
DTT, dithiothreitol; 
ESI-MS, electrospray ionization mass spectrometry; 
RP-HPLC, reversed-phase high-pressure liquid chromatography; 
PB, phosphate buffer; 
DMF, dimethylformamide; 
TEA, triethylamine; 
Tris, tris(hydroxymethyl)aminomethane; 
EDTA, Ethylenediaminetetraacetic acid; 
SEC, size exclusion chromatography 
 
  
 212 
 
 
 
Figure 5.S1. Structures of compounds 1-7. 
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Figure 5.S2. Structures of compounds S1-S14. 
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Figure 5.S3. Schematic synthesis of compound 1. 
 
Synthesis of compound 1. 
5-formyl-1,3-phenylene bis(trifluoromethanesulfonate) (S2). 
 
 
Compound S2 was synthesized according to modified literature procedures.
155,205
 Under 
N2, 3,5-dihydroxy-benzaldehyde (2.00 g, 14.5 mmol, 1.0 eq) was dissolved in CH2Cl2 (20 
mL) and TEA (43.4 mmol, 6.05 mL, 4.4 g). The mixture was cooled in an ice bath at 0 
°C and a solution of (CF3SO2)2O (8.9 g, 31.5 mmol, 2.2 eq) in CH2Cl2 (10 mL) was 
added dropwise. The reaction mixture was stirred for another 2 h and allowed to warm up 
to rt during this period. H2O (50 mL) was added and the product was extracted with 
CH2Cl2 (2×30 mL). The combined organic layers were washed with 1 M HCl (30 mL), 
H2O (30 mL) and brine (20 mL), dried over Na2SO4 and then solvent was removed in 
vacuo. The brown residue was purified by silica gel flash column chromatography 
(Hex/EtOAc 4:1) to yield S2 (3.86 g, 67%) as a slightly yellowish powder. 
1
H NMR (δ, 
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CDCl3):  10.021 (s, 1H), 7.845 (d, J = 2.0 Hz, 2H), 7.484 (t, J = 2.2 Hz, 1H). 
13
C NMR 
(δ, CDCl3): 187.527, 158.932, 150.049, 121.983, 120.774, 117.337. 
3-formyl-5-((trimethylsilyl)ethynyl)phenyl trifluoromethanesulfonate (S3). 
 
 
Compound S3 was synthesized according to modified literature procedures.
155,205
 
Compound S2 (3.6 g, 8.95 mmol, 1.0 eq) was dissolved in THF (40 mL) and TEA (20 
mL). Pd(PPh3)2Cl2 (63.5 mg, 0.09 mmol, 0.01 eq) and CuI (34.7 mg, 0.18 mmol, 0.02 eq) 
were added to the reaction mixture. The mixture was cooled in an ice bath at 0°C and a 
solution of TMS-acetylene (1.27 mL, 8.95 mmol, 1.0 eq) in THF (20 mL) was slowly 
added dropwise. The reaction was monitored by TLC. The mixture was stirred for 
another 2 h during which time the temperature was allowed to rise to rt. The solvents 
were removed in vacuo and sat. NH4Cl (30 mL) and EtOAc (50 mL) were added. The 
layers were partitioned and the aqueous layer was extracted with EtOAc (50 mL). The 
combined organic layers were washed with H2O (50 mL) and brine (50 mL), dried over 
Na2SO4 and solvent was removed in vacuo. Purification by silica gel flash column 
chromatography (Hex/EtOAc 30:1) gave S3 (1.72 g, 4.9 mmol, 55.5%) as a colorless oil. 
1
H NMR (δ, CDCl3): 9.965 (s, 1H), 7.948 (d, J = 1.0 Hz, 1H), 7.692 (dd, J = 1.0, 1.0 Hz, 
1H), 7.564 (dd, J = 1.0, 1.5 Hz, 1H), 0.254 (s, 9H).
 13
C NMR (δ, CDCl3): 189.185, 
149.601, 138.101, 133.285, 129.713, 120.926, 100.941, 99.540, 79.803, 68.189, -0.383. 
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3-ethynyl-5-hydroxybenzaldehyde (S4). 
 
 
Compound S4 was synthesized according to modified literature procedures.
155,205
 S3 (1.7 
g, 4.85 mmol, 1.0 eq) was dissolved in MeOH (15 mL). A solution of LiOH (1.0 g, 23.8 
mmol, 5 eq) in MeOH (15 mL) was added at 0°C, and next the temperature was allowed 
to rise to rt overnight. The mixture was extracted with Et2O (3 × 15 mL) and the 
combined organic layers were washed with H2O (10 mL) and brine (10 mL) and dried 
over Na2SO4. The solvent was removed in vacuo and purification by silica gel flash 
column chromatography (Hex/Et2O 2:1) gave S4 (0.55 g, 77%) as a white powder. 
1
H 
NMR (δ, CDCl3): 9.895 (s, 1H), 7.537 (dd, J = 1.5, 1.5 Hz, 1H), 7.336 (dd, J = 1.0, 1.0 
Hz, 1H), 7.213 (dd, J = 1.0, 1.0 Hz, 1H), 6.094 (s, 1H), 3.126 (s, 1H);
 13
C NMR (δ, 
CDCl3): 191.476, 156.345, 137.802, 127.061, 124.955, 115.343, 113.589, 81.798, 
78.762. 
3-(((2E,6E)-2,6-dimethyl-8-((tetrahydro-2H-pyran-2-yl)oxy)octa-2,6-dien-1-yl)oxy)-
5-ethynylbenzaldehyde (S8). 
 
 
Compounds S5, S6 and S7 were prepared as previously described.
40,206
 Bromide S7 
(0.036 g, 1.136 mmol) and S3 (0.292 g, 2.0 mmol) were dissolved in DMF (15 mL) in a 
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flame dried 50 mL flask. K2CO3 (0.50 g, 3.62 mmol) was added to the reaction flask, 
then left to stir at 100 °C for 3 h until TLC analysis (2:1 Hex:EtOAc v/v) indicated 
almost complete conversion to the product. The solvent was removed in vacuo and the 
crude product was further purified by silica gel column chromatography with gradient 
elution (Hex:Et2O) from 1:0 (v/v) going to 5:1 (v/v) to afford 0.27 g of compound S8 (0.7 
mmol, 62% yield) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 9.910 (s, 1H), 
7.542 (dd, J = 1.0 Hz, 1H), 7.373 (dd, J = 1.0 Hz, 1H), 7.265 (dd, J = 1.0 Hz, 1H), 5.538 
(t, J = 7.0 Hz, 1H), 5.357 (t, J = 6.5 Hz, 1H), 4.610 (m, 1H), 4.420 (s, 2H), 4.235 (dd, J = 
9.5, 6.5 Hz, 2H), 4.004 (m, 1H), 3.95–3.83 (m, 1H), 3.495 (m, 1H), 3.135 (s, 1H) 2.201 
(m, 2H), 2.081 (t, J = 7.5 Hz, 2H), 1.714 (s, 3H), 1.671 (s, 3H), 1.66–1.46 (m, 5H). 13C 
NMR (125 MHz, CDCl3) δ 191.132, 159.165, 139.845, 139.436, 137.626, 130.257, 
129.160, 127.406, 126.765, 124.698, 120.982, 114.326, 97.817, 82.006, 78.458, 63.552, 
62.238, 38.865, 30.639, 25.905, 25.417, 19.552, 16.350, 13.779. HR-ESI-MS calcd for 
C24H30O4Na [M+Na]
+
 405.2037, found 405.2051. 
3-ethynyl-5-(((2E,6E)-8-hydroxy-2,6-dimethylocta-2,6-dien-1-yl)oxy)benzaldehyde 
(S9). 
 
 
Protected alkyne-aldehyde S8 (0.25 g, 0.65 mmol) was dissolved in i-PrOH (15 mL) in a 
25 mL flask. PPTS (10 mg) was added as catalyst. The reaction was then refluxed at 75 
°C for 4 h, when TLC analysis indicated complete conversion to the product. It was then 
quenched by adding sat. NaHCO3 (5 mL) and EtOAc (50 mL). The organic layer was 
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then separated and dried over Na2SO4. The solvent was removed in vacuo and afforded 
49 mg of compound S9 (25% yield) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 
9.901 (s, 1H), 7.536 (dd, J = 1.0 Hz, 1H), 7.365 (dd, J = 1.0 Hz, 1H), 7.257 (dd, J = 1.0 
Hz, 1H), 5.519 (t, J = 7.0 Hz, 1H), 5.386 (t, J = 6.5 Hz, 1H), 4.419 (s, 2H), 4.126 (d, J = 
7.0, 2H), 3.115 (s, 1H) 2.195 (m, 2H), 2.064 (t, J = 7.0 Hz, 2H), 1.701 (s, 3H), 1.657 (s, 
3H). 
13
C NMR (125 MHz, CDCl3) δ 191.476, 156.345, 139.640, 141.820, 137.802, 
127.061, 124.955, 124.481, 115.343, 113.573, 81.798, 80.220, 78.762, 68.229, 65.987, 
27.067, 22.822, 15.116, 14.676. 
(2E,6E)-8-(3-ethynyl-5-formylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl diphosphate 
(1). 
 
 
Alcohol S9 (25 mg, 0.084 mmol, 1 eq) was added to CCl3CN (50.5 uL, 0.5 mmol, 6 eq) 
in a 25 mL flask. In a separate 5 mL flask, (Et3NH)2HPO4 salt (0.25 mmol, 75.6 mg, 3 
eq) was added to dry CH3CN  (3 mL), and placed in an oil bath at 30 °C for 5 min to 
dissolve the salt. This solution was added drop-wise to the mixture of alcohol S9 and 
CCl3CN solution over 3 h at rt, and was left to stir for an additional 50 min at rt. The slow 
addition of salt solution to the reaction flask was critical to significantly increase the 
yield. The solvent was removed in vacuo and NH4HCO3 (25 mM, 5 mL) was added to the 
resulting solution and a white precipitate was formed. The solution was filtered and 
purified by RP-HPLC with a semi-preparative column under the following conditions: 
detection at 254 nm; flow rate at 5.0 mL·min-1; 5 mL injection loop; solvent A: 25 mM 
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NH4HCO3 in H2O, solvent B: CH3CN. compound 1 eluted from 20–25% solvent B. 
Fractions containing pure 1 were collected and lyophilized. The resulting salt was 
dissolved in D2O and its concentration was measured following a previously established 
NMR-based quantification
5
 to yield 4 mL of 2.0 mM solution of 1 (3.84 mg, 10% yield). 
1
H NMR (500 MHz, CDCl3) δ 9.712 (s, 1H), 7.549 (dd, J = 1.0 Hz, 1H), 7.371 (dd, J = 
1.0 Hz, 1H), 7.297 (dd, J = 1.0 Hz, 1H), 5.458 (t, J = 7.0 Hz, 1H), 5.265 (t, J = 7.0 Hz, 
1H), 4.432 (s, 2H), 4.279 (d, J = 6.5, 2H), 3.436 (s, 1H) 2.077 (m, 2H), 1.947 (t, J = 7.5 
Hz, 2H), 1.553 (s, 3H), 1.532 (s, 3H). 
31
P NMR: (121 MHz, D2O) δ -6.465 (d, J = 17.2, 
1P), -3.505 (d, J = 16.5, 1P). HR-ESI-MS calcd for C15H26O8P2 [M-H]
–
 395.1025, found 
395.0907. 
Enzymatic studies of FPP-analogue 1 using a continuous fluorescence assay.  
 
 
Figure 5.S4. Fluorescence-based PFTase enzyme assay for prenylation of model peptide 
3 using varying concentrations of 1. 
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GFP-CVIA: Protein was prepared as previously described with one modification.
80,136
 In 
the final phenyl sepharose chromatography step, after the protein was loaded onto the 
column and washed with buffer as explained in the original work, the protein was eluted 
from column by adding water instead of buffer.  
LC-MS analysis of GFP for determination of prenylation efficiency. Purified 
prenylated GFP was analyzed by LC-MS to ensure complete prenylation. Proteins were 
stored in Tris·HCl (50 mM, pH 7.5) prior to injection into the LC-MS instrument.  The 
LC-MS method used was a gradient consisting of 0–100% solvent A (H2O, 0.1% 
HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 min. 
 
Figure 5.S5. A) Schematic representation of prenylation of GFP-CVIA (3) with FPP-
analog 1 to yield functionalized GFP 4. ESI mass spectra of B) GFP-CVIA (3) and C) 
GFP prenylated with bifunctional analogue 1 to yield 4, showing successful prenylation 
of GFP 3. The deconvoluted mass spectra are shown in the insets. 
 
Coupling reaction between bifunctionalized-GFP (4) with aminooxy-dansyl (S10). 
Aminooxy-dansyl (S10) (3.2 µL of 10 mM solution in DMSO) was added to 42 µL of 4 
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(stock solution of 60 µM in PB). PB (1 M, pH 7.0, 2.5 µL) was added and the reaction 
was initiated by adding 40 mM m-phenylendiamine as a catalyst and was allowed to 
proceed for 2 h at rt. The mixture was then purified by a NAP-5 column to remove excess 
dye. LS-MS analysis of the sample showed only oxime-ligated protein and no free 
aldehyde was detected suggesting that the reaction had proceeded to completion. 
LC-MS analysis of GFP for determination of oxime ligation efficiency. The crude 
oxime ligation reaction of bifunctionalized-GFP 4 and aminooxy-dansyl S10 was 
analyzed by LC-MS to ensure complete ligation reaction. The LC-MS method used was a 
gradient of 0–100% solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 
min. 
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Figure 5.S6. A) Schematic representation of oxime ligation reaction between 
bifunctionalized-GFP (4) and aminooxy-dansyl (S10) to yield oxime-GFP (S12). ESI 
mass spectra of B) pure 4 and C) oxime-GFP 4, indicating successful oxime ligation 
reaction. The deconvoluted mass spectra are shown in the insets. 
 
Coupling reaction between bifunctionalized-GFP (4) with azide-TAMRA (S11). 
Azide-TAMRA (S11) (7 µL of 2.2 mM solution in DMSO) was added to 100 µL 4 (stock 
solution of 40 µM in PB). CuSO4 (1 mM), TCEP (1 mM), TBTA (100 M) were added 
and the reaction was allowed to proceed for 3 h. LC-MS analysis of the sample showed 
the presence of both the clicked protein S13 and the free alkyne-protein 4. The ratio of 
free alkyne-protein 4 to its respective clicked product S13, was ~2, indicating only ~35% 
completion of click reaction had been achieved within this time and range of reactant 
concentrations. The reaction was repeated using 50% more azide-TAMRA S11 (225 µM) 
and was allowed to proceed for 16 h. LC-MS analysis of the reaction mixture showed 
>90% conversion of 4 to its respective clicked product S13.  
LC-MS analysis of GFP for determination of click ligation efficiency. The crude click 
ligation reaction of bifunctionalized-GFP 4 and azide-TAMRA S11 was analyzed by LC-
MS to evaluate the conversion of the ligation reaction. The LC-MS method used was a 
gradient consisting of 0–100% solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% 
HCO2H) in 25 min. 
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Figure 5.S7. A) Schematic representation of click reaction between the bifunctionalized-
GFP 4 with azide-TAMRA S11 to yield labeled GFP S13. ESI mass spectra of B) pure 4 
and C) S13, showing successful click reaction between S11 and 4. The deconvoluted 
mass spectra are shown in the insets. 
 
Simultaneous coupling reaction between bifunctional-GFP 4 with azide-TAMRA 
S11 and aminooxy-dansyl S10. Azide-TAMRA (S11) (7 µL of 2.2 mM solution in 
DMSO) and aminooxy-dansyl (S10) (7 µL of 10 mM solution in DMSO) were added to 
100 µL 4 (stock solution of 40 µM in PB). CuSO4 (1 mM), TCEP (1 mM), TBTA (100 
M) and m-phenylenediamine (40 mM) were added and the reaction was allowed to 
proceed for 15 h. LC-MS analysis of the sample showed >90% conversion of click 
reaction and >99% of oxime ligation on the protein. 
LC-MS analysis of GFP for determination of simultaneous ligations reaction 
efficiency. Crude reaction mixture of simultaneous click and oxime ligations of 
bifunctionalized-GFP 4 with azide-TAMRA S11 and aminooxy-dansyl S10 was analyzed 
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by LC-MS to evaluate conversion of ligation reactions. The LC-MS method used was a 
gradient of 0–100% solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 
min. 
 
 
Figure 5.S8. A) Schematic representation of simultaneous click and oxime reactions 
between the bifunctionalized-GFP (4) with aminooxy-dansyl S10 and azide-TAMRA S11 
to yield GFP S14. ESI mass spectra of B) pure 4 and C) S14, showing successful 
simultaneous click and oxime reactions between S10, S11 and 4. The deconvoluted mass 
spectra are shown in the insets. 
 
LC-MS analysis of GFP for determination of simultaneous ligations reaction 
efficiency. Crude reaction mixture of simultaneous click and oxime ligations of 
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gradient of 0–100% solvent A (H2O, 0.1% HCO2H) to B (CH3CN, 0.1% HCO2H) in 25 
min. 
Synthesis of azido-bisMTX. 
 
 
To a solution of N-hydroxysulfosuccinimide (43.4 mg, 200 μmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, 19.2 mg, 100 μmol) in 0.1 M 
MES buffer:DMSO (9:1, 1 mL) at pH 6.5 was added 5-azidopropionic acid (2.9 mg, 20 
μmol) and the mixture was stirred for 1 h at rt followed by addition of amino-bisMTX207 
(19.1 mg, 16 μmol) in 0.1 M NaHCO3:DMSO (29:1, 3 mL) to the reaction mixture. The 
reaction mixture was stirred at rt in dark for 5 h. Next, the crude reaction mixture was 
purified by RP-HPLC using a C8-semi-preparative HPLC column with an H2O/0.1% 
TFA and CH3CN/0.1% TFA gradient. The reation gave 12 mg (83%) of pure product. 
ESI-MS calcd for C61H85N23O11 [M+3H]
3+
 439.5599, found 439.4167. 
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Figure 5.S9. A) Schematic representation of simultaneous click and oxime reactions 
between the bifunctionalized-GFP 4 with aminooxy-TAMRA 5 and azide-bisMTX 6 to 
yield GFP 7. ESI mass spectra of B) pure 4 and C) 7, showing successful simultaneous 
click and oxime reactions between 4, 5 and 6. The deconvoluted mass spectra are shown 
in the insets. 
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Evaluation of the chemically induced self-assembly of TAMRA-GFP-bisMTX  (7) 
with dimeric DHFR proteins by HP-SEC. 
  
 
Figure 5.S10. Self-assembly of nanorings observed by SEC (13-DHFR
2
 with 7). Pink 
curve: bisMTX-GFP-TAMRA (7, Peak A).  Blue curve: monomeric 13-DHFR
2
 (Peak 
B). Black and Red curves: induced oligomerization of 13-DHFR
2
 with 7 indicating the 
major products as the internal monomer (Peak D) and dimer (Peak C). 
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Figure 5.S11. Self-assembly of nanorings observed by SEC (1-DHFR
2
 with 7). Blue 
curve: bisMTX-GFP-TAMRA (7, Peak A).  Red curve: induced oligomerization of 13-
DHFR
2
 with 7 indicating the major products as the internal monomer (Peak C). Black 
curve: induced oligomerization of 1-DHFR
2
 with 7 indicating the major products as the 
much higher order species. Pink curve: oligomerization of 1-DHFR
2
 with bisMTX-C9 
dimerizer for comparison. 
Confocal microscopy.  
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Laser and filter settings for FRET between GFP and TAMRA 
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Figure 5.S12. Imaging of HPB-MLT cells treated with TG-1DDCD3 at either 4 °C 
(Left) or 37 °C (Right).  Cells were treated for 1 h. Arrows indicate red punctuates on the 
cell membrane at 4 °C (Left) or within the cell at 37 °C (Right) corresponding to the 
FRET between GFP and TAMRA using above-mentioned filter settings. Magnification: 
60x. 
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Figure 5.S13. Imaging of HPB-MLT cells treated with TG-13DDCD3 at 37 °C for 1 h 
(top panel) and for 24 h (bottom panel). A & E: GFP channel; B & F: TAMRA channel; 
C &G: Overlay of the GFP and TAMRA channels indicate the intact assembled protein 
(co-localized yellow punctuates); D & H: Observed FRET between GFP and TAMRA 
using above-mentioned filter settings. (FRET images were acquired right after GFP and 
TAMRA imaging and shows a different area of the same slide) Magnification: 40x.   
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Figure 5.S14. Imaging of HPB-MLT cells treated with TG-1DDCD3 at 37 °C for 1 h 
(top panel) and for 24 h (bottom panel). A & E: GFP channel; B & F: TAMRA channel; 
C &G: Overlay of the GFP and TAMRA channel indicates intact assembled protein (co-
localized yellow punctuates); D & H: Observed FRET between GFP and TAMRA using 
above-mentioned filter settings. (FRET images were acquired right after GFP and 
TAMRA imaging and shows a different area of the same slide) Magnification: 40x.  
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Flow cytometry 
 
 
Figure 5.S15. Determination of CD3 receptor binding ability of assembled protein 
nanostructures in comparison to the anti-CD3 monoclonal antibody (Grey: untreated 
HPB-MLT cells; Red: HPB-MLT cells treated with 1 µM TG-13DDCD3; Green: HPB-
MLT cells treated with 1 µM TG-1DDCD3; Blue- HPB-MLT cells treated with FITC 
labeled anti-CD3 monoclonal antibody). 
 
 
Figure 5.S16. Determination of CD3-specific binding of the assembled protein 
nanostructures to the HPB-MLT CD3 receptors (Left: GFP channel, Right: TAMRA 
channel). Grey: untreated HPB-MLT cells; Red: HPB-MLT cells treated with 1 µM 
bisMTX-GFP-TAMRA (7); Green: HPB-MLT cells treated with 1 µM TG-1DDCD3; 
Blue: HPB-MLT cells treated with 1 µM TG-13DDCD3. 
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       A                  B 
 Figure 5.S17. Determination of the dose dependent CD3 receptor binding of assembled 
protein nanostructures (GFP channel); A) HPB-MLT cells treated with increasing 
concentrations of TG-13DDCD3 and B) with TG-1DDCD3 (grey: untreated; blue: 0.1 
µM; green: 0.5 µM; red: 1 µM). 
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       A      B 
 
                                           C 
Figure 5.S18. Determination of the dose dependent CD3 receptor binding of assembled 
protein nanostructures (TAMRA channel);  A) HPB-MLT cells treated with increasing 
concentrations of TG-13DDCD3 and B) with TG-1DDCD3 (grey: untreated; blue: 0.1 
µM; green: 0.5 µM; red: 1 µM); C) Comparison of the TG-13DDCD3 and TG-1DDCD3 
dose dependence using mean fluorescence values obtained from TAMRA channel. 
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Figure 5.S19. Determination of the binding specificity of the assembled protein 
nanostructures:  CD3 negative Daudi B cells were with treated with 1 µM TG-13DDCD3 
(grey: untreated cells; blue: TG-13DDCD3 treated CD3
-
 Daudi B lymphoma cells at 4 °C 
(2 h)). 
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NMRs. 
 
1
H-NMR of compound 1 
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31
P-NMR of compound 1 containing H3PO4 as an internal standard. 
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